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Dopamine (DA) receptors, members of the G-protein coupled receptors (GPCRs) family, 
are divided in two groups based on their transmembrane structural homology domains: D1R-like 
(D1R, D5R sub-types) and D2R-like DA receptors (D2R, D3R and D4R sub-types). Disturbances 
in dopaminergic neurotransmission are associated with several CNS disorders. Hence, DA receptor 
selective ligands have been sought as pharmacological agents to normalize perturbations in the 
dopaminergic system. Despite several notable efforts, the discovery of highly selective ligands for 
dopamine receptor sub-types has proved challenging due to close transmembrane structural 
similarity, especially between DA receptor sub-types within the same group.  
The 1-phenylbenzazepine scaffold is a well-known template for the discovery of D1R-like 
ligands with numerous such highly potent and selective compounds possessing a wide range of 
functional activity (i.e. full agonists, partial agonists, antagonists).  Several compounds with 1-
phenylbenzazepine framework are used as research tools in pharmacological studies.  Fenoldopam 
(2, Figure 4), a selective D1R-like partial agonist, is currently the only compound from this class 
in use clinically (as a fast-acting anti-hypertensive drug).  In addition to being potential therapeutic 
agents for Parkinson’s and Alzheimer’s disease, 1-phenylbenzazepine derived D1R partial 
agonists and antagonists have been extensively studied for their role in attenuating cocaine 
priming-induced reinstatement of drug-seeking behavior.  Aspects related to the chemistry and 
pharmacology of 1-phenylbenzazepines as well as receptor targets as embodied in the thesis are 
reviewed in Chapter 1.  
v 
 
In our work, we have attempted to address some prominent issues and gaps prevalent in 
currently available D1R-like selective 1-phenylbenzazepines. Consequently, as detailed in our first 
aim - Chapter 2, a series of C8, C3’ and C4’ 1-phenylbenzazepines were synthesized and evaluated 
for their affinity and selectivity towards D1R-like receptors. Our main goal was to replace the 
pharmacokinetically labile catechol moiety via replacement of the C8 hydroxyl group with various 
amide, sulfonamide and urea isosteres.  In addition, modifications on the 1-phenyl ring were 
performed.  We hypothesized that such modifications to the catechol moiety and 1-phenyl ring 
would not compromise the D1R affinity, activity and selectivity. An added benefit of these 
modifications is that on theoretical grounds, the metabolic stability of the analogs would be 
enhanced.  Results from the structure-affinity relationship (SAR) studies revealed that the isosteric 
replacements did not yield the desired D1R affinity.  Thus, we can conclude that amide, 
sulfonamide and urea groups are not suitable bioisosteres for the C8 hydroxyl group in the 1-
phenylbenzazepine scaffold.  The results also tend to suggest (in line with historical research on 
the scaffold) a requirement for the presence of the C8 hydroxyl group for D1R affinity,  
The second aim of our project (Chapter 3) was to explore halo and methyl substitutions in 
the 1-phenyl ring of 1-phenylbenzazepines. Extensive SAR studies have been done on the C3’ 
position on the 1-phenyl ring but the C2’ position has been underexplored in the literature. We 
hypothesized that substituents at the C2’ position can significantly impact the orientation of the 
pendant 1-phenyl ring of 1-phenylbenzazepines. The orientation of 1-phenyl group might in turn 
play a role in affinity and selectivity of these molecules. We substituted the 1-phenyl ring at the 
C2’ position with larger halo groups such as chloro and bromo and methyl as well as a smaller 
fluoro group. Moreover, the 1-phenyl ring was disubstituted at the C2’ and C6’ positions with 
chloro groups that would theoretically disfavour coplanarity of the aryl rings. Results from the 
SAR studies of these substitutions revealed that C2’ halo (particularly fluoro) and methyl groups 
are well tolerated for D1R/D5R activity and selectivity, resulting in molecules with single-digit 
nanomolar affinity. As some molecules exhibited moderate D5R versus D1R selectivity, this study 
has provided new avenues towards finding novel D5R selective compounds.  
In another effort to explore the significance of conformational changes in 1-
phenylbenzazepines, in our third aim (Chapter 4), we synthesized and evaluated novel 
conformationally rigid benzazepines (i.e. fluoreno azepines). Via direct arylation chemistry, we 
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achieved rigidification of the benzazepine scaffold in which both aryl rings are directly connected 
via C9 and C2’, thus forcing coplanarity of the aryl rings.  Our goal was to determine the extent to 
which rigidification of the benzazepine scaffold in this manner would affect affinity and selectivity 
for D1R/D5R. We hypothesized that rigidification of 1-phenyl ring in this manner would have a 
significant impact on D1R/D5R activity and selectivity since the pendant 1-phenyl ring is no 
longer allowed to rotate freely and may lock the molecule in a bioactive conformation. 
Serendipitously, though lacking significant affinity for dopamine receptors, in this process we 
discovered a novel class of highly selective and potent 5-HT6 serotonin receptor ligands. These 
fluoreno azepines are pharmacophorically distinct from currently available 5-HT6 ligands. 
Molecular docking studies indicate weaker H-bonding interactions between oxygenated groups 
and binding-pocket amino acid residues of D1R which led to reduced affinity towards D1R. 
Conversely, docking studies of the most active analogs at the 5-HT6 receptor revealed H-bonding 
interactions between the hydroxyl groups and Asp106, a protonated nitrogen and Thr196 and pi-
pi interactions bewtween the aryl rings and Phe188 and Phe284. Several of these novel compounds 
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G protein-coupled receptors (GPCRs) are the largest and most diverse group of membrane 
receptors in eukaryotes.1 GPCRs regulate numerous diverse physiological processes and have 
druggable sites that are accessible at the cell surface which makes this class of proteins an attractive 
pharmaceutical target.  Drugs that target GPCRs account for approximately 27% of the global 
market share of therapeutic drugs.2 GPCRs form the largest human membrane protein family, with 
almost 800 members overall, of which about half are olfactory receptors. The GPCR superfamily 




Figure 1. GPCR family tree.4 
 
Aminergic GPCRs, which belong to class A rhodopsin-like GPCRs, are of critical 
importance as they are the targets for 314 approved drugs to date.5 Human aminergic GPCRs are 
further classified into subfamilies based on their ability to recognize specific biogenic amines as 
their endogenous agonist. Approximately forty-two human aminergic GPCRs have been identified 
including adrenergic, muscarinic, dopaminergic, histaminergic, serotoninergic, and trace amine 
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receptors.6 Each subfamily can be further categorized into subgroups that consist of closely related 
sub-types. 
 
1.2.   Dopamine Receptors 
Dopamine (DA) is a catecholamine-based neurotransmitter associated with regulation of 
movement, emotion, cognition, and reward. Dopamine is an endogenous ligand for all dopamine 
receptors (DR), one of the prominent GPCRs.  In 1972,  the existence of the DR was revealed in 
mammals and soon after, it was discovered that dopamine stimulates adenylyl cyclase (AC) 
activity.7,8 Biochemical and pharmacological studies showed that dopamine bound at multiple 
sites,9 suggesting two major sub-types of dopamine receptors: one was coupled to AC to stimulate 
it and the other was independent of AC.10 Subsequently, dopamine receptors were classified into 
two families, D1R-like (D1 and D5) and D2R-like (D2, D3 and D4) receptors, based on 
pharmacological properties and their ability to regulate cyclic adenosine monophosphate (cAMP) 
generation.10 In the human central nervous system (CNS), the relative density of dopamine 
receptors is D1R > D2R > D3R > D5R > D4R.11 Dysregulation of dopamine neurotransmission 
and its receptors leads to several neurological and pathological conditions, such as 
hyperprolactinemia, Parkinson’s disease, schizophrenia, Tourette’s syndrome, attention 
deficit/hyperactivity disorder (ADHD), and Huntington’s disease.12,13,14,15 Dopamine receptor 
agonists and antagonists are used to alleviate symptoms associated with these conditions. 
 
1.2.1. DR Signaling and Selectivity 
D1R-like receptors stimulate adenylate cyclase activity by coupling to Gαs/olf which then 
activates protein kinase A (PKA) and other signaling molecules.16 D1R agonists increase cAMP 
which phosphorylates cAMP response element binding protein (CREB) at Ser133. CREB 
regulates the transcription of many genes involved in a variety of drug responses.17, 18 D1R-like 
receptors can also directly or indirectly mediate signaling at voltage-gated ion channels as well as 
NMDA and GABAA receptors through actions on DARPP-32, the MAPK pathway, and other 
kinases and phosphatases.19 There is evidence that dopamine receptors can have other protein-
4 
 
protein interactions, such as receptor oligomerization or interactions with scaffolding or other 
regulatory proteins, which can also affect dopamine receptor signaling.20 
The design of selective D1R compounds is complicated because the signaling pathways 
activated by D1R are dependent on several factors including cellular machinery of a given cell (G 
proteins or β-arrestins) and differences in membrane dynamics (highly lipophilic neuronal cells 
vs. renal proximal tubular cells).21,22 Studies have shown that structurally dissimilar D1R agonists 
that are similar in terms of their acute functional profile are functionally selective regarding long-
term receptor trafficking.23 To truly test the functional selectivity of compounds, researchers must 
identify independent signaling pathways because signaling pathways that are dependent on other 
pathways can confound the results. Hence, functional selectivity promises to provide more exciting 
findings in the drug discovery and development realm. 
A major mediator of D2R-like (D2, D3, and D4) signaling is the Gαi/o class of G proteins 
that inhibits adenylate cyclase and cAMP accumulation.24,25 Both D2 and D4 receptors inhibit 
adenylate cyclase in most clonal and in situ cells;26,27 however, inhibition of adenylate cyclase by 
D3R is usually undetectable without molecular manipulation. In addition to D2-like receptor 
signaling through adenylate cyclase, D2-like receptors modulate many other signaling pathways, 
including phospholipases, ion channels, mitogen activated protein (MAP) kinases, and the Na+/H+ 
exchanger.28 D2-like receptors can also regulate Na+ channels and L, N, and P/Q-type Ca2+ 
channels, and the regulation of these ion channels may involve Gβγ actions.29,30,31,32 In addition, 
D2-like receptor signaling tends to inhibit Ca2+ channel activity.32 Interestingly, D2 receptors can 
also stimulate phospholipase D, which catalyzes the hydrolysis of phosphatidylcholine to form 
choline and phosphatidic acid.33 
 
1.2.2. Sub-type Structures 
Among DA receptor sub-types, D1R and D5R share 78% homology, while D3R and D4R 
have 75% and 53% similarity with the D2R respectively.34,35 The N-terminal stretch has similar 
number of amino acids in all receptor sub-types while having a variable number of N-glycosylation 
sites. D1R and D5R possess two such sites, D2R receptor has four, D3R has three, and D4R 
possesses only one N-glycosylation site.36,37 The C-terminal is about seven times longer for the 
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D1-like receptors than for the D2-like receptors and is rich in serine, threonine, and cysteine 
residues. In D1-like receptors, the cysteine residue is located near the beginning of the C-terminus, 
whereas in D2-like receptors it is located near end of the N-terminus (Figure 2). As in all GPCRs, 
DA receptors possess two cysteine residues in extracellular loops 2 and 3, which have been 
suggested to form an intramolecular disulfide bridge to stabilize the receptor structure.38,39  
 
Figure 2. Schematic of structures highlighting comparative general differences between D1- and 
D2-like dopamine receptors.39 
 
The D2-like receptors have a long third intracellular loop, which is common to receptors 
inhibiting adenylyl cyclase, whereas the D1R-like receptors have a short third loop. The D1R and 
D5R third intracellular loop and the C-terminus are similar in size but divergent in their sequence. 
The external loop between TM4 and TM5 is considerably different in the two receptor sub-types, 
shorter (27 amino acids) in the D1R than in the D5R (41 amino acids).36,37 Highly conserved 
residues are present in the core of the protein and define a binding pocket that is most likely the 
agonist binding site.40 The D2R exists as two alternatively spliced isoforms D2S and D2L.41 In 
spite of several efforts, no obvious differences have emerged so far between the two isoforms. 
Both variants share the same distribution pattern, both isoforms inhibited adenylyl cyclase and 
revealed the same pharmacological profile.42,43 Splice variants of the D3R have also been 
identified wherein one transcript carries a 113-bp deletion in TM3 and the second variant derives 





In situ hybridization techniques and immunocytochemistry analysis have been utilized over 
the years to study the distribution of dopamine receptors in the brain.46 The dopaminergic neurons 
in substantia nigra pars compacta, ventral tegmental area, and hypothalamus give rise to three 
major dopaminergic pathways in the brain, the nigrostriatal, the mesolimbocortical, and the 
tuberoinfundibular (Figure 3).47 
 
Figure 3.   Major dopaminergic pathways in the brain.47 
 
Distribution of dopamine receptors is summarized in Table 1. D1R are more widespread 
than any other dopamine receptor. Studies found the abundance of mRNAs for D1R in cortical, 
limbic, and hypothalamic brain regions as well as caudate, nucleus accumbens and olfactory 
tubercule.48 D1R in substantia nigra pars reticulata are on terminals of the striatonigral pathway 
neurons.49,50 D5R, however, are poorly expressed in rat brain. mRNAs of D5R are expressed 
restrictively to the hippocampus, parafascicular nucleus of thalamus and the lateral mamillary 
nucleus.51 Further studies revealed the distribution of D5R in various forebrain regions including 
striatum, cerebral cortex, lateral thalamus, and diagonal band area.52 In the neostriatum, both D1R 
and D5R antibodies tagged the medium spiny neurons but D5R antibodies labeled only the large 
spiny neurons.53 Within the same pyramidal neuron cells, D1R are located on dendritic spines and 
D5R are on dendritic shafts.54 The D1R are distributed into the pars reticulate of the substantia 
nigra, but D5R are not detected in this area.55 These dissimilarities between D1R and D5R at 
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subcellular distribution suggest that even though having analogous pharmacology, they are 
functionally different. 
 
Table 1.   Dopamine receptor sub-types distribution. 




































The highest concentration of D2R mRNA was found in substantia nigra, nucleus 
accumbens, olfactory tubercle, neostriatum and ventral tegmental area as well as in granule cells 
of hippocampal formation, septal region, cingulate, prefrontal, enthorinal and temporal cortex.56 
Immunohistochemical analysis study suggests that D2R are more concentrated in spine heads and 
dendrices than in somata in the spiny neurons of striatum.26,57 The immunoreactivity of D2R with 
specific monoclonal antibodies is also found in the central nucleus of amygdala and internal 
plexiform layers.57 D3R mRNAs are found in the Islands of Calleja and in the nucleus accumbens, 
as well as low level of D3R mRNAs was spotted in putamen and in anterior caudate.58 In the rat 
brain, D3R mRNAs, mainly detected in the islands of Calleja, hippocampus, nucleus accumbens, 
and stria terminalis.59 The granule cells of Islands of Calleja are enriched with both D3R binding 
RNAs and mRNAs, while in nucleus accumbens, they are mainly expressed in neurons of the 
ventromedial shell subdivisions and rostral pole.60 In contrast, D4R mRNAs shows a limited 
expression in the central nervous system. mRNAs for D4R are significantly expressed in the 
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hypothalamus, olfactory bulb, thalamus and frontal cortex.61 Subtype specific antibodies binding 
study for these receptors revealed the presence of GABAergic interneuron modulator D4R in 
cerebral cortex and in hippocampus as well as in globus pallidus and reticular nucleus of 
thalamus.62  
 
1.2.4.  Functions and therapeutic implications 
The role of dopamine receptors in motor functions has been well established.63 D1R, D2R 
and D3R in ventral striatum are primarily involved in forward locomotion. Decreased DA release 
triggered by activation of D2R auto-receptors has been linked to decreased locomotor activity.56 
Studies have also shown the necessity of synergistic interaction between simultaneously stimulated 
D1R and D2R for locomotor activity.64,65 This finding was later confirmed by targeted gene 
inactivation of D1R in mouse.66 Contrary to activated D1R and D2R, activated D3R present in 
nucleus accumbens have inhibitory role on locomotor activity. Studies show D3R agonists inhibit 
while antagonists induce the locomotion.67,68 A summary of dopamine receptor functions are listed 
in Table 2. 
 
Table 2. Dopamine receptor sub-types functions.  








































DA receptors in hippocampus play an important role in cognition and memory.69,70 Several 
animal models have shown significant improvement in memory retention attributed to activation 
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of D1R and D2R in the hippocampus by post training administration of agonists.71,72 In monkeys, 
DA neurons in the area A10 have been reported to be involved in cognitive behavior and learning 
process via transient changes in impulsive activity.73  
Mesolimbic DA is primarily involved in reward and reinforcement mechanisms.74,75,76,77 
Various models have been developed for the study of correlation between drug abuse and 
dopamine release. In the case of drug self- administration, D1R plays an acquiescent role while 
D2R mediates drug reinforcement; collectively reinforcing drug effects.78,79 The opposite role of 
D1R and D2R was observed while studying the effects of respective agonists on cocaine seeking 
behavior. D1R agonists inhibited the cocaine seeking behavior, while D2 receptor agonists 
promoted this behavior.80D3R is also involved in modulating reward and reinforcement. 
Previosuly, D3R partial agonists and antagonists have been shown to inhibit cocaine self-
administration in animal addiction models.81,82 Several additional behaviors, including yawning, 
hypothermia, ejaculatory behavior, alcohol consumption, and inhibition of sniffing are associated 
with nucleus accumbens D3R.83  
The role of D4R and D5R in the physiology of dopaminergic system is still mostly 
unknown. There are pharmacological evidences to establish possible links between mood disorders 
and D4R gene polymorphism. However, these findings are inconsistent and open to re-
evaluation.84,85,86 There is a lack of selective agents that can differentiate between D1R and D5R 
which in turn causes scarce data to understand the physiological role of D5R in the CNS. Gene 
knockout techniques have proven to be an effective way to determine the involvement of D5R in 
ADHD and in the locomotor stimulant effect of cocaine.87,88 Very recently, it has been revealed 
that D5R is linked to the activation of brain-derived neurotrophic factor (BDNF) and protein kinase 
B signaling which indicates a possible association with mood stabilizers and antidepressant 
effect.89 Development of selective D5R  tools is essential to understand the role of D5R in 








1.2.5. D1R/D5R Selective Ligands: An Overview 
Dopaminergic ligands have been at the center of CNS drug development for several 
decades. Most structures with potent DR activity possess a dopamine core such as ergolines, 
aporphines, benzazepines, aminotetralins and phenylpiperidines, from which several therapeutic 
drugs have been developed.90, 91, 92, 93,94 Dopaminergic pharmacophores continue to serve as the 
basis of therapeutic development for a wide range of brain disorders including PD, depression and 
substance abuse disorder. Substituted piperidines, piperazines, indoles, thiazoles, quinolines and 
indans are also frequently incorporated as major pharmacological functions, or as auxiliary 
functions combined with the traditional pharmacophores in the recently developed dopamine 
drugs.95,96 One of the objectives of such structural modifications is to optimize selectivity of 
developed molecules against various dopamine receptors. Agents possessing selectivity for a 
specific DR may demonstrate distinct type of clinical actions in neurological disorders. Though 
some sort of selectivity is achieved between main classes of receptors i.e. D1-like versus D2-like, 
complete selectivity within the DA receptor sub-types (e.g. D1 versus D5) remains a challenge. 
 
1.2.6. D1R: Therapeutic Significance of Currently Available Ligands  
Studies since 1990s have provided ample information on SAR at the D1R. However, lack 
of information on the exact three-dimensional orientation of amino acid residues at the binding 
sites of D1R still hampers the rational design and development of potent and selective D1R agents. 
Current knowledge on D1R agonist and antagonist pharmacophores, and the intrinsic SAR, 
remains empirical. Previously, computer-aided analysis on the conformations of the current 
available full agonists and quantitative structure–activity relationship (QSAR) characterizing D1R 
antagonists has greatly stimulated the advances in this field.97, 98 Notable D1R ligands from all 







Table 3. Summary of representative D1R ligands and their therapeutic potential. 
Activity Ligands Therapeutic Utility References 
Full agonist SKF81297 Substance abuse disorder 101 
Full agonist Dihydrexidine Anti-parkinsonian activity 122, 123 
Full agonist ABT-431 Anti-parkinsonian activity 128 
Full agonist PF-2334 Memory improvement 129, 130 
Partial agonist Fenoldopam Antihypertensive 109, 110 
Partial agonist SKF38393 Substance abuse disorder 100 
Partial agonist SKF83959 Cognitive enhancement 102 
Partial agonist PF-4211 Cognitive enhancement 131, 132 
Antagonist SCH-23390 Substance abuse disorder 103 
Antagonist Ecopipam Anti-obesity properties 104 
 
 
1.2.6.1.      Benzazepines: First Generation D1R/D5R Ligands 
First generation high affinity D1R/D5R selective catechol-based 
phenyltetrahydrobenzazepines were developed in 1980s. D1R selective agents possessing partial 
agonistic or antagonistic properties with high affinity such as SKF-38393,99 SKF-81297,100 SKF -
83959,101 SCH-23390,102 ecopipam103 etc. (Figure 4) have been reported to have cognitive-
enhancing properties in nonhuman primates. SKF81297 was shown to decrease cocaine craving in 
humans and motivation to seek cocaine and masks the reinforcing effects of cocaine during self-
administration.104,105 Various pharmacological studies have exhibited the substance abuse disorder 
treatment potential of D1R partial agonist agents like SKF 83959 and SKF 38393. D1R agonists 
are known to elevate working memory which provides a different approach to treat negative and 





Figure 4: Representative D1R benzazepine derivatives. 
 
Fenoldopam108 mesylate (Corlopam) is a drug and synthetic benzazepine derivative which 
acts as a selective D1R partial agonist.  It was approved by the Food and Drug Administration 
(FDA) in September 1997 as an antihypertensive agent. It is a selective D1R agonist with no effect 
on beta adrenoceptors, although there is evidence that it may have some alpha-1109 and alpha-2 
adrenoceptor antagonist activity.110 D1R stimulation activates adenylyl cyclase and raises 
intracellular cyclic AMP, resulting in vasodilation of most arterial beds, including renal, 
mesenteric, and coronary arteries to cause a reduction in systemic vascular resistance.111 These 
catechol-based ligands, however, suffer from poor pharmacokinetic (PK) profiles (poor 






SAR Analysis of Benzazepines 
The therapeutic potential of D1R benzazepine ligands has led to a wealth of information 
on the structure–activity relationships (SARs). A tentative SAR has been established for typical 
high affinity D1R full agonists based on Nichol’s and Mailman’s conceptual model of the agonists 
(Figure 5).113  Figure 5 depicts the various functionalization on 1-phenylbenzazepine to-date. 
Rings A and C have been the targets of most of these modifications with a focus on replacing the 
catechol moiety of ring A due to its metabolic lability.  
 
  
Figure 5. Structural modifications on benzazepines. 
 
Alterations in ring B and C has been fixated on improving the selectivity and activity of 
this scaffold towards D1R-like receptors. Small chain N-alkyl substitutions have been favorable 
towards the activity of benzazepines towards D1R. Several substitutions at different positions have 
been carried out on ring C including having a fused ring between C2 and C2’.  
The modifications shown in Figure 5 have led to several definitive conclusions on 
functionalized 1-phenylbenzazepines which are outlined in Figure 6. The SAR analysis is 
summarized as follows: 
• A catechol moiety, or a catechol ring with halogen replacement of the two hydroxyl groups 
is preferred. C8-OH serves as a hydrogen-bond donor to the serine residues in the active 
site of the D1R.114,115 
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• A hydrophobic substituent attached to the C1 of the ethylamine side chain is preferred. 
Such a component is postulated to interact with the hydrophobic binding domain of the 
D1R active site.116 
• Chloro substitution at C6 position is favorable for D1R affinity.  
 
 
Figure 6. Established SAR of benzazepines. 
 
Conformationally Rigid Derivatives of Arylbenzazepines. 
The first-generation catechol benzazepines possess a degree of conformational mobility at 
C1 chiral center position. This mobility allows the phenyl ring to interact with the proposed 
accessory binding site of the D1R, likely equatorially.117,118 It was hypothesized that the preferred 
binding of benzazepines to D1R might be the consequence of a π-π interaction between the C1-
aromatic ring and Phe, Tyr, or Trp residue on the receptor surface.119 To test this concept, 
conformationally constrained benzazepines were developed as shown in Figure 7. Binding studies 
of stereoisomers of C2 and C2’ ethylene-bridged benzazepine (7) revealed that the trans structure 
of 7 had the Ki of 3.3 nM which is 143-fold more potent than its cis isomer. Similarly, the C2 and 
C2’ methylene-bridged benzazepine also favored the trans form R-enantiomer (8).120 The potential 
of the conformationally rigid 2, 2’-bridged benzazepines was further explored by producing a large 
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series of substituted analogs, one of which is shown in Figure 7 (9).121 All these compounds 
showed binding affinities of less than 5 nM towards D1R.  
 
 
Figure 7.   Examples of rigidified benzazepines 
 
Conformational restriction of SKF 38393 via connecting the 1-phenyl ring to the azepine 
moiety via an ethylene bridge (11) resulted in a decrease in D1R affinity, with the trans-isomer 
having 85-fold higher D1R affinity than the corresponding cis-isomer. Similar tethering via oxy-
methylene or thio-methylene functionalities (10) had mixed results – a slight decrease in D1R 
affinity in the case of the oxy-methylene bridged compound and a slight increase in D1R affinity 
for the thio-methylene bridged compound.  Conformational restriction of the 1-phenyl ring of SKF 
38393 by tethering to the catechol ring via a methylene or ethylene bridge results in an 




1.2.6.2.    Dihydrexidine-like Analogs: Second Generation D1R/D5R Ligands 
Another significant milestone in the development of D1R/D5R agonists was achieved with 
the discovery of Dihydrexidine (DHX, 12),122 a highly potent 4-phenyl substituted 
tetrahydroisoquinoline (Figure 8).  DHX had an impressive anti-parkinsonian effect in several 
clinical trials.123 Dinapsoline (13), a DHX derivative, was developed by introducing a one carbon 
bridge between the two aryl rings, while removing the six-membered ring originally attached to 
the catechol unit.124 The efficacy of this compound was assessed in rats with unilateral 6-
hydroxydopamine lesions of the medial forebrain bundle, a standard rat model of Parkinson's 




Figure 8.   Representative D1R non-benzazepine ligands. 
 
Doxanthrine (14), a heterocyclic bioisostere of DHX, displayed very high affinity for D1R 
as a full agonist with no affinity towards D2R. It has been shown to be orally active in producing 
contralateral rotation in the 6-hydroxydopamine rat model of Parkinson's disease.125 A common 
characteristic of DHX derivatives is longer alkyl chain N-substitution leads to lower affinities of 
these molecules for D1R. Abbott group discovered A-86929 (15),126 another bioisostere of DHX 
with full, selective D1R-like agonism in which the unsubstituted phenyl moiety has been replaced 
by a propylthiophene. As with DHX, despite its short duration of action, it was proven very active 
in Parkinsonian monkeys.127 With the aim to increase bioavailability, Abbott developed the 
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corresponding diacetate prodrug ABT-431 (15) as a clinical candidate for the treatment of 
Parkinson’s disease.128 Unfortunately, catechol and catechol-like analogs suffer from very low 
bioavailability and/or a poor safety profile. The low bioavailability is ascribed to the essential 
catechol moiety, whereas the safety profile could be linked to D5R agonism or on/off target 
activity.129 
 
1.2.6.3. Non-catechol D1R/D5R Ligands 
Recently, potent non-catechol D1R orthosteric agonists were reported by Pfizer in 2014 
and 2015 as shown in Figure 9. These compounds consist of a substituted phenoxy central core 
with mono- or bicyclic N-containing heterocycle and by another mono- or bicyclic heteroaryl 
substituents linked to the oxygen atom.130 These compounds display D1R affinity in the low 
nanomolar range (Ki < 10 nM). Further profiling of these compounds showed good 
pharmacokinetic properties in the rat. The differentiated profile of non-catechol agonists was 
further demonstrated in vivo where sustained efficacy without tachyphylaxis was observed in a 
cynomolgus monkey eye-blink rate model. This model is a functional marker of dopamine activity 
resulting from the activation of central D1R.  Similarly, sustained efficacy has been demonstrated 
in the 6-OHDA-lesioned rat model of Parkinson’s disease after six administrations.131 Preclinical 
data of some of these compounds demonstrate significant enhancement of cognitive impairment 
in Rhesus monkey models of spatial and working memory impairment, induced by increased 
memory load or ketamine.132   
 
 
Figure 9.   Representative non-catechol D1R ligands from Pfizer.  
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PF-06649751 (tavapadon, 20) was well tolerated and displayed significant reductions in 
MDS UPDRS (Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease 
Rating Scale) scores.133  A subsequent phase II study in Parkinson’s disease patients with motor 
fluctuations was terminated in September 2017 due to insufficient efficacy.   It appears that no 
further activity has been undertaken in the field as Pfizer terminated its research activities in 
neuroscience in early 2018. However, in October 2018 it was announced that Pfizer and Bain 
Capital created a new company called Cerevel Therapeutics that would develop Pfizer’s former 
neuroscience assets, including a D1R agonist which is in phase II.134  
 
1.2.7. D5R Selective Ligands 
There is a plethora of ligands selective for D2, D3 and D4 receptors.135 However, the 
selectivity between D1R and D5R is still a largely unsolved problem in the field (Table 4). 
Discovery of potent D5R ligands will enrich the knowledge about the function of the receptor, 
provide information about its topography, as well as lead to novel potential therapeutics and tools. 
The ~80% sequence homology around the highly conserved transmembrane domains of D1R and 
D5R is likely to be responsible for the lack of selective D1R or D5R ligands. 
 
Table 4.  Relative affinities (Ki, nM) of selected compounds towards D1R and D5R. 
Compound D1R D5R D1R/D5R References 
SKF38393 (1) 150 100 1.50 100 
SKF83959 (3) 1.18 7.56 0.16 102 
SCH23390 (6) 0.35 0.30 1.17 103 
Dihydrexidine (12) 2.2 14.0 0.16 122 
Dinapsoline (13) 5.5 10.0 0.55 124 
Doxanthrine (14) 98.0 7.0 14.0 125 




D5R displayed identical affinity profile to cloned D1R for pharmacological drugs but a 10-
fold higher affinity for the endogenous agonist DA, providing the first evidence of discrimination 
between the D1R-like receptor sub-types.136 None of the typical D1R ligands reported in Table 4 
markedly distinguishes D5 from D1R, except for CY208243,137 which is 10-fold selective for 
D5R. Doxanthrine,125 a DHX derivative, showed 14-fold selectivity towards D5R which is the 




Figure 10. Examples of D5R selective ligands. 
 
To better understand D5R selectivity, Wittig et al. started a step towards D5R selective 
compounds originating from the lead LE300.138 The examples of some of these ligands along with 
their relative selectivity towards D5R versus D1R are depicted in Figure 10. It was discovered that 
ligands with greater selectivity towards D5R had a lower degree of rigidification in the central 
azepine ring. This approach was a step away from traditional benzazepine moiety that are 
D1R/D5R non-selective. The most active compounds showed high binding affinities in the 
nanomolar range to D5R and represented the first step to a structurally new class of dopaminergic 
ligands with binding selectivity to the D5R subtype. This will provide a long-sought opportunity 
to better evaluate the properties and functions of D5R in the brain. Pharmacological profile of this 




1.3.    Limitations of Currently Available D1R/D5R Ligands  
The clinical application of D1R agonists have been diminished by their poor 
pharmacokinetic (PK) profiles and adverse side-effects. Several ligands with high binding affinity 
and selectivity for D1R such as SKF-81297, SKF-83959, and SKF-38393 have entered clinical 
trials as anti-parkinson, anti-psychotic or substance abuse disorder drugs but were eventually 
discontinued. Arylbenzazepines with catechol moiety suffer from low intrinsic partial agonistic 
activity along with poor oral bioavailability and rapid tolerance. Ecopipam, a D1R antagonist, 
showed some promise in treatment of obesity. The longevity of the study, however, was hampered 
by its poor PK profile.139,140   More efforts are necessary to substitute the catechol moiety to 
improve the PK profile of arylbenzazepines while maintaining the selectivity and potency of these 
compounds. In addition, arylbaenzazepines lack the selectivity towards D1R versus D5R. To date, 
no research has extensively focused on developing arylbenazepines that is selective for one class 
of D1R-like receptors. Human trial of intravenous DHX was terminated due to hypotension. DHX 
class of compounds were modified and studied for almost a decade for their therapeutic potential 
towards Parkinson’s disease with companies like Abbott involved in the process. These catechol 
or catechol-like analogs failed to produce a viable drug candidate due to low bioavailability and 
poor safety profile. New class of D1R selective compounds have been reported recently by Pfizer. 
According to several patent filings, these compounds have entered clinical trials for PD. However, 
there are efficacy issues with this class of compounds which has caused the trials to be terminated 
pre-maturely. 
 
1.4.    Serotonin Receptors 
Serotonin or 5-hydroxytryptamine (5-HT) is a neurotransmitter. Serotonin is primarily 
found in the gastrointestinal (GI) tract, platelets, and in the central nervous system (CNS) of 
animals and in all bilateral animals.141 It is popularly thought to be a contributor to feelings of 
well-being and happiness.142 Serotonin is secreted by nuclei that originate in the median raphe of 
the brain stem and project to many brain and spinal cord areas, especially to the dorsal horns of 
the spinal cord and to the hypothalamus.143 After the first 5-HT receptor was cloned (the 5-HT1A 
receptor was the first of the many serotonin receptors to be cloned and characterized),144 it became 
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clear that the mammalian family of serotonin receptors was large, and indeed it has proven to be 
much larger than that of any of the other GPCR-type neurotransmitter receptors. 
 
  
Figure 11.    Dendrogram showing the evolutionary relationship between various human 5-HT 
receptor protein sequences.145 
 
Seven serotonin receptor families have been identified to date that are further classified 
into 14 sub-types based on pharmacological and structural characteristics, and transductional 
mechanisms (Figure 11).146 All but one (5-HT3) serotonin receptors are G-protein coupled. 
Serotonin receptors are either positively (5-HT4, 5-HT6, and 5-HT7) or negatively (5-HT1 and 5-
HT5) coupled to AC.146 However, 5-HT2 receptors couple to the hydrolysis of inositol 
phosphates.147 The brain 5-HT system has been linked to various physiological functions including 
sleep148, cognition149, feeding behavior150, thermoregulation151 and pain control.152 Dysregulation 
of the 5-HT system has been associated with psychiatric disorders such as depression153 and 
schizophrenia.154 
 
1.4.1. Serotonin Receptor Signaling  
Besides the well-known cAMP cascade with Adenyl Cyclase (AC) either inhibited by Gαi 
or activated by GαS,
155 positive coupling to Gαq leads to activation of the phospholipase C (PLC) 
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pathway,156 and Gα12 is implicated in the regulation of Rho GEF (Rho guanine nucleotide 
exchange factor).157 In addition, signaling through Gβγ subunits is known to interact with several 
effectors, including PLCβ2 and β3,158 AC,159 phosphoinositide 3-kinase (IP3 kinase),160 
components of the mitogen activated protein kinase (MAPK, also named ERK for extracellular-
signal-regulated kinase) cascade, and K+ and Ca2+ channels.161 To date, the accepted classification 
of serotonin receptors comprises seven families. 5-HT1 receptors (1A, 1B, 1D, 1E, and 1F) are 
negatively coupled to AC thus causing the decrease in cAMP.162 5-HT2 receptors (2A, 2B and 2C) 
activate the phospholipase C cascade which in turn causes an increase in Ca2+. 5-HT3 receptors, 
the only 5-HT-gated ion channel receptor so it has no effect on cAMP or Ca2+ production. 5-HT4, 
5-HT6, 5-HT7 receptors are positively coupled to AC whereas 5-HT5 receptors (5A and 5B) are 
negatively coupled.163 The downstream signaling pathway for all serotonin receptors (except 5-
HT3) are shown in Figure 12. 5-HT4/6/7 are grouped together because of their similar positive 
effect on AC. 5-HT1/5 show negative effect on AC and decreasing the cAMP production. 5-HT2 
group of receptors activate PLC pathway that affects the calcium concentration in the cells.  
 
 
Figure 12.   Representation of signaling pathways for all 5-HT receptor sub-types164 
 
1.4.2. Sub-type Structures 
Given the vast diversity of 5-HTRs, the efforts to crystallize these receptors are challenging 
and ongoing. To date, out of 14 5-HTRs depicted in Figure 12, only 4 have been successfully 
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crystallized and characterized; 5-HT1B,165 5-HT2A,166 5-HT2B167 and 5-HT2C.168  The structures 
of the remaining therapeutically significant 5-HT receptors have been generated via computer-
aided technologies. The structural homology between all 5-HT receptors are shown in Figure 13.  
 
 
Figure 13.   Serotonin receptor homology.146 
 
1.4.3. Distribution 
A summary of the distribution of 5-HT receptor sub-types is presented in Table 5. The 
density of 5-HT1A binding sites is high in hippocampus, lateral septum, cortical areas (particularly 
cingulate and entorhinal cortex), and the mesencephalic raphe nuclei (both dorsal and median 
raphe nuclei). In contrast, levels of 5-HT1A binding sites in the basal ganglia and cerebellum are 
barely detectable.169 High density of 5-HT1B sites is found in the rat basal ganglia, particularly 
the substantia nigra, globus pallidus, ventral pallidum and entopeduncular nucleus, but also many 
other regions.170 It has been difficult to determine the distribution of 5-HT1D receptors because 
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protein levels appear to be low and there is a lack of radioligands able to discriminate 5-HT1D 
from 5-HT1B receptors.171 The rat 5-HT1B binding site suggest that the 5-HT1D site is present in 
various regions, but especially the basal ganglia (particularly the globus pallidus, substantia nigra 
and caudate putamen) and the hippocampus and cortex.172 
 
Table 5.  Serotonin receptor sub-types distribution. 
Receptors Distribution 
5-HT1A Raphe nuclei, hippocampus 
5-HT1B Substantia nigra, globus pallidus, basal ganglia 
5-HT1D Brain 
5-HT2A Platelets, cerebral cortex 
5-HT2B Stomach 
5-HT2C Hippocampus, substantia nigra 
5-HT3 Area postrema, enteric nerves 
5-HT4 Cortex, smooth muscle 
5-HT5 Brain 
5-HT6 Brain 
5-HT7 Anterior thalamus, hippocampus 
 
 
The 5-HT2A receptor is the classical 5-HT2 receptor which was originally identified in the 
vascular (most blood vessels) and non-vascular smooth muscle. The receptor is also present in 
platelets and is rather prominently expressed in the brain.173 In areas such as the cortex, 5-HT2A 
receptors have been localized on GABAergic interneurons and on glutamatergic projection 
neurons.174 The presence of 5-HT2B receptor-like immunoreactivity was reported in rat brain, 
although the immunostaining is cerebellum, lateral septum, dorsal hypothalamus and medial 
amygdala. Autoradiographic studies have identified 5-HT2C receptor in the choroid plexus, 
cortex, nucleus accumbens, hippocampus, amygdala, caudate and substantia nigra in rat brain.175  
5-HT3 receptors are present in the CA1 pyramidal cell layer in the hippocampus, the dorsal 
motor nucleus of the solitary tract and the area postrema.176 In the periphery, they are located on 
pre- and postganglionic autonomic neurons and on neurons of the sensory nervous system.  The 
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existence of the endogenous 5-HT4 receptor had been widely recognized in both central and 
peripheral tissues, although there has been confusion between 5-HT3 and 5-HT4 receptors.177 The 
activation of 5-HT4 receptor has been found to trigger acetylcholine release in the guinea pig ileum 
and contracts the esophagus and colon.178 The 5-HT5 receptors are essentially limited in 
distribution to the central nervous system (CNS), it has also been found on neurons and neuronal-
like cells of the carotid body.179 
The existence of the 5-HT6 receptor has been suspected in striatum and in neuroblastoma 
cells. High levels of 5-HT6 receptor mRNA are consistently detected within the striatum (caudate 
nucleus) of rat, guinea pig and human.180 Dense signals were found in the frontal, entorhinal and 
piriform cortices, nucleus accumbens, cerebellum, caudate-putamen, hippocampus, olfactory 
tubercle and islands of Calleja.  
In various species, including human brain, 5-HT7 binding is found in anterior thalamus 
and the hippocampus at high levels.181 Other regions expressing intermediate levels are the septum 
and hypothalamus, other hippocampal regions, the anterior cingulate and other cerebral cortical 
areas (in pyramidal cells and on GABAergic neurons), some amygdala and brainstem nuclei and 
basal ganglia, and Purkinje cells in the cerebellum.182 
 
1.4.4. Functions and therapeutic implications 
In rat models, administration of 5-HT1A receptor agonists causes a wide range of 
behavioral and physiological effects including hyperphagia, hypothermia, altered sexual behavior 
and a tail flick response.183 In addition, there is adequate clinical studies attesting to the anxiolytic 
and antidepressant activity of 5-HT1A receptor agonists.184,185,186 Activation of central 5-HT1B 
receptors is attributed to increased corticosterone and prolactin secretion, hypophagia, 
hypothermia, penile erection and a stimulus cue in drug discrimination tests.187, 188  
Literature evidence shows 5-HT2A receptor selective antagonists such as MDL 100907 
inhibit the head shake response while 5-HT2B:2C receptor selective antagonists do not.189, 190 
Currently, there is considerable interest in the role of the 5-HT2A receptor in antipsychotic drug 
action. Typical antipsychotic drugs are shown to have high affinity for the 5-HT2A binding site191, 
and the evidence of an association between schizophrenia and treatment outcome and certain 
polymorphic variants of the 5-HT2A receptor.192 There are little available data on the functional 
26 
 
effects of activation of the central 5-HT2B receptor. It has not yet been proven that the native 5-
HT2B receptor in brain couples to phosphatidylinositol hydrolysis. When administered alone, 5-
HT2C receptor antagonists are anxiolytic in various animal models.193  
Chronic stimulation of 5-HT2B receptor present in interstitial cells of the heart valves and 
endothelial cells of pulmonary arteries leads to fibrosis of the heart valves and increases mitogenic 
signaling on pulmonary artery endothelial cells and fibroblasts. Bryan Roth and colleagues have 
shown that drugs inducing valvular disease and pulmonary arterial hypertension are 5-HT2B 
receptor agonists such as fenfluramine.194 As a result of these findings, fenfluramines and the 
antiparkinsonian pergolide, which is also 5-HT2B agonist were taken off market.195 
Pharmaceutical industry has put in place 5-HT2B receptor screens to stop the development of 
drugs with 5-HT2B receptor agonism.196 Summary of 5-HT receptor involvement in various 
physiological functions are listed in Table 6. 
Table 6.  Serotonin receptor sub-types functions. 
Receptors Functions 
5-HT1A Regulates sleep, feeding, depression and anxiety197 
5-HT1B Neuronal inhibition, behavioral changes, 5-HT mediated artery 
contraction198 
5-HT1D Locomotion, anxiety, vascular vasoconstriction in the brain199 
5-HT2A Psychiatric disorders, including schizophrenia, depression and anxiety200 
5-HT2B Differentiation of cranial neural crest cells and heart development201 
5-HT2C Body weight regulation and obesity, psychiatric and neurological 
disorders202 
5-HT3 Neuronal mechanisms underlying emesis, pain, anxiety and drug 
addiction203 
5-HT4 Regulate gastrointestinal motor and sensory functions204 
5-HT5 Psychiatric conditions, vasoconstrictive and vasodilatory effects205 
5-HT6 Motor control, emotionality, cognition and memory194, 195 






5-HT6 receptor antagonists are hypothesized to improve cognition, learning, and 
memory.206 5-HT6 receptor antagonists such as latrepirdine and idalopirdine were evaluated as 
novel treatments for Alzheimer's disease and other forms of dementia.207 5-HT6 antagonists have 
also been shown to reduce appetite and produce weight loss. Recently, the 5HT6 agonists have 
been demonstrated to be active in rodent models of depression, anxiety, and obsessive-compulsive 
disorder (OCD), and such agents may be useful treatments for these conditions208, 209  
The 5-HT7 receptor plays a role in smooth muscle relaxation within the vasculature and in 
the gastrointestinal tract210 as well as involved in thermoregulation, circadian rhythm, learning and 
memory, and sleep. It is also speculated that this receptor may be involved in mood regulation, 
suggesting that it may be a useful target in the treatment of depression.211, 212 
 
1.4.5. Selectivity Among Serotonin Receptors: Study of 5-HT6R 
Due to the enormous diversity of serotonin receptor sub-types, there is a need for selective 
5-HT receptor ligands. The selective interaction of ligands with individual sub-types allows for 
research on their distinct physiological properties with implied therapeutic significance. The aim 
of current research on serotonin receptor ligands has been to achieve a greater level of control over 
the broad spectrum of functions. This research has produced effective ligands for some of the 
receptor sub-types,213 which has led to important structure–activity relationship (SAR) discoveries 
for those sub-types. There are several receptor sub-types for which improvements on the currently 
available ligands are needed. Ongoing efforts to this end have produced many novel classes of 
ligands214 and several binding studies to elucidate the requirements for the desired selectivity and 
potency.215 The evolution of these ligands has helped clarify the physiological profile for 
serotonergic receptors and the therapeutic value of 5-HT receptor ligands. 
5-HT6 receptor, a member of 5-HT receptor superfamily, is a typical GPCR that enhances 
adenylyl cyclase activity.216 5-HT6Rs are involved in the modulation of cognitive processes217 and 
mood regulation along with numerous motivated behaviors. Hence, major therapeutic potential of 
5-HT6R lies in the treatment of obesity and related metabolic disorders,218 as well as in disorders 
associated with learning and memory like AD.219 Few 5-HT6 receptor ligands have been in clinical 
development stage for potential use as potential anti-dementia, anti-psychotic, and anti-obesity 
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drugs.213 Currently, a selective 5-HT6 receptor  antagonist, HEC30654AcOH, in clinical trial  for 
its effect in healthy subjects. Moreover, a bioimaging study of SLV354, a selective 5-HT6 agonist, 
on schizophrenic human subjects was conducted in 2012. The results of this clinical trials have not 
been made public, but it highlights the significance of 5-HT6 as therapeutic target for various 
neurological abnormalities.  
 
1.4.6. 5-HT6R: Currently Available Ligands  
The first ligands for the 5-HT6R were discovered in the late 1990s by using high-
throughput screening technologies on compound libraries.220 Since then, a growing number of 
scientific publications and patent applications for the ligands of this receptor have been reported 
(Figure 14).  Ro-04-06790 (25) (Ki = 47 nM) and Ro-63- 0563 (26) (Ki =12 nM)
221 are the first 5-
HT6 selective ligands found via high-throughput screening. Both ligands are 5-HT6 antagonists. 
SB-271046 (27)222 (Ki =1.3 nM) is a highly potent selective 5-HT6 receptor agonist with good oral 
bioavailability in a rat model but lacked good blood brain barrier (BBB) penetrability. Series of 
bicyclic heteroarylpiperazines related to SB-271046 have been synthesized to improve the BBB 
penetrability profile. One strategy involves the introduction of SB-271046 derivatives with 
conformational constraint and removal of an acidic NH group. This effort was successful in 
producing the drug candidate SB-699929 (28)223 (Ki =2.5 nM). SB-699929 showed a brain-blood 
ratio of 3:1 in rats with good oral bioavailability in various species. Molecular modeling studies 
have suggested that 5-HT6 ligands bind to common amine sites in the binding pocket of the 




Figure 14.   Examples of 5-HT6 receptor ligands. 
 
More recently there are new approaches of designing dual targeting ligands with 5-HT6 
that play a role in cognition. There is an impetus to design dual 5-HT6/D3R antagonists that display 




31)226 is a neutral antagonist of 5-HT6 that was envisioned from a well-known 5-HT6 antagonist, 
Interpirdine (30).227 In contrast to Intepirdine, CPPQ has displayed neuroprotective properties 
against astrocyte damage induced by doxorubicin. Success of CPPQ has promoted further research 
in similar molecular moiety for designing dual antagonists of 5-HT6/D3 receptors.226 New 
investigations are ongoing to establish which interactions are taking place at the 5-HT6 receptor. 
 
1.5.    Clinical Potential and Limitations of Currently Available 5-
HT6R Ligands 
Currently, there are several selective antagonists of 5-HT6R that have entered clinical 
trials, but none of these drugs has been approved yet. Idalopirdine (33)228 (Fig. 11), the most 
promising candidate for the treatment of cognitive defects associated with AD and schizophrenia, 
failed to meet its primary endpoint in phase III clinical trials.  Celapirdine (29)229, another potent 
5-HT6R selective antagonist developed by Wyeth/Pfizer, failed to make progress after phase II 
clinical trials due to adverse side-effects. GlaxoSmithKline developed interpirdine227 for the 
treatment of AD, but the drug development was discontinued after phase III trials for unspecified 
reasons. Full and partial agonists of 5-HT6R such as WAY-181187 (34)230,231 and E-6837232(32), 
respectively, have shown promise towards anti-obesity treatment in rat models. It is not clear at 
this time the extent to which the clinical failures of the drugs are attributable to the specific drugs 
examined or to the targeting strategy itself.  Thus, obtaining novel 5-HT6 receptor ligands from 






















Modifications of benzazepines at the C7 and C8 position by replacing the catechol moiety 
to improve the pharmacokinetics of such compounds has been attempted previously. A few early 
reports discussed the possibility of replacing the catecholic component by replacing the 7-hydroxy 
by a 7-halo group.233 The replacement of 7-hydroxy with halogens led to antagonistic activity of   
the studied benzazepines.  The continuation of this work was focused on replacing the catechol 
moiety with bioisosteres such as amines, amides and heterocycles in C7 or C8 positions.234 
Representatives of these compounds are shown in Figure 15.  
 
Figure 15.   Known C8 modifications. 
 
The binding affinity of these compounds were studied at human dopamine receptors.  7-m-
chlorophenyl (37) methylamino- and 7-(m- or o-toluoyl) (38 and 39) methylamino-substituted 
benzazepines displayed Ki values of 270 - 370 nM at the D1R. Replacing the 7- hydroxyl of 
benzazepine with an amino group (35) resulted in modest binding affinity of this compound (Ki 
value 330 nM). Substitution of the amino group with substituted aryl group (36) decreased the 
binding affinity slightly (756 nM) at the D1R. Another class of compounds with C8 modifications 
were also reported (40-42). Surprisingly, all the C8 modified compounds had binding affinity 
>10,000 nM.  Lack of affinity of compounds with C8 benzylamines, benzylalcohol and the 
heterocylic compound further solidified the importance of 8-hydroxy substitution. These 
compounds were also evaluated at human serotonin receptors with negligible affinities reported. 
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Given the modest affinity of these compounds for D1R, no pharmacokinetic studies of these 
compounds were reported in this study. 
In another attempt to improve pharmacokinetic profile of benzazepines, Wu and colleagues 
at Schering-Plough Research Institute modified the D15/D5R antagonist SCH 39166 (43) at C8 
position to synthesize series of compounds as shown in Figure 16 and studied their PK profile.235 
The H-bond donating ability of these compounds at the C8 position was kept intact by replacing 
the C8-hydroxy with benzimidazolones (43a and 43b), benzothiazolones (43c and 43d) and 
indazole 43e. The study showed that the compounds were active and selective towards D1R-like 
receptors. PK profiles of these compounds showed that the benzimidazolone 43a, lacking a 
phenolic group, displayed much higher plasma concentration in rats compared to 43 after oral 
dosing at 10 mg/kg and provided excellent oral bioavailability. Compound 43b with an extra 
hydrogen bond donor moiety displayed lower oral bioavailability. Similarly, the benzothiazolone 
43c and corresponding analog 43d displayed an extremely high AUC in rats. In contrast, the 
indazole 43e did not greatly improve the PK profile. 
 






2.2. Ligand Design 
 
Goal:   Use the benzazepine scaffold to study the effect of C7, C8, C3’ and C4’ functional group 
variations on D1R/D5R affinity and selectivity.  
 
The target analogs 44, 45, 46 and 47 are designed to be pharmacokinetically improved 
analogs of Fenoldopam (2) (Figure 17) with high D1R affinity.  Modifications at the C8 position 
provide isosteres of the catechol moiety and such modifications are expected to increase the 
metabolic stability of the proposed analogs. Substituents on the C1 phenyl ring will be varied to 
study the impact on affinity as well as to potentially optimize the physicochemical properties of 
the analogs. Although we have taken a conceptually similar (i.e. isosteric replacement) approach 
towards improving the pharmacokinetic properties of 1-phenylbenzazepines as that delineated in 
previous studies (i.e. Figures 15 and 16), the proposed ligands in our study are structurally unique 
from the previous studies in the following ways: 
a) A 6-Cl group (as present in Fenoldopam) is retained in the modified compounds herein 
to improve binding affinity of synthesized analogs.  A 6-Cl group is beneficial for D1R 
binding as established from previous SAR studies.236 
b) A 3’-Me substitution is retained in the analogs as, based on previous SAR studies on 
1-phenylbenzazepines, this was expected to afford strong affinity of the synthesized 
analogs towards D1R-like receptors.236 
c) As compared to the benzazepines in Figure 15, the compounds we propose to 
synthesize contain N-methyl or N-ally substituent groups at the N3 position (rather than 
an N-H group).  N-methyl and N-allyl groups are well tolerated for D1R affinity as 
established from previous studies.237 
d) Unlike the compounds in Figure 16, our compounds lack a C7 chloro group – a 
functionality which appears to favor antagonist rather than agonist function in the 
scaffold.238 
Analogs 44 consist of compounds with no C8 substitution, 7-methoxy and 7-hydroxy 
groups, 3’-Me and 4’-OMe and 4’-OH groups. These analogs lack metabolically liable groups as 
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compared to 2 which could improve their metabolic stability. However, lack of the 8-hydroxy 
group might negatively affect the D1R affinity of these compounds. Analogs from the 44 series 
are nitrated and aminated at C8 position to create compounds in the 45 series. The nitro and amino 
groups provide hydrogen bond donors and acceptors at the C8 position which may positively affect 
the binding affinities of these compounds.  
 
Figure 17.   Proposed modifications inspired by Fenoldopam (2). 
 
The amino compounds from series 45 are a gateway to the amide/urea series (46) and 
sulfonamide series (47). Replacement of the 8-hydroxy group with short alkyl chain amides, 
sulfonamides and urea are potential bioisosteric replacements for the C8 hydroxyl group in the 
catechol moiety of Fenoldopam. While the H-bonding ability of target analogs are intact at the C8 
position, amide, sulfonamide and urea functional groups could potentially improve the metabolic 
stability of the analogs as compared to Fenoldopam.  In this series of analogs, N3-Me and 3’-Me 
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groups are retained based on the previously established favorability of these substitutions for D1R 
affinity.237 
 
2.3. Synthesis  
The aldehyde (48) was converted to nitrostyrene (49) via Henry reaction using 
nitromethane and ammonium acetate in acetic acid. Compound 49 was then reduced with lithium 
borohydride to give a phenethylamine (50). Epoxidation of 51 was achieved with mCPBA to 
produce 52. The amine (50) was coupled with epoxide (52) to give aminoalcohol (53). Thereafter, 
53 was cyclized in the presence of trifluoroacetic acid and concentrated sulfuric acid to produce a 
benzazepine (54). O-demethylation of 54 produced 55. Compound 54 was diversified in the N-
position with methyl (57) and allyl groups (56) via reductive amination and SN2 reactions, 
respectively. The respective N-substituted analogs were demethylated using BBr3 to afford 








aReagents and conditions: (a) CH3NO2, NH4OAc, AcOH, reflux, 6h, 92%; (b) 1. LiBH4, TMSCl, 
anhyd. THF, reflux, 6h; 2. MeOH, 20%KOH, 45%; (c) 1. mCPBA, DCM, rt, 12h; 2. NaOH, rt, 
(88 - 96%); (d) Silica gel, THF, reflux, 24h; (53-78)%; (e) TFA, H2SO4 (18M), rt, 5h, (36-58)%; 
(f) BBr3, DCM, 0℃, 18h, (34-58)%.; (g) Allyl bromide, Et3N, DCM, rt, 18h, (55-63)%; (h) HCHO, 




Scheme 2 was deployed to functionalize the C8 position of substituted 1-
phenylbenzazepines synthesized in Scheme 1. In this regard, compound 57a (see Scheme 1) was 
demethylated to give a phenol 60 which was in turn nitrated at the C8 position to afford compound 
61. The nitro group of compounds 61 was reduced to o-aminophenol 62. Various amides (63), 
sulfonamides (64) and urea (65) were subsequently prepared from 62.  
 
 
aReagents and conditions: (a) BBr3, DCM, 0 ℃, 18h, (34-55) %; (b) conc. HNO3, AcOH, rt, 2h, 
(70-86) %; (c) 1. LiBH4, TMSCl, anhyd. THF, reflux, 6h; 2. MeOH, 20% KOH, (45-54) %; (d) 
(R’CO)2O, DCM, rt, 3h, (76-82) %; (e) sulfonic anhydride, DCM, rt, 3h, (34-40)%; (f) KOCN, 





2.4. Structure-activity correlations  
D1R, D2R and D5R binding assays were performed by the Psychoactive Drug Screening 
Program (PDSP).  The sequence of the screening process at the PDSP is outlined in Figure 18. 
Briefly, compounds were tested initially in a primary radioligand binding assays at each receptor.  
In the primary binding assays, the compounds were tested at a concentration of 10 µM. Compounds 
that displayed a minimum of 50% inhibition in the primary assays were advanced to secondary 
binding assays to determine Ki values at each receptor.   
 
 
Figure 18.   Sequence of screening process at PDSP. 
 
An example of primary binding assay data for selected compound from Scheme 2 is presented 
in Table 7. In primary binding assays, compounds are tested in triplicate or quadruplicate at a single 
concentration of 10 μM. Results are normalized and transformed to percentage values. Compounds 
with a minimum of 50% inhibition at 10 μM are tagged for secondary radioligand binding assay 
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to determine equilibrium binding affinity at specific target receptors. Compounds selected for 
secondary binding assays are tested at 11 concentrations (0.1, 0.3, 1, 3, 10, 30, 100, 300 nM, 1, 3, 
10 μM) and in triplicate.  Compounds with strong affinity (Ki < 100 nM) may be further evaluated 
for functional activity. 
In secondary functional assays, potential agonist hits are subjected to full concentration-
response studies to determine their efficacy and potency. Potential antagonist hits are subjected to 
full concentration-response studies to determine IC50 values against EC50 to EC80 concentrations 
of a reference agonist. For studies of ligand functional selectivity and bias among multiple 
signaling pathways, concentration-response results are analyzed using the Black and Leff 
operational model to quantify bias. Secondary functional assays provide maximum activation or 
inhibition after normalization (in percentage values), concentration range used in the assay (lowest 
and highest concentrations), Hill slope of the concentration-response curve and corresponding 
potency. 
Results of the secondary binding assay are presented in Table 8 for analogs derived from 
Scheme 1. As expected, the tested compounds were selective towards D1R and D5R.  Study of 
receptor affinities of evaluated compounds shows the impact of C7 and C8 substitutions in the 
synthesized benzazepines on dopamine receptor affinities. Compounds with a 7-methoxy 
substituent group (54a-c, 56a-c, 57a-c) showed no affinity towards the dopamine receptors. 
However, compounds with a 7-hydroxy moiety (55a-c, 58a-c, 59a-c) showed modest affinity 
towards D1R-type receptors. Overall, the data suggests that a C7 hydroxy substituent on the 










Table 7.  Primary binding assay data for selected compounds from Scheme 2 at D1R, D2R 
and D5R. 
 
aExperiments carried out in quadruplets. 
 
C7 methoxy substituted compounds (54a, 56a, 57a, 54b, 56d, 57b, 54c, 56c and 57c) 
showed no affinity towards any of the dopamine receptors. 3’-Me (54b-59b), 4’-OMe (54c, 56c 
    Mean % Inhibitiona 
Cmpd # R R’ D1R D2R D5R 
63a H Me 47.39 12.45 39.96 
63b H n-butyl 79.79 23.89 28.46 
63c H isobutyl 77.43 22.25 27.12 
63d H acryl 74.04 12.8 39.34 
63e Me Me 89.05 13.88 43.87 
63f Me n-butyl 81.73 5.22 53.6 
63g Me isobutyl 67.43 -0.36 21.39 
63h Me acryl 65.74 8.16 37.65 
64 H SO2CH3 95.39 -3.15 83.63 
65a Me CONH2 78.06 -2.22 46.14 
65b H CONH2 45.21 1.14 34.63 
(+)-Butaclamol   86.25   
Haloperidol    98.6  
SKF 83566     99.13 
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and 57c) and 4’-OH (55c, 58c and 59c) substitutions seem to have little effect on the overall affinity 
of these compounds towards D1R. Compound 58a (Ki = 30.1 nM) with the highest affinity towards 
D1R has 7-hydroxy, N-Me substitutions with no substituent in the 1-aryl ring. Compounds 58b 
and 58c (Ki = 77.95 and 160.9 nM respectively) also have 7-hydroxy, N-Me substitutions with a 
methyl group in the 3’ position and a hydroxy in the 4’ position, respectively. From the SAR 
observations, it can be inferred that C7 hydroxy and N-alkyl substituted compounds showed 
affinity towards D1R and D5R with N-methyl substitution showing more than 3-fold higher 
affinity as compared to an N-allyl group. Moreover, it can be posited that 7-hydroxy and N-Me 
substitutions are more important for D1R affinity than the substituents in the 1-phenyl ring in this 
series of analogs.  
The binding affinity of analogs synthesized from Scheme 2 were assessed at dopamine 
D1R, D2R and D5R (data in Table 9 as Ki values in nM).  Nitro or amine substitution at the C8 
position of 1-phenylbenzazepines resulted in no significant improvement in affinity of these 
compounds as compared to traditional catechol benzazepines. Compound 61d with a nitro group 
at the C8 position was found to be the most active (Ki = 38.1 nM) towards D1R. This Ki value is 
comparable to compound 58a (Ki = 30.1 nM) from Table 8. Compound 61d notably has a 3’-Me 
group, a favorable substitution for D1R affinity. The presence of an amine group at the C8 position 
allowed for modest affinity towards D1R-type receptors (Ki = 71.9 for 62c and 210.4 nM for 62b 
at D1R and D5R respectively). Overall, no significant selectivity and affinity trend is observed for 
the analogs in Table 9. 
Binding affinity of the amide (63a - 63h), sulfonamide (64) and urea (65a and 65b) analogs 
were also assessed at D1R, D2R and D5R (Table 10). The studied compounds are D1-type 
selective with no affinity towards D2R. Comparing 3’-Me substituted (63e-h and 65a) vs. 3’-
unsubstitued (63a-d and 65b) amides, the former groups of analogs show higher affinity towards 
D1R. Among 3’-unsubstituted compounds, acrylamide (63d) was found to be the most active (Ki 
= 1497.9 nM) followed by urea (65b), n-butylamide (63b) and isobutylamide (63c). Among 3’Me 
substituted analogs, n-butylamide had the highest affinity (Ki = 634.4 nM) towards D1R. Overall, 
the amides (63a – 63h) and urea (65a and 65b) showed comparable D1R affinities while the 




Table 8.  Binding affinities of C7, N3, C3’ and C4’ modified arylbenzazepines at 
D1R, D2R and D5R. 
 
     Ki (nM)a 
Cmpd # R R’ R’’ R’’’ D1Rb D2Rc D5Rd 
54a Me H H H na na na 
55a H H H H na na 470 
56a Me Allyl H H na na na 
57a Me Me H H na na na 
58a H Me H H 30.1 ± 1.3 na 187.4 ± 7.3 
59a H Allyl H H 102 na 297 
54b Me H Me H na na na 
55b H H Me H na na na 
56b Me Allyl Me H na na na 
57b Me Me Me H na na na 
58b H Me Me H 77.9 ± 4.1 na 165.2 ± 4.9 
59b H Allyl Me H 281.4 ± 9.4 na 740.6 ± 12.5 
54c Me H H OMe na na na 
55c H H H OH na na na 
56c Me Allyl H OMe na na na 
57c Me Me H OMe na na na 
58c H Me H OH 160.9 ± 5.5 na 412.9 ± 9.8 
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aExperiments carried out in triplicate; b [3H] SCH23390 used as radioligand; c [3H]N-methylspiperone used as radioligand; d [3H]SCH23390 used as radioligand;   
ena 
– not active (<50% inhibition in a primary assay when tested at 10µM). 
 




aExperiments carried out in triplicate; b [3H]SCH23390 used as radioligand; c [3H]N-methylspiperone used as radioligand; d [3H]SCH23390 used as radioligand;   
ena 
– not active (<50% inhibition in a primary assay when tested at 10µM. 
 
 
59c H Allyl H OH na na na 
(+)-Butaclamol     4.0 ± 0.2   
Haloperidol      5.5 ± 0.3  
SKF 83566       3.9 ± 0.2 
     Ki (nM)a. 
Cmpd # R R’ R’’ D1Rb D2Rc D5Rd 
61a NO2 H H na na na 
61b NO2 Me H na na na 
61c NO2 Me Me 4354.1 ± 67.3 na na 
61d NO2 H Me 38.1 ± 2.0 na 97.9 ± 3.6 
62b NH2 Me H 210.4 ± 7.1 na 269.8 ± 8.4 
62c NH2 Me Me 71.9 ± 3.9 na 146.4 ± 5.8 
(+)-Butaclamol    4.0 ± 0.2   
Haloperidol     5.5 ± 0.3  
SKF 83566      3.9 ± 0.2 
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aExperiments carried out in triplicate; b [3H]SCH23390 used as radioligand; c [3H]N-methylspiperone used as radioligand; d [3H]SCH23390 used as radioligand;   
ena 






    Ki (nM)a. 
Cmpd # R R’ D1Rb D2Rc D5Rd 
63a H Me na na na 
63b H n-butyl 1970.1 ± 41.4 na na 
63c H isobutyl 2938.3 ± 36.2 na na 
63d H acryl 1497.9 ± 18.9 na na 
63e Me Me 1364.9 ± 14.0 na na 
63f Me n-butyl 634.4 ± 12.5 na 2959.3 ± 29.6 
63g Me isobutyl 4734.8 ± 55.9 na na 
63h Me acryl 4979.6 ± 61.3 na na 
64 H SO2CH3 113.7 ± 5.1 na 165.7 ± 6.8 
65a Me CONH2 na na na 
65b H CONH2 1761.9 ± 17.6 na na 
(+)-Butaclamol   4.0 ± 0.2   
Haloperidol    5.5 ± 0.3  
SKF 83566     3.9 ± 0.2 
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2.4.1. Functional Assay 
 The most active compound from Table 8 (compound 58a) was further tested in agonist and 
antagonist mode with a GPCR Biosensor Assay. The targeted pathway for this assay is cAMP 
secondary messenger pathway that monitors the activation of a GPCR via Gi and Gs secondary 
messenger signaling in a homogenous, non-imaging assay format.  β-galactosidase (β-Gal) is used 
as functional reporter in the assay. β-Gal fused to cAMP competes with cAMP generated by cells 
to bind to a cAMP-specific antibody. Active β-Gal is formed by complementation of exogenous 
ligand to any unbound cAMP. Active enzyme coverts a chemiluminescent substrate, generating 
an output signal detectable on a standard microplate reader. The graphical representation of GPCR 
Biosensor Assay is shown in Figure 19. 
 The agonist control for the assay was dopamine, the endogenous ligand for D1R 
whereas SCH 39166 (Ecopipam) was selected as the antagonist control. The results of the assay 
are shown in Table 11. The assay revealed compound 58a to be a D1R antagonist with modest 
IC50 value of 130.32 nM which is ~78-fold less potent as compared to the control antagonist, SCH 
39166 (Ecopipam).  
 
 





Table 11.  Activity of 58a in D1R cAMP functional assays. 
 
 
Compound Assay Format Result RC50 (nM)  Hill Max Response 
Dopamine Agonist EC50 12.30  1.28 103.01 
SCH 39166 Antagonist IC50 1.67  1.14 102.24 
58a Agonist EC50 >10,000   17.22 




In conclusion, we evaluated structure–activity relationships on two classes of modified 
benzazepines. As compared to Fenoldopam, which served as an inspiration for the designed 
analogs, the catechol (7-hydroxy/8-hydroxy) moiety was replaced with 7-methoxy/8-H 
substitutions.  In addition, the molecules contained 3’-Me, 4’-methoxy and 4’-OH groups on the 
1-phenyl ring of the benzazepine in order to analyze the effect of these substitutions on D1R 
affinity. The accumulated data demonstrates the importance of the catechol moiety for D1R-like 
receptor affinity. Compounds with a 7-methoxy group showed no activity towards D1R whereas 
compounds with 7-hydroxy group showed modest to high affinity towards D1R-type receptors. 
These findings reaffirm the significance of having a hydrogen bond donor group at C7.  
Based on the affinity data from Table 7, further modifications on compound 58a were 
made. Keeping the 7-hydroxy substitution, 8-nitro and 8-amino groups were explored as potential 
isosteres of the 8-hydroxy group. Affinity data showed that replacement of the 8-hydroxy with a 
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nitro or amino group did not significantly improve D1R affinity. For C8-nitro functionalized 
analogs, there is a lack of hydrogen-bond donor which is in direct contrast with C8-hydroxy 
substitution of traditionally most active 1-phenylbenzazepines.   Compared to a hydroxy group, 
nitro group is larger which might have hindered the ability of the nitro analogs to have good 
interactions with the binding pocket amino-acid residues.  
Further modifications of amino compounds from Table 9 were carried out. 7-hydroxy and 
N-Me substitution were kept intact based on their favorable effect on binding affinity. Diverse 
functionalization was made on the 8-amino group.  The affinity of the 8-amido/7-hydroxy analogs 
showed that the conversion of the 7-amino group into an amide was unfavorable for the activity at 
the targeted receptors. The most active compound in this series, 64 had lower D1R affinity as 
compared to original aminophenol 62c. A possible reason for the decrease in affinity might be 
attributed to the larger size of the amides as compared to their parent amines. Having C8-amide 
substitution provides a possibility of conformational isomerism called “rotamers” which are 
common with amide groups. The possibility of this low-energy side-chain conformations can also 
play a role in ligand-receptor interaction which in-turn can have possible effect on affinity of 
studied amide analogs. These results, however, are not definitive. More functionalization studies 
should be conducted at the C8 position with isosteres.  Receptor docking studies may also be useful 
to enhance our understanding of the SAR in this series.  
A brief representation of trends observed in this study are shown in Figure 20.  The SAR 
trends shown in Figure 20 will benefit from further structural diversifications of the benzazepine 
scaffold in future; this work can be used as a foundation for such further studies. 
 
 






General experimental procedures 
Unless otherwise stated, chemicals were purchased from Fischer Scientific (USA) and used 
without further purification. Reactions were carried out in air-dried glassware under a nitrogen 
atmosphere. HRESIMS spectra were obtained using an Agilent 6520 QTOF instrument. 1H NMR 
and 13C NMR spectra were recorded using Bruker DPX-600 spectrometer (operating at 400 or 500 
or 600 MHz for 1H; 101 or 125 or 150 MHz, respectively, for 13C) using CDCl3, Acetone-d6, 
DMSO-d6 or Methanol-d4 as solvents. Tetramethylsilane (δ 0.00 ppm) served as an internal 
standard in 1H NMR and CDCl3 (δ 77.0 ppm) in 
13C NMR as solvent. Chemical shift (δ 0.00 ppm) 
values are reported in parts per million and coupling constants in Hertz (Hz). Splitting patterns are 
described as singlet (s), doublet (d), triplet (t), and multiplet (m). Reactions were monitored by 
TLC with Whatman Flexible TLC silica gel G/UV 254 precoated plates (0.25 mm). TLC plates 
were visualized by UV (254 nm). Silica gel column chromatography was performed with silica 
gel 60 (EMD Chemicals, 230-400 mesh, 0.063 mm particle size). 
 
General procedure A: epoxidation of styrenes  
To a stirred solution of desired styrene (1 equiv.) in DCM (125 mL) was slowly added 
mCPBA (2 equiv.) at 0 °C and the resulting reaction mixture was warmed to rt and stirred for 12 
h. The progress of the reaction was monitored by TLC. After completion of the reaction, the 
reaction mixture was quenched with aqueous NaOH (3M, 100 mL) and extracted with DCM (3*50 
mL). The combined organic layer was washed with brine, dried over anhydrous Na2SO4 and 






General procedure B: coupling of 2-(4-(benzyloxy)-3-methoxyphenyl)ethan-1-amine with 
epoxides 
To a solution of epoxide (1 equiv.) and amine (1.5 equiv.) in anhydrous THF (100 mL) 
was slowly added Bis(trifluoromethane)sulfonimide lithium (1.1 equiv.) at rt and the resulting 
reaction mixture was refluxed for 24 h. After completion (the reaction progress was monitored by 
TLC), THF was evaporated, the reaction mixture was quenched with saturated NaHCO3 (25 mL) 
and extracted with EtOAc (3 x 30 mL). The combined organic phase was dried with Na2SO4 and 
concentrated to give a crude viscous liquid, which was purified by silica gel column 
chromatography to yield the purified product as a viscous oil.  
 
General procedure C: amino alcohol cyclization 
To a stirred solution of the respective amino – alcohols (1 equiv.) in TFA (30 mL) was 
added 18 M H2SO4 (cat.) at rt and the resulting reaction mixture was stirred for 5 h at rt. Anhydrous 
NaOAc (2 equiv.) was added and stirred for an additional 15 min. TFA was evaporated and the 
reaction mixture was neutralized with 14 M NH4OH to give a solid residue. The residue was 
dissolved in EtOAc (25 mL), washed with water and brine. The organic phase was dried over 
Na2SO4 and concentrated under reduced pressure to give a crude residue, which was purified by 
silica gel column chromatography to give the pure product.  
 
General procedure D: N-methylation 
To a stirred solution of secondary amine (1 equiv.) in acetonitrile (100 mL) was added 
paraformaldehyde (3 equiv.) and the reaction mixture was stirred at rt for 30 mins. Sodium 
triacetoxyborohydride (1.5 equiv.) was added to the reaction mixture and the resulting reaction 
mixture was stirred for 12 h at the same temperature. After completion of the reaction (monitored 
by TLC), it was quenched with saturated NaHCO3 (20 mL), washed with water and extracted with 
EtOAc (2 x 25 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure to give 
the crude compound. This crude compound was purified by silica gel flash chromatography to 
afford the purified N – methylated product.  
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General procedure E: N-allylation 
To a stirred solution of secondary amine (1 equiv.) in acetonitrile (80 mL) was added TEA 
(2 equiv.) followed by allyl bromide (1.5 equiv.) at rt and the resulting reaction mixture was stirred 
at the same temperature for 12 h. After completion of the reaction (monitored by TLC), the reaction 
mixture was quenched with water, washed with NaHCO3 (25 mL) and extracted with EtOAc (2 x 
25 mL). The combined organic layer was dried over anhydrous Na2SO4 and evaporated under 
vacuum to give the crude compound, which was purified by silica gel flash chromatography to 
give the pure N – allylated product. 
 
General procedure F: O-demethylation with BBr3 
To a stirred solution of compound (1 equiv.) in DCM (20 mL) was slowly added BBr3 (4 
equiv.) at 0 oC and the reaction mixture was warmed to rt and stirred at the same temperature for 
18 h. After completion, ice water was added to the reaction mixture, and the mixture allowed to 
stir for 30 min.  The obtained precipitate was filtered to give the pure compound. 
 
General procedure G: O-nitration of phenol 
Substituted phenol (1 equiv.) was dissolved in acetic acid (5 mL) and fuming nitric acid (1 
equiv.) slowly added to the solution. The reaction was stirred at rt for 2 h. The completion of the 
reaction was confirmed by the TLC. Acetic acid was evaporated under vacuum to obtain a yellow 
residue. The crude residue was basified with sat. NaHCO3. The final product was obtained as a 
yellow solid which was purified by silica gel flash chromatography. 
 
General procedure H: reduction of o-nitrophenol 
Lithium borohydride (4 equiv.) was suspended in anhyd. THF under nitrogen and the 
suspension was cooled to 0 ℃. Trimethyl chlorosilane was added to the mixture and stirred for 15 
min.  The 2-nitrophenol substrate was added slowly to the reaction mixture in portions. The 
reaction was refluxed overnight. After the completion of the reaction as confirmed by TLC, it was 
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cooled to 0 ℃ and quenched with methanol. The clear solution obtained was evaporated under 
vacuum to get a viscous residue. The residue was basified with sat. NaHCO3 to obtain a white 
solid as product which was purified using silica gel flash chromatography.  
 
General procedure I: amidation of o-aminophenol 
Starting material (o-aminophenol) (1 equiv.) was dissolved in DCM (20 mL) and to the 
solution was added the corresponding anhydrides (1.5 equiv.). The reaction was stirred for 3 h. 
The completion of the reaction was confirmed by TLC. The mixture was diluted with hexane to 
obtain a cloudy solid that was filtered to give an off-white solid. The final product was purified 
using silica gel flash chromatography to obtain a white solid as pure product.  
 
(E)-2-chloro-1-methoxy-3-(2-nitrovinyl)benzene (49): To a stirred solution of 48 in acetic acid, 
CH3NO2 and NH4OAc were added simultaneously. The solution was refluxed for 6 h. After 
completion, the crude mixture was dissolved in EtOAc and washed with water and brine. The 
combined organic layer was dried over Na2SO4 and evaporated to give the desired product 49 as a 
yellow solid. Yield: 92%, mp: 91 - 95℃. 
1H NMR (500 MHz, Acetone-d6) δ 9.25 (s, 1H), 8.41 (d, J = 13.6 Hz, 1H), 7.97 (d, J = 13.6 Hz, 
1H), 7.49 (dd, J = 7.75 Hz, 1.05 Hz, 1H), 7.30 (t, J = 15.9 Hz, 1H), 7.22 (dd, J = 8.1, 1.3 Hz, 1H). 
13C NMR (125 MHz, Acetone-d6) δ 160.3, 136.5, 134.8, 131.4, 126.8, 118.5, 116.0, 113.5, 56.2 
ppm. HRESIMS calculated for C9H9ClNO3 [M+H]
+ 213.0193, found 213.0163. 
 
2-(2-chloro-3-methoxyphenyl)ethan-1-amine (50): To a suspension of LiBH4 in anhyd THF, 
TMSCl was added drop-wise under nitrogen. The mixture was cooled to 0 ℃ and stirred for 10 
min. Compound 49 was added very slowly to the mixture. The reaction was brought to rt and 
heated to 60 ℃ for 6 h. After completion, it was cooled, quenched with methanol, and basified 
with 20% KOH. The crude mixture was dissolved in EtOAc and washed with water and brine. The 
combined organic layer was dried over Na2SO4 and evaporated to give the crude product 50 as a 
dark yellowish liquid. Yield: 45%. 
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1H NMR (500 MHz, CD3OD) δ 7.05 (t, J = 13 Hz, 1H), 6.89 (dd, J = 6.73, 1.15 Hz, 1H), 6.78 (dd, 
J = 6.28, 0.95 Hz, 1H), 2.87 (m, 2H), 2.82 (m, 2H). 13C NMR (150 MHz) δ 153.9, 139.1, 127.1, 




2-phenyloxirane (52a): Synthesized according to general procedure A. White viscous liquid. 
Yield: 95%. 
 1H NMR (500 MHz, Acetone-d6) δ 7.49 (d, J = 7.1 Hz, 2H), 7.43 (m, 3H), 7.25 (dd, J = 6.73, 1.95 
Hz, 2H), 7.03 (dd, J = 6.75, 1.95 Hz, 2H), 5.12 (s, 2H), 3.82 (dd, J = 3.86, 2.7 Hz, 1H), 3.06 (dd, 
J = 5.4, 4.1 Hz, 1H), 2.78 (dd, J = 5.43, 2.55 Hz, 1H). 13C NMR (150 MHz) δ 136.6, 127.4, 127.0, 
126.8, 124.6, 124.2, 58.3, 48.6 ppm. HRESIMS calculated for C8H9O [M+H]
+ 121.0575, found 
121.0575. 
 
2-(m-tolyl)oxirane (52b): Synthesized according to general procedure A. Clear liquid. Yield: 
98%. 
1H NMR (600 MHz, CDCl3) δ 7.13 (t, J = 7.9 Hz, 1H), 7.01 (d, J = 7.7 Hz, 1H), 6.98 (d, J = 5.5 
Hz, 2H), 3.74 – 3.70 (m, 1H), 3.02 (dd, J = 5.5, 4.2 Hz, 1H), 2.69 (dd, J = 5.6, 2.6 Hz, 1H), 2.24 
(s, 2H) ppm. 13C NMR (150 MHz, CDCl3) δ 138.2, 137.5, 129.0, 128.4, 126.0, 122.7, 52.4, 51.1, 
21.4 ppm. HRESIMS calculated for C17H19ClNO [M+H]
+ 288.1077, found 288.1076. 
 
2-(4-methoxyphenyl)oxirane (52c): Synthesized according to general procedure A. Yield: 92%.  
1H NMR (600 MHz, CDCl3) δ 7.03 (d, J = 9.0 Hz, 1H), 6.71 (d, J = 8.9 Hz, 1H), 3.64 (dd, J = 4.2, 
2.6 Hz, 1H), 3.62 (s, 2H), 2.94 (dd, J = 5.4, 3.9 Hz, 1H), 2.63 (dd, J = 5.5, 2.5 Hz, 1H) ppm. 13C 
NMR (150 MHz, CDCl3) δ 159.7, 129.4, 126.8, 114.0, 55.2, 52.2, 50.9 ppm. HRESIMS calculated 
for C9H11O2 [M+H]




6-chloro-7-methoxy-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine (54a): Synthesized 
according to general procedure C. White solid. Yield: 46%. mp: 156.4 – 158.0 °C.  
 1H NMR (600 MHz, CDCl3) δ 7.38 (t, J = 15 Hz, 2H), 7.32 (d, J = 7.32 Hz, 1H), 7.12 (d, J = 8.50 
HZ, 2H) 6.64 (d, J = 8.64 Hz, 1H) 6.44 (d, J = 8.70 Hz, 1H) 4.67 (d, J = 9.6 6Hz, 1H) 3.84 (s, 3H), 
3.70 (m, 2H), 3.50 (m, 1H), 3.7 (m, 2H), 2.92 (t, J = 24.06 Hz, 1H) ppm. 13C NMR (150 MHz, 
CDCl3) δ 154.1, 139.8, 137.2, 135.7, 129.2, 128.2, 127.6, 127.2, 122.7, 109.8, 77.2, 77.0, 76.8, 
56.2, 50.6, 45.6, 44.7, 27.4 ppm. HRESIMS calculated for C17H19ClNO [M+H]
+ 288.1077, found 
288.1076. 
 
6-chloro-7-methoxy-1-(m-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (54b): Synthesized 
according to general procedure C. White solid. Yield: 46%. mp: 180.4 – 181.8 °C. 
1H NMR (400 MHz, CDCl3) δ 7.28 (s, 1H), 7.26 (d, J = 7.6 Hz, 1H), 7.13 (d, J = 7.5 Hz, 1H), 6.94 
(s, 1H), 6.91 (d, J = 7.8 Hz, 1H), 6.67 (d, J = 8.7 Hz, 1H), 6.53 (d, J = 8.7 Hz, 1H), 4.61 (d, J = 
9.3 Hz, 1H), 3.86 (s, 3H), 3.74 (d, J = 12.9 Hz, 1H), 3.66 (dd, J = 16.1, 7.0 Hz, 1H), 3.51 (dd, J = 
13.0, 7.2 Hz, 1H), 3.45 – 3.36 (m, 2H), 3.00 – 2.92 (m, 1H), 2.35 (s, 3H) ppm. 13C NMR (100 
MHz, CDCl3) δ 154.5, 139.3, 136.3, 134.2, 129.3, 128.6, 128.4, 128.2, 124.7, 120.7, 118.2, 110.3, 





Synthesized according to general procedure C. Yield: 47%. mp: 151.3 – 152.7 °C. 
1H NMR (400 MHz, DMSO) δ 7.15 (d, J = 8.6 Hz, 1H), 7.00 (d, J = 8.6 Hz, 1H), 6.92 (d, J = 8.7 
Hz, 1H), 6.53 (d, J = 8.7 Hz, 1H), 4.61 (t, J = 5.5 Hz, 1H), 3.81 (s, 1H), 3.80 (s, 3H), 3.78 (s, 3H), 
3.76 (s, 1H), 3.72 (dd, J = 8.1, 3.7 Hz, 2H), 3.56 (d, J = 5.5 Hz, 1H), 3.01 (t, J = 10.3 Hz, 1H) ppm. 
13C NMR (100 MHz, DMSO) δ 158.7, 153.9, 137.6, 136.3, 132.5, 129.7, 128.0, 124.7, 121.5, 
118.3, 114.8, 110.8, 56.6, 55.5, 49.6, 44.72, 44.29, 27.2 ppm. HRESIMS calculated for 
C18H21ClNO2 [M+H]




6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (55a): Synthesized according to 
general procedure F. Off-white solid. Yield: 43%. mp: 134.6 – 135.8 °C. 
 1H NMR (600 MHz, CD3OD) δ 7.42 (t, J = 15.24 Hz, 2H), 7.34 (t, J = 12.34 Hz, 1H), 7.21 (d, J 
= 7.45 HZ, 2H) 6.71 (d, J = 8.46 Hz, 1H) 6.54 (d, J = 8.84 Hz, 1H) 4.67 (d, J = 2.14 Hz, 1H) 3.73 
(m, 2H), 3.53 (m, 3H), 3.16 (t, J= 10.74, 3H). 13C NMR (150 MHz, CD3OD) δ 162.7, 162.4, 154.1, 
139.0, 137.3, 135.73, 129.2, 128.2, 127.6, 127.2, 122.7, 109.8, 56.2, 50.6, 45.6, 44.7, 27.4. 
HRESIMS calculated for C16H17ClNO [M+H]
+ 274.0920, found 274.0922. 
 
6-chloro-1-(m-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (55b): Synthesized according to 
o-demethylation procedure F. Grey solid. Yield: 31%. mp: 122.3 – 124.2 °C. 
1H NMR (600 MHz, DMSO) δ 7.31 (t, J = 7.6 Hz, 1H), 7.15 (d, J = 7.6 Hz, 1H), 7.05 (s, 1H), 6.99 
(d, J = 7.5 Hz, 1H), 6.75 (d, J = 8.5 Hz, 1H), 6.38 (d, J = 8.5 Hz, 1H), 4.61 – 4.56 (m, 1H), 3.54 
(d, J = 4.9 Hz, 2H), 3.47 – 3.41 (m, 2H), 3.36 – 3.30 (m, 1H), 2.99 (t, J = 10.7 Hz, 1H), 2.33 (s, 
3H). 13C NMR (150 MHz, DMSO) δ 151.7, 140.2, 137.7, 136.9, 133.8, 128.5, 128.4, 127.4, 127.0, 
124.9, 119.9, 113.6, 48.8, 44.8, 43.6, 26.7, 20.8 ppm. HRESIMS calculated for C17H19ClNO 
[M+H]+ 288.1077, found 288.1100. 
 
6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (55c): Synthesized 
according to general procedure F. Grey solid. Yield: 38%. mp: 135.8 – 136.9 °C. 
1H NMR (400 MHz, DMSO) δ 6.96 (d, J = 8.1 Hz, 1H), 6.76 (d, J = 8.0 Hz, 1H), 6.69 (d, J = 8.3 
Hz, 1H), 6.43 (d, J = 8.4 Hz, 1H), 5.76 (s, 1H), 4.31 (d, J = 5.0 Hz, 1H), 3.25 – 3.11 (m, 1H), 3.09 
– 2.90 (m, 1H), 2.88 – 2.79 (m, 1H), 2.68 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 155.6, 136.3, 
129.7, 129.2, 129.1, 128.9, 126.7, 126.3, 126.2, 116.1, 75.0, 59.0, 56.3, 28.9 ppm. 
 HRESIMS calculated for C16H17ClNO2 [M+H]
+ 290.0870, found 290.0879. 
 
3-allyl-6-chloro-7-methoxy-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine (56a): 
Synthesized according to general procedure E. White solid. Yield: 43%. mp: 162.5 – 163.2 °C. 
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 1H NMR (500 MHz, CDCl3) δ 7.35 (t, J = 14.9 Hz, 2H), 7.26 (d, J = 7.32 Hz, 1H), 7.16 (d, J = 
7.65 Hz, 2H) 6.61 (d, J = 8.55 Hz, 1H) 6.52 (d, J = 8.50 Hz, 1H) 5.87 (m, 1H) 5.14 (t, J = 29.05 
Hz, 2H) 4.32 (d, J = 8.35 Hz, 1H) 3.84 (s, 3H), 3.41 (m, 1H), 3.14 (m, 4H), 2.94 (m, 2H). 
HRESIMS calculated for C20H23ClNO [M+H]
+ 328.1390, found 328.1376. 
 
3-allyl-6-chloro-7-methoxy-1-(m-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (56b): 
Synthesized according to general procedure E. Yield: 58%. mp: 172.1 – 173.8 °C. 
1H NMR (400 MHz, CDCl3) δ 7.28 (s, 1H), 7.26 (d, J = 7.5 Hz, 1H), 7.10 (d, J = 7.5 Hz, 1H), 7.00 
(s, 2H), 6.64 (d, J = 8.6 Hz, 1H), 6.55 (d, J = 8.6 Hz, 1H), 5.92 (td, J = 16.9, 6.6 Hz, 1H), 5.20 (t, 
J = 12.3 Hz, 2H), 4.34 (d, J = 8.4 Hz, 1H), 3.87 (s, 3H), 3.49 (dd, J = 14.6, 7.4 Hz, 1H), 3.25 – 
3.11 (m, 4H), 3.03 (dd, J = 10.1, 9.7 Hz, 1H), 2.92 (dd, J = 11.8, 9.0 Hz, 1H), 2.47 – 2.39 (m, 1H), 
2.37 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 153.4, 143.0, 140.1, 138.3, 138.1, 134.9, 134.85, 
129.1, 128.4, 127.2, 126.7, 125.3, 122.1, 118.37, 108.8, 62.4, 60.3, 56.1, 54.0, 49.3, 30.5, 21.5 
ppm. HRESIMS calculated for C21H25ClNO [M+H]
+ 342.1546, found 342.1600. 
 
3-allyl-6-chloro-7-methoxy-1-(4-methoxyphenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (56c): 
Synthesized according to general procedure E. Yield: 61%. mp: 155.4 – 157.1 °C. 
1H NMR (400 MHz, CDCl3) δ 7.07 (d, J = 8.7 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 6.70 (d, J = 8.7 
Hz, 1H), 6.58 (d, J = 8.2 Hz, 1H), 5.95 (m, 1H), 5.56 (dd, J = 22.4, 13.6 Hz, 2H), 4.60 (d, J = 9.6 
Hz, 1H), 3.93 (dd, J = 9.9, 3.5 Hz, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.85 – 3.82 (m, 2H), 3.81 (d, J 
= 3.8 Hz, 1H), 3.72 (d, J = 6.3 Hz, 3H), 3.40 (dd, J = 16.4, 10.7 Hz, 2H). 13C NMR (126 MHz, 
Acetone) δ 159.9, 155.2, 137.7, 130.1, 128.9, 126.4, 125.7, 124.8, 122.93, 122.33, 119.7, 115.42, 
115.34, 111.2, 61.9, 56.6, 55.6, 54.0, 30.4, 29.3, 27.8 ppm. HRESIMS calculated for C21H25ClNO2 
[M+H]+ 358.1496, found 358.1496. 
 
6-chloro-7-methoxy-3-methyl-1-(m-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (57b): 
Synthesized according to general procedure D. Yield: 81%. mp: 174.5 – 176.1 °C. 
1H NMR (500 MHz, Acetone) δ 7.31 (t, J = 7.6 Hz, 2H), 7.18 (d, J = 7.6 Hz, 1H), 7.09 (s, 1H), 
7.04 (d, J = 7.7 Hz, 1H), 6.91 (d, J = 8.6 Hz, 1H), 4.77 (d, J = 10.1 Hz, 1H), 3.88 (s, 3H), 3.81 – 
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3.72 (m, 2H), 3.70 – 3.61 (m, 1H), 3.53 (dd, J = 15.9, 10.2 Hz, 2H), 3.25 (dd, J = 20.5, 8.9 Hz, 
1H), 3.09 (s, 3H), 2.33 (s, 3H), 2.31 – 2.26 (m, 1H) ppm. 13C NMR (125 MHz, Acetone) δ 155.1, 
141.3, 139.4, 138.1, 129.8, 128.8, 128.3, 126.2, 122.8, 122.3, 119.7, 111.0, 61.5, 56.6, 55.9, 46.6, 
46.3, 28.2, 21.5 ppm. HRESIMS calculated for C19H23ClNO [M+H]
+ 316.1390, found 316.1390. 
 
6-chloro-7-methoxy-1-(4-methoxyphenyl)-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine 
(57c):  Synthesized according to general procedure D. Yield: 82%. mp: 155.4 – 157.1 °C. 
1H NMR (500 MHz, Acetone) δ 7.16 (d, J = 8.6 Hz, 2H), 6.94 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.6 
Hz, 1H), 6.66 (d, J = 7.7 Hz, 1H), 4.44 – 4.39 (m, 1H), 3.90 – 3.87 (m, 1H), 3.85 (s, 3H), 3.81 (s, 
3H), 3.76 (d, J = 2.3 Hz, 1H), 3.24 (dd, J = 14.6, 9.5 Hz, 1H), 3.10-3.14 (m, 2H), 3.00 – 2.89 (m, 
1H), 2.64 – 2.55 (m, 1H), 2.51 (s, 3H). 13C NMR (125 MHz, Acetone) δ 211.8, 206.6, 159.2, 154.6, 
140.2, 130.1, 128.0, 124.8, 122.5, 122.2, 119.7, 117.1, 114.7, 110.1, 62.8, 56.66, 56.45, 55.5, 48.6, 
47.4 ppm. HRESIMS calculated for C19H23ClNO2 [M+H]
+ 333.1339, found 333.1320. 
 
6-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (58a): Synthesized 
according to general procedure F. Grey solid. Yield: 28%. mp: 143.5 – 145.1 °C. 
1H NMR (600 MHz, CDCl3) δ 7.34 (t, J = 14.8 Hz, 2H), 7.26 (t, J = 10.4 Hz, 1H), 7.16 (d, J = 7.6 
HZ, 2H) 6.69 (d, J = 8.7 Hz, 1H) 6.46 (d, J = 8.2 Hz, 1H) 4.33 (d, J = 8.4 Hz, 1H) 3.34 (m, 1H), 
3.18 (m, 2H), 3.10 (m, 2H) 2.80 (s, 3H) 13C NMR δ 149.8, 142.9, 138.9, 137.8, 128.6, 128.3, 127.3, 
126.5, 120.2, 112.9, 62.6, 55.9,49.2, 47.4, 30.8 ppm. C17H19ClNO [M+H]
+ 288.1077, found 
288.1170. 
 
6-chloro-3-methyl-1-(m-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (58b): Synthesized 
according to general procedure F. Yield: 51%. mp: 142.6 – 144.0 °C. 
1H NMR (600 MHz, DMSO) δ 10.08 (s, 1H), 7.31 (t, J = 7.6 Hz, 1H), 7.16 (d, J = 7.4 Hz, 1H), 
7.05 (s, 1H), 7.00 (d, J = 7.3 Hz, 1H), 6.74 (d, J = 8.3 Hz, 1H), 4.56 (d, J = 6.7 Hz, 1H), 3.54 (d, 
J = 69.6 Hz, 4H), 3.32 (s, 3H), 2.77 (s, 3H), 2.33 (s, 3H) ppm. 13C NMR (125 MHz, DMSO) δ 
151.9, 138.0, 137.1, 128.7, 127.6, 125.3, 124.1, 123.2, 120.7, 119.9, 118.1, 113.8, 59.6, 53.7, 44.5, 
27.0, 21.0 ppm. HRESIMS calculated for C18H21ClNO [M+H]
+ 302.1233, found 302.1236. 
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3-allyl-6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (59a): Synthesized 
according to general procedure F. White solid. Yield: 40%. mp: 137.3 – 139.3 °C. 
 1H NMR (600 MHz, CDCl3) δ 7.34 (t, J = 15.1 Hz, 2H), 7.25 (t, J = 14.6 Hz, 1H), 7.15 (d, J = 7.6 
Hz, 2H) 6.71 (d, J = 8.4 Hz, 1H) 6.49 (d, J = 8.4 Hz, 1H) 5.89 (m, 1H) 5.16 (t, J = 30.3 Hz, 2H) 
4.33 (s, 1H) 3.30 (m, 1H), 3.27 (m, 4H), 2.95 (t, J = 18.1 Hz, 2H) 2.43 (t, J = 12.9 Hz, 1H). 
HRESIMS calculated for C19H21ClNO [M+H]
+ 314.1233, found 314.1232. 
 
3-allyl-6-chloro-1-(m-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (59b): Synthesized 
according to general procedure F. Off-white solid. Yield: 48%. mp: 151.3 – 152.7 °C. 
1H NMR (400 MHz, DMSO) δ 10.45 (s, 1H), 7.35 (t, J = 7.6 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 
7.07 (s, 1H), 7.04 (d, J = 7.6 Hz, 1H), 6.73 (d, J = 8.6 Hz, 1H), 6.20 (d, J = 8.6 Hz, 1H), 6.01 (td, 
J = 17.1, 7.0 Hz, 1H), 5.55 (s, 1H), 5.53 – 5.48 (m, 1H), 4.72 (d, J = 10.1 Hz, 1H), 3.81 (dd, J = 
25.8, 12.8 Hz, 1H), 3.68 (dd, J = 16.3, 7.0 Hz, 1H), 3.45 (ddd, J = 27.2, 19.4, 10.6 Hz, 1H), 2.98 
(dd, J = 22.1, 10.9 Hz, 1H), 2.34 (s, 1H) ppm. 13C NMR (100 MHz, DMSO) δ 152.4, 141.2, 138.6, 
137.1, 134.9, 129.4, 129.3, 128.4, 127.9, 127.7, 126.7, 125.9, 120.4, 114.4, 59.8, 58.1, 51.8, 44.3, 
26.7, 21.5 ppm. HRESIMS calculated for C20H23ClNO [M+H]
+ 328.1390, found 328.1382. 
 
3-allyl-6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (59c): 
Synthesized according to general procedure F. Off-white solid. Yield: 34%. mp: 132.5 – 134.1 °C. 
1H NMR (400 MHz, Acetone) δ 7.10 (d, J = 8.7 Hz, 2H), 6.93 (d, J = 8.7 Hz, 2H), 6.77 (d, J = 8.6 
Hz, 1H), 6.36 (d, J = 8.6 Hz, 1H), 5.56 (dd, J = 29.6, 14.3 Hz, 2H), 5.25 (d, J = 10.0 Hz, 1H), 4.34 
– 4.29 (m, 1H), 4.11 (dd, J = 15.4, 8.1 Hz, 1H), 3.95 – 3.70 (m, 4H), 3.57 – 3.40 (m, 2H), 3.06 
(dd, J = 22.3, 11.4 Hz, 1H) ppm. 13C NMR (100 MHz, Acetone) δ 160.2, 155.5, 137.9, 130.4, 
130.0, 125.8, 125.1, 123.1, 122.5, 120.0, 115.5, 111.5, 62.2, 56.8, 54.2, 46.3, 28.1 ppm. HRESIMS 
calculated for C19H21ClNO2 [M+H]
+ 330.1183, found 330.1211. 
 
6-chloro-8-nitro-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (61a): Synthesized 
according to general procedure G. Yellow solid. Yield: 74%. mp: 201.4 – 202.8 °C. 
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1H NMR (600 MHz, CDCl3) δ 11.15 (s, 1H), 7.67 (s, 1H), 7.42 (t, J = 7.6 Hz, 1H), 7.39 (s, 1H), 
7.19 (d, J = 7.7 Hz, 2H), 7.08 (d, J = 7.5 Hz, 2H), 4.94 (dd, J = 14.3, 8.1 Hz, 1H), 4.86 (dd, J = 
14.3, 4.0 Hz, 1H), 4.64 – 4.58 (m, 1H), 4.48 – 4.44 (m, 1H), 3.99 – 3.94 (m, 1H), 3.54 (ddd, J = 
15.4, 7.7, 3.3 Hz, 1H), 3.40 (ddd, J = 15.4, 8.8, 3.4 Hz, 1H) ppm. 13C NMR (150 MHz, CDCl3) δ 
140.9, 136.3, 135.3, 131.9, 127.9, 127.6, 126.1, 124.4, 118.9, 113.2, 64.8, 58.6, 42.0, 25.3, 24.7 
ppm. HRESIMS calculated for C16H16ClN2O3 [M+H]
+ 319.0771, found 319.0800. 
 
6-chloro-3-methyl-8-nitro-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (61b): 
Synthesized according to general procedure G. Yellow solid. Yield: 80%. mp: 198.7 – 200.0 °C 
1H NMR (600 MHz, Acetone) δ 7.60 (s, 1H), 7.49 – 7.45 (m, 2H), 7.40 (dd, J = 13.0, 7.2 Hz, 2H), 
7.34 (d, J = 8.0 Hz, 1H), 5.20 (d, J = 6.0 Hz, 1H), 4.11 – 3.95 (m, 2H), 3.88 – 3.76 (m, 1H), 3.69 
– 3.58 (m, 1H), 3.50 – 3.36 (m, 2H), 3.14 (s, 3H). 13C NMR (150 MHz, CDCl3) 140.9, 136.5, 
131.9, 128.1, 128.0, 127.6, 126.4, 126.1, 118.9, 113.2, 64.8, 58.6, 42.0, 25.3, 24.7 ppm. HRESIMS 
calculated for C17H18ClN2O3 [M+H]
+ 333.0298, found 333.0220. 
 
6-chloro-8-nitro-1-(m-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (61c): Synthesized 
according to general procedure G. Yellow solid. Yield: 80%. mp: 188.9 – 191.2 °C. 
1H NMR (600 MHz, Acetone) δ 7.37 (d, J = 7.5 Hz, 1H), 7.31 (dd, J = 15.6, 8.1 Hz, 2H), 7.23 (s, 
1H), 7.22 (s, 1H), 4.96 (d, J = 9.8 Hz, 1H), 3.98 – 3.89 (m, 1H), 3.86 – 3.76 (m, 1H), 3.73 – 3.66 
(m, 1H), 3.65 – 3.56 (m, 1H), 3.00 (s, 3H) ppm. 13C NMR (150 MHz, Acetone) δ 150.6, 146.6, 
140.1, 139.4, 133.5, 129.7, 129.6, 129.0, 125.9, 124.5, 122.5, 121.7, 60.8, 54.4, 45.3, 28.4, 21.1 
ppm. HRESIMS calculated for C17H18ClN2O3 [M+H]
+ 333.0298, found 333.0276. 
 
6-chloro-3-methyl-8-nitro-1-(m-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (61d): 
Synthesized according to general procedure G. Yellow solid. Yield: 78%. mp: 210.4 – 212.6 °C. 
 1H NMR (600 MHz, Acetone) δ 7.23 (t, J = 7.6 Hz, 1H), 7.19 (s, 1H), 7.09 (d, J = 7.5 Hz, 1H), 
7.04 (s, 1H), 6.99 (d, J = 7.5 Hz, 1H), 4.88 (d, J = 9.4 Hz, 1H), 3.80 (dd, J = 13.7, 9.7 Hz, 2H), 
3.71 (d, J = 14.7 Hz, 1H), 3.60 (dd, J = 25.4, 14.3 Hz, 2H), 3.15 (s, 1H), 2.93 (s, 3H), 2.22 (s, 3H). 
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13C NMR (150 MHz, Acetone) δ 150.0, 146.1, 139.6, 138.9, 132.9, 129.2, 129.1, 128.5, 125.4, 
124.0, 122.0, 121.2, 60.3, 53.9, 45.0, 44.8, 28.0, 20.5 ppm. HRESIMS calculated for 
C18H20ClN2O3 [M+H]
+ 347.1084, found 347.1100. 
 
8-amino-6-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (62b): 
Synthesized according to general procedure H. Off-white solid. Yield: 45%. mp: 137.0 – 138.9 
°C. 
1H NMR (600 MHz, CDCl3) δ 7.32 (d, J = 7.8 Hz, 2H), 7.27 – 7.23 (m, 1H), 7.08 (dd, J = 14.3, 
7.6 Hz, 3H), 5.78 (s, 1H), 5.72 (s, 1H), 4.25 (d, J = 10.4 Hz, 1H), 3.53 (dt, J = 14.4, 10.6 Hz, 2H), 
3.26 (dd, J = 16.7, 4.7 Hz, 2H), 3.10 – 3.05 (m, 1H), 2.96 (t, J = 10.9 Hz, 1H), 2.57 (s, 3H). 13C 
NMR (150 MHz, CDCl3) δ 141.9, 137.3, 136.3, 132.9, 128.9, 128.6, 127.1, 125.4, 119.9, 114.2, 
65.7, 59.6, 43.0, 26.3, 25.6 ppm. HRESIMS calculated for C17H20ClN2O [M+H]




Synthesized according to general procedure H. Off-white solid. Yield: 54%. mp: 134.8 – 136.0 
°C. 
1H NMR (600 MHz, CDCl3) δ 6.97 (dd, J = 14.1, 7.5 Hz, 2H), 6.82 (s, 1H), 6.78 (d, J = 3.1 Hz, 
3H), 6.77 (s, 1H), 5.72 (s, 1H), 5.66 (s, 1H), 4.75 (d, J = 9.7 Hz, 1H), 4.12 (d, J = 10.6 Hz, 1H), 
3.50-3.39 (m, 2H), 3.20 – 3.13 (m, 3H), 3.01 – 2.95 (m, 1H), 2.67 (s, 3H), 2.49 (s, 3H). 13C NMR 
(150 MHz, CDCl3) δ 138.6, 137.3, 132.8, 129.6, 129.3, 128.9, 128.7, 128.0, 127.8, 125.6, 119.9, 
114.2, 68.0, 61.1, 59.6, 42.9, 25.6, 21.5 ppm. HRESIMS calculated for C18H22ClN2O [M+H]
+ 
317.1342, found 317.1350. 
 
N-(9-chloro-8-hydroxy-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-
yl)acetamide (63a): Synthesized according to general procedure I. White solid. Yield: 78%. mp: 
154.4 – 156.2 °C. 
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1H NMR (600 MHz, Acetone) δ 7.41 (s, 1H), 7.32 (dd, J = 13.6, 7.0 Hz, 2H), 7.28 – 7.22 (m, 2H), 
7.05 (dd, J = 18.9, 7.1 Hz, 3H), 4.29 (d, J = 10.5 Hz, 1H), 3.60 (dd, J = 17.3, 10.8 Hz, 1H), 3.53 – 
3.46 (m, 1H), 3.38 (dd, J = 17.3, 7.6 Hz, 1H), 3.27 (dd, J = 19.8, 12.1 Hz, 2H), 2.99 – 2.91 (m, 
1H), 2.77 (s, 3H), 2.59 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 170.2, 129.2, 129.1, 128.6, 128.5, 
127.6, 127.3, 124.3, 124.2, 123.4, 119.7, 65.7, 59.0, 42.9, 29.7, 26.6, 23.8 ppm. HRESIMS 
calculated for C19H22ClN2O2 [M+H]
+ 345.1292, found 345.1244. 
 
N-(9-chloro-8-hydroxy-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-
yl)butyramide (63b): Synthesized according to general procedure I. 82%. White solid. Yield: mp: 
148.7 – 150.1 °C. 
1H NMR (500 MHz, Acetone) δ 7.44 (td, J = 7.3, 2.7 Hz, 4H), 7.39 – 7.36 (m, 1H), 7.30 (dd, J = 
7.6, 2.1 Hz, 2H), 7.25 (d, J = 7.3 Hz, 1H), 5.09 (dd, J = 49.6, 9.5 Hz, 1H), 2.88 (s, 3H), 2.71 (d, J 
= 13.0 Hz, 2H), 2.65 (t, J = 7.3 Hz, 2H), 2.36 (t, J = 6.1 Hz, 2H), 1.75 (dd, J = 14.9, 7.3 Hz, 2H), 
1.65 (dd, J = 14.8, 7.5 Hz, 2H), 1.04 (t, J = 9.3 Hz, 2H), 0.91 (t, J = 7.5 Hz, 2H). 13C NMR (150 
MHz, CDCl3) δ 170.6, 143.1, 129.3, 129.2, 129.1, 128.6, 127.5, 127.2, 124.2, 123.6, 119.7, 65.6, 





yl)isobutyramide (63c): Synthesized according to general procedure I. White solid. Yield: 76 %. 
mp: 144.6 – 145.9 °C. 
1H NMR (500 MHz, CDCl3) δ 7.45 (dd, J = 12.1, 5.2 Hz, 2H), 7.37 (dd, J = 13.4, 6.1 Hz, 1H), 
7.29 (s, 1H), 7.20 (dd, J = 21.7, 7.6 Hz, 2H), 5.10 (d, J = 9.5 Hz, 1H), 3.75 (dd, J = 17.9, 11.1 Hz, 
1H), 3.53 – 3.44 (m, 1H), 3.38 (dd, J = 19.2, 12.4 Hz, 2H), 3.30 – 3.20 (m, 1H), 2.99 – 2.93 (m, 
1H), 2.88 (s, 2H), 2.68 (s, 2H), 1.40 (d, J = 7.0 Hz, 6H). 13C NMR (150 MHz, CDCl3) δ 174.0, 
141.1, 129.3, 129.2, 128.7, 128.7, 128.5, 127.8, 127.5, 127.3, 65.5, 58.9, 34.4, 31.7, 26.7, 22.8, 
19.0 ppm. HRESIMS calculated for C21H26ClN2O2 [M+H]





yl)acrylamide (63d): Synthesized according to general procedure I. Greyish solid. Yield: 81%. 
mp: 161.4 – 163.1 °C. 
1H NMR (600 MHz, CDCl3) δ 7.31 (d, J = 7.8 Hz, 1H), 7.26 (d, J = 7.3 Hz, 1H), 7.07 – 7.01 (m, 
1H), 6.32 (d, J = 17.6 Hz, 1H), 6.05 (d, J = 9.7 Hz, 1H), 5.78 (d, J = 10.3 Hz, 1H), 5.02 – 4.85 (m, 
1H), 3.65 (t, J = 5.8 Hz, 1H), 3.58 (dd, J = 17.7, 10.7 Hz, 1H), 3.54 – 3.45 (m, 1H), 3.38 (dd, J = 
16.2, 8.3 Hz, 1H), 3.31 – 3.14 (m, 2H), 2.76 (s, 1H), 2.57 (s, 2H). 13C NMR (150 MHz, CDCl3) δ 
170.3, 143.0, 135.7, 131.4, 129.5, 129.4, 129.2, 129.1, 128.6, 128.5, 127.5, 127.2, 125.5, 124.3, 
124.1, 67.9, 59.0, 42.9, 34.2, 25.6 ppm. HRESIMS calculated for C20H22ClN2O2 [M+H]
+ 
357.1292, found 357.1274. 
 
N-(9-chloro-8-hydroxy-3-methyl-5-(m-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-
yl)acetamide (63e): Synthesized according to general procedure I. Off-white solid. Yield: 68%, 
mp:151.6 – 152.8 °C. 
1H NMR (400 MHz, CDCl3) δ 7.28 – 7.20 (m, 1H), 7.08 (dd, J = 20.4, 7.5 Hz, 2H), 6.92 – 6.81 
(m, 4H), 6.67 (dd, J = 8.7, 4.0 Hz, 2H), 6.43 (d, J = 8.7 Hz, 1H), 6.32 (d, J = 8.7 Hz, 1H), 5.51 (s, 
1H), 4.75 (d, J = 9.6 Hz, 1H), 4.41 (d, J = 10.6 Hz, 1H), 4.12 – 4.00 (m, 1H), 3.89 (dd, J = 13.8, 
9.1 Hz, 1H), 3.75 (d, J = 10.4 Hz, 1H), 3.57 (ddt, J = 27.4, 19.2, 9.6 Hz, 3H), 3.42 – 3.32 (m, 1H), 
3.31 – 3.14 (m, 2H), 3.05 (s, 2H), 2.88 (s, 3H), 2.29 (d, J = 12.0 Hz, 6H). 13C NMR (100 MHz, 
CDCl3) δ 150.3, 141.5, 140.7, 138.9, 135.8, 135.2, 129.1, 128.6, 128.3, 125.4, 120.2, 114.0, 64.8, 
62.5, 58.5, 55.8, 48.1, 42.6, 25.4, 21.5 ppm. HRESIMS calculated for C20H24ClN2O2 [M+H]
+ 
359.1448, found 359.1430. 
 
N-(9-chloro-8-hydroxy-3-methyl-5-(m-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-
yl)butyramide (63f): Synthesized according to general procedure I. White solid. Yield: 63%, 
mp:156.2 – 157.9 °C. 
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.30 (m, 1H), 7.18 (dd, J = 17.9, 7.7 Hz, 1H), 7.06 – 6.94 
(m, 2H), 5.02 (dd, J = 30.1, 9.4 Hz, 1H), 3.79 – 3.56 (m, 2H), 3.53 – 3.46 (m, 1H), 3.42 – 3.19 (m, 
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3H), 2.93 (d, J = 5.7 Hz, 1H), 2.87 (d, J = 5.0 Hz, 1H), 2.68 (s, 2H), 2.39 (s, 3H), 1.93 – 1.78 (m, 
3H), 1.09 (t, J = 7.2 Hz, 3H); 1H NMR (126 MHz, CDCl3) δ 170.6, 143.0, 141.1, 139.2, 138.8, 
129.8, 129.6, 129.3, 128.9, 128.6, 128.3, 125.4, 119.8, 65.7, 59.1, 42.9, 38.8, 35.7, 26.6, 21.6, 18.4, 
13.7 ppm. HRESIMS calculated for C22H28ClN2O2 [M+H]
+ 387.1841, found 387.1843. 
 
N-(9-chloro-8-hydroxy-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-
yl)methanesulfonamide (64): Synthesized according to general procedure I. Grey solid. Yield: 
40%. mp: 149.6 – 152.6 °C. 
1H NMR (400 MHz, DMSO) δ 7.48 (d, J = 6.9 Hz, 2H), 7.42 (d, J = 6.6 Hz, 1H), 7.27 (d, J = 6.7 
Hz, 3H), 6.44 (s, 1H), 4.77 (d, J = 9.6 Hz, 1H), 3.80 (d, J = 11.8 Hz, 2H), 3.68 – 3.55 (m, 2H), 
3.49 – 3.37 (m, 2H), 3.08 (s, 1H), 2.87 (s, 3H), 2.07 (d, J = 5.4 Hz, 3H). 13C NMR (100 MHz, 
DMSO) δ 146.0, 140.5, 137.0, 136.2, 129.6, 129.0, 128.0, 122.5, 121.6, 120.0, 59.5, 53.7, 44.7, 
44.3, 31.1, 27.2 ppm. HRESIMS calculated for C18H22ClN2O3S [M+H]




(65a): Synthesized according to general procedure I. White solid. Yield: 54%. mp: 184.6 – 186.1 
°C. 
1H NMR (500 MHz, Acetone) δ 8.21 (s, 2H), 7.37 – 7.30 (m, 1H), 7.22 – 7.14 (m, 2H), 7.08 (s, 
1H), 7.03 (d, J = 7.5 Hz, 1H), 4.83 (d, J = 11.4 Hz, 1H), 3.65 – 3.54 (m, 3H), 3.33 – 3.24 (m, 3H), 
2.89 (s, 3H), 2.37 (s, 3H); 13C NMR (126 MHz, DMSO) δ 157.8, 141.8, 141.5, 137.9, 137.3, 131.7, 
128.7, 128.3, 127.5, 126.5, 126.3, 122.2, 33.9, 30.9, 28.4, 24.7, 21.1 ppm. HRESIMS calculated 
for C19H23ClN3O2 [M+H]
+ 360.2201, found 360.2200. 
 
1-(9-chloro-8-hydroxy-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)urea 




1H NMR (400 MHz, DMSO) δ 10.95 (s, 1H), 8.39 (s, 1H), 7.44 (d, J = 1.9 Hz, 1H), 7.43 (d, J = 
1.9 Hz, 1H), 7.41 (s, 1H), 7.35 (d, J = 1.4 Hz, 1H), 7.33 (s, 1H), 7.22 (d, J = 1.5 Hz, 1H), 7.20 – 
7.19 (m, 1H), 6.25 (s, 1H), 4.85 (d, J = 9.5 Hz, 1H), 3.50 – 3.40 (m, 1H), 3.39 – 3.35 (m, 1H), 3.30 
(dd, J = 12.8, 2.5 Hz, 1H), 3.19 (d, J = 20.4 Hz, 1H), 3.06 (d, J = 12.3 Hz, 1H), 2.79 (s, 1H), 2.58 
(s, 3H). 13C NMR (100 MHz, DMSO) δ 158.4, 143.1, 142.4, 132.8, 129.4, 129.0, 127.4, 126.8, 
123.0, 118.8, 66.9, 60.0, 44.0, 42.1, 26.3 ppm. HRESIMS calculated for C18H21ClN3O2 [M+H]
+ 
346.1244, found 346.1241. 
 
2.6.2. Dopamine receptor binding assays 
D1R, D2R and D5R binding assays were performed by the Psychoactive Drug Screening 
Program (PDSP).  Briefly, compounds were tested initially in a primary radioligand binding assays 
at each receptor.  In the primary binding assays, the compounds were tested at a concentration of 
10 µM in quadruplicate in 96 well plates.  Compounds that displayed a minimum of 50% inhibition 
in the primary assays were advanced to secondary binding assays to determine Ki values at each 
receptor.  In secondary binding assays compounds were tested at 11 concentrations (0.1, 0.3, 1, 3, 
10, 30, 100, 300 nM, 1, 3, 10 µM) and in triplicate. Both primary and secondary binding assays 
were carried out in a final assay volume of 125 µL per well in binding buffer (50 mM HEPES, 50 
mM NaCl, 5 mM MgCl2, 0.5 mM EDTA, pH 7.4, rt Standard Wash Buffer: 50 mM Tris HCl, pH 
7.4, cold).  The radioligand concentration chosen was close to the Kd.  Radioligands used for D1R, 
D2R and D5R were [3H]-SCH23390, [3H]-N-methylspiperone and [3H]-SCH23390 respectively 
with Kds of 0.74, 0.47 and 2.03 respectively.  The total binding and nonspecific binding were 
determined in the absence and presence of the appropriate reference compound respectively 
Reference compound for D1R, D2R and D5R assays were (+)-butaclamol, haloperidol and SKF 
83586 respectively. 
 
2.6.3. GPCR cAMP Modulation Assay 
Agonist and antagonist secondary screening was performed by Eurofins DiscoveryX. 
cAMP Hunter cell lines were expanded from freezer stocks according to standard procedures. Cells 
were seeded in a total volume of 20 μL into white walled, 384-well microplates and incubated at 
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37°C for the appropriate time prior to testing. cAMP modulation was determined using the 
DiscoverX HitHunter cAMP XS+ assay. For agonist determination, cells were incubated with 
sample to induce response. Media was aspirated from cells and replaced with 15 μL 2:1 
HBSS/10mM Hepes : cAMP XS+ Ab reagent. Intermediate dilution of sample stocks was 
performed to generate 4X sample in assay buffer. 4. 5 μL of 4x sample was added to cells and 
incubated at 37°C or rt for 30 or 60 minutes. Vehicle concentration was 1%. For agonist 
determination, cells were incubated with sample in the presence of EC80 forskolin to induce 
response. Media was aspirated from cells and replaced with 15 μL 2:1 HBSS/10mM Hepes : cAMP 
XS+ Ab reagent. Intermediate dilution of sample stocks was performed to generate 4X sample in 
assay buffer containing 4x EC80 forskolin. 4. 5 μL of 4x sample was added to cells and incubated 
at 37°C or rt for 30 or 60 minutes. Final assay vehicle concentration was 1%. 
For antagonist determination, cells were pre-incubated with sample followed by agonist 
challenge at the EC80 concentration. Media was aspirated from cells and replaced with 10 μL 1:1 
HBSS/Hepes : cAMP XS+ Ab reagent. 5 μL of 4X compound was added to the cells and incubated 
at 37˚C or rt for 30 minutes. 5 μL of 4X EC80 agonist was added to cells and incubated at 37˚C or 
rt for 30 or 60 minutes. For Gi coupled GPCRs, EC80 forksolin was included. 
After appropriate compound incubation, assay signal was generated through incubation 
with 20 μL cAMP XS+ ED/CL lysis cocktail for one hour followed by incubation with 20 μL 
cAMP XS+ EA reagent for three hours at rt. Microplates were read following signal generation 
with a PerkinElmer EnvisionTM instrument for chemiluminescent signal detection. Compound 
activity was analyzed using CBIS data analysis suite (ChemInnovation, CA). For Gs agonist mode 
assays, percentage activity is calculated using the following formula: % Activity =100% x (mean 
RLU of test sample - mean RLU of vehicle control) / (mean RLU of MAX control - mean RLU of 
vehicle control). For Gs positive allosteric mode assays, percentage modulation is calculated using 
the following formula: % Modulation =100% x (mean RLU of test sample - mean RLU of EC20 
control) / (mean RLU of MAX control - mean RLU of EC20 control). For Gs antagonist or negative 
allosteric mode assays, percentage inhibition is calculated using the following formula: % 
Inhibition =100% x (1 - (mean RLU of test sample - mean RLU of vehicle control) / (mean RLU 
of EC80 control - mean RLU of vehicle control)). For Gi agonist mode assays, percentage activity 
is calculated using the following formula: % Activity = 100% x (1 - (mean RLU of test sample - 
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mean RLU of MAX control) / (mean RLU of vehicle control - mean RLU of MAX control)). For 
Gi positive allosteric mode assays, percentage modulation is calculated using the following 
formula: % Modulation =100% x (1-(mean RLU of test sample - mean RLU of MAX control) / 
(mean RLU of EC20 control - mean RLU of MAX control)). For Gi inverse agonist mode assays, 
percentage activity is calculated using the following formula: % Inverse Agonist Activity =100% 
x ((mean RLU of test sample - mean RLU of EC20 forskolin) / (mean RLU of forskolin positive 
control - mean RLU of EC20 control)). For Gi antagonist or negative allosteric mode assays, 
percentage inhibition is calculated using the following formula: % Inhibition = 100% x (mean 
RLU of test sample - mean RLU of EC80 control) / (mean RLU of forskolin positive control - 































C7-methoxy-C2’ and C6’ Modified 




Several SAR studies have been conducted on 1-phenylbenzazepines as D1R-like ligands 
to elevate these class of compounds as potential therapeutics. As alluded to earlier, 1-
phenylbenzazepines are predominantly selective towards D1R-like dopamine receptors. It has 
been well established that specific aryl and nitrogen substituent groups can significantly impact 
D1R-like affinity, D1R-like selectivity versus D2-like receptors as well as functional activity. 
Although there have been several SAR studies on 1-phenylbenzazepines as dopamine receptor 
ligands, it has not been determined how halogen or alkyl substituents in the ortho position of ring 
C in the 1-phenylbenzazepine framework impact affinity and selectivity for dopamine receptors. 
Relatively few such compounds have been synthesized (predominantly in the patent literature) and 
there is no data available concerning the D1R versus D5R affinity of the compounds.   
 
3.2. Ligand Design 
 
Goal: Use the benzazepine scaffold to identify new D1R/D5R ligands with 7-methoxy/8-hydroxy 
moiety and varying substitutions at 1-phenyl ring. 
 
We set out to examine the role of ring C ortho (C2’/C6’) halo and methyl substituents on 
D1R/D5R affinity of benzazepine scaffold.  We reasoned that such substituents might cause 
differences in receptor interactions with the substituents themselves and/or lead to modified 
conformations of the molecule that could directly influence D1R and D5R affinity and selectivity. 
Adding larger halo substituents such as bromo or chloro may favor an orthogonal conformation of 
ring C.  This conformation may be preferred for interactions of these benzazepines with various 
amino-acid residues within the D1R binding pocket. Comparison between smaller halo substituent 
like fluorine vs. larger halo substituents such as chloro or bromo might provide more insight into 






Figure 21.   Planned modifications on a representative 1-phenylbenzazepine. 
 
Figure 21 illustrates the planned ring C target compounds with 7-methoxy/8-hydroxy or 
catechol motifs in ring A. N-substitutions will be limited to H, methyl and allyl based on their 
favorability towards D1R affinity as established from previous studies.  Ring C will contain 2’-
halo, 2’-methyl, 2’,6’-dihalo or 4’-bromo substituents to create a sterically and electronically 
diverse series of analogs so that affirmative SAR can be established.  
 
3.3. Synthesis 
Primary amine (66) was reacted with various substituted epoxides 68 to give aminoalcohol 
69, which was cyclized in the presence of trifluoroacetic acid and concentrated sulfuric acid to 
produce benzazepine 70. Compound 70 was converted into catechol (71) using BBr3. N-
methylation of 70 was achieved using reductive amination by paraformaldehyde and sodium 
triactetoxyborohydrided to give 72. N-allylation of benzazepines 70 was carried out via SN2 
reaction of 70 with allyl bromide to produce 74. N-methyl and N-allyl analogs 72 and 74 were 





aReagents and Conditions: (a) 1. mCPBA, DCM, rt, 12h; 2. NaOH, rt, (88 - 96%); (b) 68, LiNF2, 
THF, reflux, 24 h, (56 - 76) %; (c) 1. TFA, H2SO4, rt, 5h; 2. NaOAc, (43 - 54%); (d) BBr3, DCM, 
0 oC, 4 h, (67 - 80%); (e) HCHO, Na(OAc)3BH, ACN, rt, 12 h, (23 - 48%); (f) Allyl Bromide, 
TEA, ACN, rt, 16 h, (56 - 64%).  
____________________________________________________________________________ 
 
3.4.    Structure-activity correlations 
The binding affinity of analogs 70a-75g were assessed at dopamine D1, D2 and D5 
receptors.  Data for these assessments are presented in Table 11 as Ki values in nM.  Compounds 
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70a-e had D1R affinities ranging from 72 to 147 nM.  Affinities at D5R for this group was slightly 
lower overall (ranging from 82 to 530 nM), so that as a group, compounds 70a-e were slightly 
more selective for D1R over D5R.  Compound 70c is interesting as it is the only compound of the 
70a-e sub-set that was D5R selective over D1R (3-fold). Compounds 70a, 70d, 70d and 70e 
displayed modest selectivity for D1R over D5R (up to 3-fold). Surprisingly, catechol 71b did not 
have any affinity for either D1R or D5R.  However, substitution of the chloro group in 71b for a 
bromo group (71d) resulted in strong D1R and D5R affinity.  In comparing phenols 71b and 71d 
to their C7 methoxy analogs (70b and 70d respectively), it is apparent that the effect of cleavage 
of the C7 methoxy group to give 71b and 71d, results in opposite effects at D1R (reducing affinity 
for 71b but increasing affinity for 71d). This situation was mirrored at D5R.  Compounds 70e and 
71e with a p-bromo group show lower affinity (2-4-fold) towards D1R and D5R compared to 
compounds 70d and 71d which have an o-bromo moiety. 
Compounds 72b-d are the N-methylated analogs of 70b-d respectively; compounds 72b-d 
as a group displayed stronger D1R affinity than their N-des-methyl counterparts. Compounds 72b 
and 72d had the strongest D1R affinity of any compound evaluated for this study (Ki of 14 and 16 
nM for 72b and 72d respectively).  The compounds with mono-halogen substituents (72b and 72d) 
showed modest D1R selectivity over D5R (3-fold and 4-fold respectively), but this selectivity was 
reversed in the dichloro substituted compound 72c.  
Similar trends as for the N-methylated analogs were seen for the N-allylated analogs 74b-
d.  In that regard, both the mono-halo substituted analogs 74b and 74d were D1R selective whereas 
the dichloro substituted analog (74c) was D5R selective.  In general, the N-Me analogs showed 
higher affinity towards D1R-type compared to N-H analogs whereas N-allyl analogs displayed 
lower affinity for D1R and D5R than their N-methyl congeners. The catecholic analogs 73d and 
75d are the O-demethylated analogs of 72d and 74d respectively; both 73d and 75d showed lower 
D1R and D5R affinity than their methylated precursors and both also had modest D1R selectivity 
versus D5R (in the 3- to 4-fold range).  
The binding affinities of compounds 70f-75f and 70g-75g were also analyzed at dopamine 
D1R, D2R and D5R. Compounds 70f-75f belong to the sub-set with o-fluoro substitution while 




Table 12.  Binding affinities of C2’, C6’ functionalized analogs at D1R, D2R and 
D5R. 
 
      Ki (nM)a. 
Cmpd # R R’ X X’ X’’ D1Rb D2Rc D5Rd 
70a Me H H H H 126.4 ± 9.1 na
e
 309.9 ± 23 
70b Me H H Cl H 147.4 ± 4.1 na 482.8 ± 29.4 
70c Me H Cl Cl H 76.1 ± 3.6 na 25.4 ± 2.6 
70d Me H H Br H 72 ± 5.6 na 82 ± 6.2 
70e Me H H H Br 122.3 ± 10.1 na 530.1 ± 47 
70f Me H H F H 71.98 ± 2.8 na 29.98 ± 1.7 
70g Me H H Me H 59.37 ± 3.8 na 299.36 ± 11.4 
71b H H H Cl H na >10,000 na 
71d H H H Br H 26 ± 3.1 na 67 ± 7.1 
71e H H H H Br 366.5 ± 54.9 na 99.6 ± 7.2 
71f H H H F H 205.16 ± 9.7 na 72.01 ± 4.6 
71g H H H Me H 119.04 ± 6.9 na 147.27 ± 7.6 
72b Me Me H Cl H 14 ± 2.3 na 46.4 ± 3.8 
72c Me Me Cl Cl H 144.6 ± 9.0 na 49.1 ± 3.7 
72d Me Me H Br H 16 ± 1.4 na 47 ± 3.2 
72f Me Me H F H 5.65 ± 0.6 na 6.66 ± 0.7 
72g Me Me H Me H 7.96 ± 0.4 na 18.3 ± 1.6 




Experiments carried out in triplicate; 
b
[3H] SCH23390 used as radioligand; 
c
[3H]N-methylspiperone used as radioligand; 
d
[3H]SCH23390 used 
as radioligand;   
e
na – not active (<50% inhibition in a primary assay when tested at 10µM). 
 
Compound with o-F substitution had D1R affinities ranging from 5 to 1221 nM. Affinities 
at D5R for these groups were comparable overall ranging from 6 to 691 nM. Compounds 70f, 72f 
and 74f with a 7-methoxy moiety had significantly higher affinities towards D1R compared to 
their catechol counterparts (71f, 73f and 75f). Compounds 72f and 73f that have methyl substituted 
nitrogen group displayed higher affinities for target receptors compared to compounds with no N-
substitution (70f and 71f). N-allyl substitution (74f and 75f) also resulted in modestly potent 
analogs with 7-methoxy compound (74f) with higher affinity than the catechol 75f. The most 
active compound in the sub-set was 72f with 5 nM affinity towards D1R and 6 nM affinity towards 
D5R contains a 7-methoxy/8-hydroxy moiety with N-methyl substitution.  
The next subset of compounds consists of o-Me substitution (70g-75g). Compounds in this 
subset showed affinities towards D1R ranging from 8 to 119 nM whereas for D5R, affinities ranged 
from 18 to 622 nM. Overall, D5R affinity data was lower than D1R which shows these compounds 
are more selective towards D1R. 7-methoxy/8-hydroxy moiety (70g, 72g and 74g) are more 
73f H Me H F H 30.03 ± 2.9 na 104.04 ± 5.2 
73g H Me H Me H 36.63 ± 3.2 na 121.56 ± 4.9 
74b Me Allyl H Cl H 48.3 ± 8.2 na 264.4 ± 13.6 
74c Me Allyl Cl Cl H 1044 ± 59.2 1507.8 ± 89.2 479.1 ± 39.2 
74d Me Allyl H Br H 41 ± 2.8 na 501 ± 64 
74f Me Allyl H F H 18.26 ± 1.8 na 73.11 ± 3.8 
74g Me Allyl H Me H 24.55 ± 4.2 na 175.59 ± 6.3 
75d H Allyl H Br H 132.9 ± 8.9 na 442.2 ± 56 
75f H Allyl H F H 1221.8 ± 17.6 na 691.19 ± 4.2 
75g H Allyl H Me H 87.34 ± 5.8 na 622.16 ± 41.2 
(+)-Butaclamol      4.04 ± 0.2   
Haloperidol       5.58 ± 0.3  
SKF 83566        3.95 ± 0.2 
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favored compared to traditional catechol substitution (71g, 73g and 75g). The catechol compounds 
were at least 2-3-fold less potent than non-catechol ones. Moreover, N-methyl substitution seems 
favorable for D1R-type affinity. Compounds 70g (Ki = 59.37 nM and 71g (Ki = 147.27 nM) have 
lower affinity values compared to compounds 72g (Ki = 7.96 nM) and 73g (Ki = 36.63 nM) 
respectively. However, as the alkyl chain was increased from methyl to allyl in the N-position, the 
affinity values decreased (72g vs 74g; Ki = 24.55 nM and 73g vs 75g; Ki = 87.34 nM). 
Compounds with an o-Me substitution (70g-75g) displayed similar structure-activity 
relations compared to o-F sub-set of compounds. The o-Me group did not significantly change the 
activity of these compound vs. o-F group except for compound 75g (Ki = 87.34 nM) vs. 75f (Ki = 
1221.8). Compound 75g was significantly more potent (fourteen-fold) than 75f. o-F compound 
(72f) with highest affinity (Ki = 5 nM) and o-Me compound (72g) with highest affinity (Ki = 8 
nM) have similar substitution on their A and B rings. Observation of size of substituents at 2’-
position of the compounds displayed on Table 12 shows that smaller substituent such as fluorine 
and methyl groups are favored for D1R-type affinity  
 
3.4.1. Functional Assays 
The most active compound from Table 12 (72b) was further tested in agonist and 
antagonist mode with the GPCR Biosensor Assay. The agonist control for the assay was dopamine, 
the endogenous ligand for D1R whereas SCH 39166 (Ecopipam) was selected as antagonist control 
As expected, (based on structural similarity to SCH 39166), 72b displayed strong antagonist 
activity in these assays (IC50 = 9.4 nM for 72b; IC50 of positive control SCH 39166 = 1.5 nM) 
(Figure 22) (Table 14).  No agonist activity was detected for 72b.  
Similar functional assay was also conducted for compound 72f from Table 12. The results 
of the assay are shown in Table 13. Like 72b, 72f also showed antagonistic properties. The data 
shows that compound 72f is an antagonist with IC50 value of 10.72 nM which is about 5-fold less 






Table 13.  Functional activity assay of 72f in Biosensor assay at D1R 
 
Compound Assay Format Result RC50 (nM)  Hill slope Max Response 
Dopamine Agonist EC50 12.30  1.28 103.01 
SCH 39166 Antagonist IC50 1.67  1.14 102.24 
72b Agonist EC50 >10,000   16.34 
72b Antagonist IC50 9.4  1.29 96.21 
72f Agonist EC50 >10,000   17.22 
72f Antagonist IC50 10.72  1.38 94.55 
 
 
3.5. Molecular docking studies 
3.5.1. Docking studies 
In order to provide insights into the important receptor-ligand interactions between the ortho 
halogen substituted 1-phenylbenzapines and the D1R and D5R, computational docking studies 
were conducted for the series of analogs in Table 12. In this context, we explored the docked ligand 
poses and identified key interactions that have a significant impact on binding to the dopamine 
receptors for this ligand series. These efforts focused mainly on the compounds 71d, 72b and 72d, 
which displayed the best experimental binding affinities to D1R. 
Homology models of D1R and D5R were generated and utilized in the docking studies. The 
D1R homology model was constructed from the high-resolution crystal structure of the human β2-
adrenergic G protein-coupled receptor (GPCR) with pdb code 2RH1 followed by induced fit 
docking with several halogenated 1-phenylbenzazepine analogs.239 In a similar manner, the D5R 
homology model was created from the high-resolution crystal structure of the β1-adrenergic GPCR 
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with pdb code 6H7J followed by induced fit docking with the benzazepineanalogs.240 Models of 
appropriate amino acid backbone and side-chain orientations in the ligand binding site. The 
homology model building procedure involved application of the Schrodinger Prime Structure 
Prediction, Induced Fit Docking and Glide software tools in conjunction with manual intervention 
to support the formation of known key receptor-ligand interactions. The docking runs of the 1-
phenylbenzazepineanalogs into the D1R and D5R binding sites utilized the Schrodinger Glide 
methodology in Standard Precision (SP) mode. Using this approach, the Glidescore scoring 
function provided an estimate of the ligand binding affinities for the highest ranked poses of the 
ligand series in the D1R and D5R targets. 
 
3.5.1.1.1. D1 receptor outcomes 
Compounds 71d, 72b and 72d give very similar docked poses in the D1R binding pocket as 
shown in Fig. 2A with binding energies in the range −7.8 kcal/mol to −8.2 kcal/mol. The docked 
poses display the quaternary N - Asp103 salt bridge, H-bonding interactions of the ligand hydroxyl 
group to the Asn292 side chain, and for compound 71d with an additional hydroxyl group in the 
catechol moiety there is also a H-bond to the Ser198 sidechain, as well as an aromatic H-bond 
involving the pendant phenyl group and Ser188. The binding poses for the compounds 71d, 72b 
and 72d (docked as the R enantiomers), which gave the best D1R experimental affinities, are 




Figure 22.   Docked poses of compounds 71d (blue C atoms), 72b (green C atoms) and 72d (pink 
C atoms) in the D1R target. The receptor targets are depicted by secondary structure elements and 
grey carbon atoms for select residues. Key quarternary N-Asp salt bridges are depicted by the pink 
dashed lines, H-bonding interactions by the yellow dashed lines, aromatic H-bonding by the 
turquoise dashed lines and π-π stacking by the blue dashed lines. Docking studies were performed 
with the R enantiomers.  
 
3.5.1.1.2. D5 receptor outcomes 
In the D5R binding site, the main receptor-ligand interactions for the docked poses of 
compounds 71d, 72b and 72d comprise the quaternary N - Asp120 salt bridge, hydrogen bonding 
interactions of the ligand hydroxyl group to the Asn316 or Ser229 sidechain, and again for 
compound 71d there is another hydrogen bond with its second catechol hydroxyl group to Ser233, 
as well as π-π hydrophobic interactions involving the ligand aromatic rings with Phe312 and 
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Trp116. Compounds 72b and 72d form docked poses with binding energies of −8.2 kcal/mol and 
−8.1 kcal/mol, respectively, which are very similar to those in the D1R binding pocket. The 
binding poses for the compounds 71d, 72b and 72d (docked as the R enantiomers), which gave 
the best D1R experimental affinities, are depicted in Figure 23. 
 
 
Figure 23.   Docked poses of compounds 71d (blue C atoms), 72b (green C atoms) and 72d 
(pink C atoms) in the D5R target. The receptor targets are depicted by secondary structure 
elements and grey carbon atoms for select residues. Key quarternary N-Asp salt bridges are 
depicted by the pink dashed lines, H-bonding interactions by the yellow dashed lines, aromatic 
H-bonding by the turquoise dashed lines and π-π stacking by the blue dashed lines. Docking 
studies were performed with the R enantiomers. 
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Overall, the computationally predicted binding energies for the docked series of halogen 
substituted 1-phenylbenzapine derivatives in Table 12 are similar in both the D1R and D5R 
structures or a little better in D5R because of the slightly stronger hydrogen bonding and π-π 
hydrophobic interactions. In this context, the docking scores do not align with the selectivity trends 
derived from the experimental binding affinities. This is at least partially attributable to the modest 
nature of the observed D1R/D5R experimental selectivities of the ring C halogenated analogs. 
Furthermore, D1R and D5R are very similar structurally in the ligand binding pocket, which 
provides justification for the close computational binding energies for most of the compounds in 
these two target sites. The docking outcomes for the compounds in Table 12 involved the R 
enantiomers whereas the affinity data were obtained with racemic mixtures and this could also 
have an impact on the match between the experimental and computational results. Docking 
simulations were investigated with the S enantiomers, however, they generated similar trends 
compared to the R enantiomers with, in general, slightly worse predicted binding energies in both 
the D1R and D5R targets. 
 
3.6. Conclusion 
 In conclusion, this study allowed us to obtain useful SAR information with regards to the 
effect of C2’ and C6’ halogen substituents on the affinity of 1-phenyl-benzazepines at D1R, D2R 
and D5R. As is evident from examination of the data, the compounds in this study maintain 
selectivity for D1-like receptors over D2R.  However, selectivity for D1R over D5R or vice versa 
was only modest.  From the affinity data, it was observed that having 2’-halo or 2’-methyl 
substitution increases D1R affinity as compared to no substitution in C2’ position. Moreover, 
smaller groups at C2’ such as fluoro demonstrated several fold higher affinities compared to larger 
halo substitutions such as chloro and bromo at C2’ position. Affirmation of N-alkyl substitution 
favorability for D1R/D5R affinity was also observed in the compounds studied.  
In some instances, it was observed that compounds with an 8-hydroxy/7-methoxy motif 
displayed higher affinity than the corresponding catechol congeners.  This result is somewhat 
surprising given the generally accepted view of favorability of a catechol motif for D1-like affinity 
in 1-phenylbenzazepines. The presence of an 8-hydroxy/7-methoxy motif (as compared to a 
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catechol moiety) may offer some advantages in pharmacokinetic stability without significantly 
compromising D1-like affinity.   
Evaluation of the functional activity of 72b and 72f affirms the idea that an 8-hydroxy/7-
methoxy moiety favors antagonist rather than agonist activity. This aligns with the generally 
accepted requirement for a catechol motif for agonist activity in the 1-phenylbenzazepine scaffold.  
A general observation is that compounds with the 2’,6’-dichloro substitution (i.e. 70c, 72c 
and 74c) had D5R versus D1R selectivity, whereas compounds with C2’ mono-halo substituents 
had a reversal in this selectivity. Although the selectivity is quite modest, examination of other 
compounds with a C2’/C6’ di-substitution pattern may be a worthwhile venture for future 
optimization of these ligands towards D5R potency and sub-type selectivity.  
Overall structural trends observed based on D1R/D5R affinity data are summarized on 
Figure 24. This SAR data will be useful for further studies. Molecular docking studies and further 
functionalization will help solidify the current results. 
 
 









General experimental procedures 
Unless otherwise stated, chemicals were purchased from Fischer Scientific (USA) and used 
without further purification. Reactions were carried out in oven – dried glassware under a nitrogen 
atmosphere. HRESIMS spectra were obtained using an Agilent 6520 QTOF instrument. 1H NMR 
and 13C NMR spectra were recorded using Bruker DPX – 600 spectrometers (operating at 400 or 
500 or 600 MHz for 1H; 101 or 125 or 150 MHz, respectively, for 13C) using CDCl3, Acetone – 
d6, DMSO – d6 or Methanol – d4 as solvents. Tetramethylsilane (δ 0.00 ppm) served as an internal 
standard in 1H NMR and CDCl3 (δ 77.0 ppm) in 
13C NMR as solvent. Chemical shift (δ 0.00 ppm) 
values are reported in parts per million and coupling constants in Hertz (Hz). Splitting patterns are 
described as singlet (s), doublet (d), triplet (t), and multiplet (m). Reactions were monitored by 
TLC with Whatman Flexible TLC silica gel G/UV 254 precoated plates (0.25 mm). TLC plates 
were visualized by UV (254 nm). Silica gel column chromatography was performed with silica 
gel 60 (EMD Chemicals, 230 – 400 mesh, 0.063 mm particle size). 
 
General procedure A: epoxidation of styrenes  
To a stirred solution of desired styrene (1 equiv.) in DCM (125 mL) was slowly added 
mCPBA (2 equiv.) at 0 °C and the resulting reaction mixture was warmed to rt and stirred for 12 
h. The progress of the reaction was monitored by TLC. After completion of the reaction, the 
reaction mixture was quenched with aqueous NaOH (3M, 100 mL) and extracted with DCM (3X50 
mL). The combined organic layer was washed with brine, dried over anhydrous Na2SO4 and 
concentrated under reduced pressure to give a pure product. 
 
General procedure B: coupling of 2-(4-(benzyloxy)-3-methoxyphenyl)ethan-1-amine  with 
epoxides 
To a solution of epoxide (1 equiv.) and amine (1.5 equiv.) in anhydrous THF (100 mL) 
was slowly added Bis(trifluoromethane)sulfonimide lithium (1.1 equiv.) at rt and the resulting 
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reaction mixture was refluxed for 24 h. After completion (the reaction progress was monitored by 
TLC), THF was evaporated, reaction mixture was quenched with saturated NaHCO3 (25 mL) and 
extracted with EtOAc (3 x 30 mL). The combined organic phase was dried with Na2SO4 and 
concentrated to give crude viscous liquid, which was purified by silica gel column chromatography 
to yield pure product as viscous oil.  
 
General procedure C: amino alcohol cyclization 
To a stirred solution of respective amino – alcohols (1 equiv.) in TFA (30 mL) was added 
18 M H2SO4 (cat.) at rt and the resulting reaction mixture was stirred for 5 h at rt. Anhydrous 
NaOAc (2 equiv.) was added and stirred for additional 15 min. TFA was evaporated and the 
reaction mixture was neutralized with 14 M NH4OH to give a solid residue. The residue was 
dissolved in EtOAc (25 mL), washed with water and brine. Organic phase was dried over Na2SO4 
and concentrated under reduced pressure to give crude residue, which was purified by silica gel 
column chromatography to give pure product.  
 
General procedure D: N-methylation 
To a stirred solution of secondary amine (1 equiv.) in acetonitrile (100 mL) was added 
paraformaldehyde (3 equiv.) and the reaction mixture was stirred at rt for 30 mins. Sodium 
triacetoxyborohydride (1.5 equiv.) was added to the reaction mixture and the resulting reaction 
mixture was stirred for 12 h at the same temperature. After completion of the reaction (monitored 
by TLC), it was quenched with saturated NaHCO3 (20 mL), washed with water and extracted with 
EtOAc (2 x 25 mL), dried over anhydrous Na2SO4, evaporated under reduced pressure to give 
crude compound, which was purified by silica gel flash chromatography to afford  pure N – 
methylated product.  
 
General procedure E: N-allylation 
To a stirred solution of secondary amine (1 equiv.) in acetonitrile (80 mL) was added TEA 
(2 equiv.) followed by allyl bromide (1.5 equiv.) at rt and the resulting reaction mixture was stirred 
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at the same temperature for 12 h. After completion of the reaction (monitored by TLC), the reaction 
mixture was quenched with water, washed with NaHCO3 (25 mL) and extracted with EtOAc (2 x 
25 mL). The combined organic layer was dried over anhydrous Na2SO4 and evaporated under 
vacuum to give crude compound, which was purified by silica gel flash chromatography to give 
pure N – allylated product. 
 
General procedure F: O-demethylation with BBr3 
To a stirred solution of compound (1 equiv.) in DCM (20 mL) was slowly added BBr3 (4 
equiv.) at 0 oC and the reaction mixture was warmed to rt and stirred at the same temperature for 
18 h. After completion, ice water was added to the reaction mixture, allowed to stir for 30 min and 
the obtained precipitate was filtered to give pure compound.  
 
2-(2-chlorophenyl)oxirane (68b): Synthesized according to general procedure A. Colorless liquid. 
Yield: 93%.  
1H NMR (600 MHz, CDCl3): δ 7.39 – 7.36 (m, 1H), 7.29 – 7.23 (m, 3H), 4.24 (dd, J = 4.3, 2.7 
Hz, 1H), 3.21 (dd, J = 5.8, 4.2 Hz, 1H), 2.69 (dd, J = 5.8, 2.6 Hz, 1H); 13C NMR (150 MHz, 
CDCl3): δ 135.5, 133.2, 129.1, 128.9, 127.0, 125.6, 50.7, 50.0 ppm. HRESIMS calculated for 
C8H8ClO [M+H]
+ 155.0258, found 155.0257. 
 
2-(2,6-dichlorophenyl)oxirane (68c): Synthesized according to general procedure A. Colorless 
liquid. Yield: 88%.  
1H NMR (400 MHz, CDCl3): δ 7.32 (d, J = 6.1 Hz, 2H), 7.20 (dd, J = 13.2 ,6.1 Hz 1H), 3.99 (t, J 
= 4.7 Hz, 1H), 3.29 (t, J = 4.6 Hz, 1H), 3.01 (dd, J = 5.0, 2.8 Hz, 1H); 13C NMR (150 MHz, 
CDCl3): δ 136.0, 132.9, 129.8, 128.4, 128.3, 128.2, 50.1, 49.3 ppm. HRESIMS calculated for 
C8H6Cl2O [M+H]




2-(2-bromophenyl) oxirane (68d):  Synthesized according to general procedure A. Yellow liquid. 
Yield: 91%.   
1H NMR (600 MHz, CDCl3): δ 7.56 (d, J = 8.1 Hz, 1H), 7.32 (t, J = 7.7 Hz, 1H), 7.25 (d, J = 7.8 
Hz, 1H), 7.18 (t, J = 7.7 Hz, 1H), 4.18 – 4.16 (m, 1H), 3.21 (dd, J = 5.8, 4.2 Hz, 1H), 2.66 (dd, J 
= 5.8, 2.8 Hz, 1H); 13C NMR (125 MHz, CDCl3): δ 137.2, 132.3, 129.2, 127.6, 126.0, 122.6, 52.2, 
50.7 ppm. HRESIMS calculated for C8H8BrO [M+H]
+ 198.9753, found 198.7900. 
 
2-(4-bromophenyl)oxirane (68e): Synthesized according to general procedure A. white liquid. 
Yield: 91%.   
1H NMR (600 MHz, CDCl3) δ 7.48 (dd, J = 8.6, 4.0 Hz, 2H), 7.16 (dd, J = 8.6, 3.9 Hz, 2H), 3.84 
(dd, J = 6.8, 4.1 Hz, 1H), 3.16 (dd, J = 9.8, 4.4 Hz, 1H), 2.76 (dd, J = 6.8, 5.1 Hz, 1H); 13C NMR 
(150 MHz, CDCl3) δ 136.7, 131.6, 127.1, 122.0, 51.8, 51.3 ppm. HRESIMS calculated for 
C8H8BrO [M+H]
+ 198.9753, found 198.7900. 
 
2-(2-fluorophenyl)oxirane (68f): Synthesized according to general procedure A. Colorless 
viscous liquid. Yield: 94%. 
1H NMR (600 MHz, CDCl3) δ 7.30 (dd, J = 6.4, 3.7 Hz, 1H), 7.21 (t, J = 7.5 Hz, 1H), 7.15 (t, J = 
7.5 Hz, 1H), 7.07 (dd, J = 11.7, 7.0 Hz, 1H) 4.17 (dd, J = 7.0, 3.4 Hz, 1H), 3.20 (dt, J = 14.1, 7.1 
Hz, 1H), 2.81 (dd, J = 5.7, 2.7 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 160.7, 129.3, 125.8, 124.9, 
124.3, 115.2, 50.4, 46.9 ppm. HRESIMS calculated for C8H8FO [M+H]
+ 139.0481, found 
139.0476. 
 
2-(o-tolyl)oxirane (68g): Synthesized according to general procedure A. White viscous liquid. 
Yield: 97%.  
1H NMR (600 MHz, CDCl3) δ 7.26 – 7.24 (m, 1H), 7.24 (d, J = 1.2 Hz, 1H), 7.23 (d, J = 2.4 Hz, 
1H), 7.21 – 7.18 (m, 1H), 4.03 (dt, J = 11.0, 5.5 Hz, 1H), 3.19 (dt, J = 9.9, 5.1 Hz, 2H), 2.73 (dt, J 
= 5.0, 2.6 Hz, 2H), 2.46 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 136.1, 135.8, 129.8, 127.6, 126.1, 
124.1, 50.4, 50.1, 18.7 ppm. HRESIMS calculated for C9H11O [M+H]
+ 135.0732, found 135.0722. 
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2-((4-(benzyloxy)-3-methoxyphenethyl)amino)-1-phenyl ethan-1-ol (69a): Synthesized 
according to general procedure B. Purified by silica gel chromatography (2% MeOH/DCM) to 
give pure product as a viscous liquid. Yield: 78%. 
1H NMR (600 MHz, CDCl3): δ 7.47 – 7.44 (m, 2H), 7.41 – 7.37 (m, 2H), 7.36 (d, J = 4.5 Hz, 3H), 
7.33 (t, J = 4.7 Hz, 2H), 7.30 (dd, J = 8.1, 3.7 Hz, 1H), 6.82 (dd, J = 7.1, 2.8 Hz, 1H), 6.75 (d, J 
= 2.0 Hz, 1H), 6.66 (dd, J = 8.2, 2.0 Hz, 1H), 5.14 (s, 2H), 4.82 – 4.77 (m, 1H), 3.89 (s, 3H), 3.03 
– 2.89 (m, 3H), 2.82 – 2.74 (m, 3H); 13C NMR (150 MHz, CDCl3): δ 149.7, 146.8, 141.8, 137.2, 
131.8, 128.6, 128.6, 127.9, 127.3, 126.1, 125.8 120.6, 114.1, 112.4, 71.10, 71.06, 56.5, 56.0, 50.5, 
35.0 ppm. HRESIMS calculated for C24H27NO3 [M+H]
+ 378.1991, found 378.1890. 
 
2-((4-(benzyloxy)-3-methoxyphenethyl)amino)-1-(2-chlorophenyl)ethan-1-ol (69b): 
Synthesized according to general procedure B. Purified by silica gel chromatography (2% 
MeOH/DCM) to give pure product as a viscous liquid. Yield: 78%.   
1H NMR (600 MHz, CDCl3): δ 7.56 (d, J = 7.7 Hz, 1H), 7.44 (d, J = 8.0 Hz, 2H), 7.38 (t, J = 10.2 
Hz, 2H), 7.32 (d, J = 7.9 Hz, 2H), 7.29 – 7.26 (m, 1H), 7.24 (t, J = 8.6 Hz, 1H), 6.82 (d, J = 8.2 
Hz, 1H), 6.77 (s, 1H), 6.66 (dd, J = 8.2, 2.0 Hz, 1H), 5.25 (dd, J = 9.7, 2.9 Hz, 1H), 5.12 (s, 2H), 
3.87 (s, 3H), 3.18-3.13 (m, 1H), 3.14 – 3.09 (m, 1H), 3.06 – 3.00 (m, 1H), 2.85 (t, J = 7.4 Hz, 2H), 
2.82 – 2.75 (m, 1H); 13C NMR (150 MHz, CDCl3): δ 149.8, 147.0, 138.1, 137.0, 131.5, 130.4, 
129.5, 129.2, 128.6, 127.9, 127.3, 127.1, 126.9, 120.6, 114.3, 112.4, 71.1, 67.0, 56.0, 53.5, 50.1, 
33.6 ppm. HRESIMS calculated for C24H27ClNO3 [M+H]
+ 412.1674, found 412.1670. 
 
2-((4-(benzyloxy)-3-methoxyphenethyl)amino)-1-(2,6-dichlorophenyl)ethan-1-ol (69c): 
Synthesized according to general procedure B. Purified by silica gel column chromatography (3% 
MeOH/DCM) to give pure product as a viscous liquid. Yield: 66%.   
1H NMR (600 MHz, CDCl3): δ 7.45 (d, J = 7.1 Hz, 2H), 7.40 – 7.36 (m,2H), 7.33 – 7.29 (m, 3H), 
7.16 (dt, J = 8.0, 5.4 Hz, 1H), 6.83 (d, J = 8.2 Hz, 1H), 6.78 (s, 1H), 6.69 (d, J = 8.1 Hz, 1H), 5.58 
(dd, J = 10.3, 4.0 Hz, 1H), 5.15 (s, 2H), 3.90 (s, 3H), 3.35 (dt, J = 11.5, 7.4 Hz, 1H), 3.26 (bs, 2H), 
3.06 (dt, J = 11.8, 7.2 Hz, 1H), 3.00 – 2.89 (m, 2H), 2.81 (dd, J = 14.1, 6.9 Hz, 2H); 13C NMR 
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(150 MHz, CDCl3): δ 149.7, 146.8, 137.2, 135.2, 134.6, 132.1, 131.0, 129.5, 129.3, 128.5, 127.9, 
127.8, 127.3, 120.9, 114.3, 112.5, 71.1, 69.5, 56.0, 51.6, 50.3, 35.1 ppm. HRESIMS calculated for 
C24H26Cl2NO3 [M+H]
+ 446.1284, found 446.1280. 
 
2-((4-(benzyloxy)-3-methoxyphenethyl)amino)-1-(2-bromophenyl)ethan-1-ol (69d): 
Synthesized according to general procedure B. Purified by silica gel column chromatography (2% 
MeOH/DCM) to give pure product as a viscous liquid. Yield: 62%. 
1H NMR (600 MHz, CDCl3): δ 7.61 (d, J = 9.8 Hz, 1H), 7.52 (d, J = 6.9 Hz, 1H), 7.47 – 7.44 (m, 
2H), 7.39 (dd, J = 10.3, 4.8 Hz, 2H), 7.36 – 7.28  (m, 2H), 7.15 (d, J = 7.7 Hz, 1H), 6.83 (d, J = 
8.1 Hz, 1H), 6.77 (s, 1H), 6.69 (d, J = 7.0 Hz, 1H), 5.15 (s, 2H), 5.09 (dd, J = 9.0, 3.2 Hz, 1H), 
3.90 (s, 3H), 3.12 (dd, J = 12.4, 3.2 Hz, 1H), 3.05 – 3.01 (m, 1H), 2.94 (dt, J = 11.9, 7.1 Hz, 1H), 
2.81 (td, J = 6.9, 3.4 Hz, 2H), 2.63 (dd, J = 12.4, 7.1 Hz, 1H) 2.26 (bs, 1H); 13C NMR (150 MHz, 
CDCl3): δ 149.7, 146.8, 141.0, 137.3, 132.6, 132.4, 128.9, 128.5, 127.8, 127.7, 127.5, 127.4, 121.7, 
120.6, 114.3, 112.5, 71.2, 70.1, 56.0, 54.4, 50.3, 35.5 ppm. HRESIMS calculated for C24H27BrNO3 
[M+H]+ 456.1169, found 456.1161. 
 
2-((4-(benzyloxy)-3-methoxyphenethyl)amino)-1-(4-bromophenyl)ethan-1-ol (69e): 
Synthesized according to general procedure B. Purified by silica gel column chromatography (3% 
MeOH/DCM) to give pure product as a viscous liquid. Yield: 59%. 
1H NMR (600 MHz, CDCl3) δ 7.45 (t, J = 8.4 Hz, 5H), 7.38 (t, J = 7.5 Hz, 3H), 7.32 (t, J = 7.3 
Hz, 1H), 7.19 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 8.2 Hz, 1H), 6.74 (d, J = 2.0 Hz, 1H), 6.64 (dd, J = 
8.2, 2.0 Hz, 1H), 5.13 (s, 2H), 4.79 (dd, J = 9.8, 3.2 Hz, 1H), 3.88 (s, 3H), 3.71 (bs, 3H), 3.07 (dt, 
J = 12.0, 7.2 Hz, 1H), 3.02 – 2.98 (m, 1H), 2.96 (dd, J = 9.6, 4.9 Hz, 1H), 2.84 – 2.80 (m, 2H), 
2.79 – 2.75 (m, 1H); 13C NMR (150 MHz, CDCl3) δ 208.2, 175.4, 173.3, 149.8, 147.0, 139.9, 
137.0, 131.7, 131.4, 130.7, 128.6, 127.9, 127.8, 127.4, 127.3, 121.9, 120.6, 114.2, 112.3, 77.4, 






2-((4-(benzyloxy)-3-methoxyphenethyl)amino)-1-(2-fluorophenyl)ethan-1-ol (69f): Synthesized 
according to general procedure B. Yellowish viscous liquid. Yield: 63%. 
1H NMR (600 MHz, CDCl3) δ 7.40 (t, J = 7.4 Hz, 1H), 7.35 (d, J = 7.6 Hz, 2H), 7.28 (t, J = 7.5 
Hz, 2H), 7.23 (d, J = 7.3 Hz, 1H), 7.06 (t, J = 7.5 Hz, 1H), 6.95 – 6.90 (m, 1H), 6.74 (d, J = 8.2 
Hz, 1H), 6.67 (s, 1H), 6.58 (d, J = 8.2 Hz, 1H), 5.07 (dd, J = 9.5, 3.0 Hz, 1H), 5.04 (s, 2H), 3.79 
(s, 3H), 3.05 – 2.99 (m, 2H), 2.96 – 2.90 (m, 1H), 2.82 – 2.78 (m, 1H), 2.76 (dd, J = 13.1, 5.8 Hz, 
2H); 13C NMR (150 MHz, CDCl3) δ 158.8, 149.8, 147.0, 137.1, 130.8, 129.5, 129.5, 128.5, 128.0, 
127.9, 127.3, 127.2, 124.5, 120.6, 115.4, 115.2, 114.3, 112.4, 71.1, 65.0, 55.9, 54.2, 50.3, 34.1 
ppm. HRESIMS calculated for C24H27FNO3 [M+H]
+ 396.1897, found 396.1897. 
 
2-((4-(benzyloxy)-3-methoxyphenethyl)amino)-1-(o-tolyl)ethan-1-ol (69g): Synthesized 
according to general procedure B. Viscous yellowish liquid. Yield: 67%. 
1H NMR (400 MHz, CDCl3) δ 7.51 – 7.48 (m, 1H), 7.46 (d, J = 7.2 Hz, 2H), 7.39 (t, J = 7.3 Hz, 
2H), 7.32 (dd, J = 8.3, 6.1 Hz, 1H), 7.22 (dd, J = 8.0, 1.4 Hz, 1H), 7.19 (dd, J = 7.4, 1.6 Hz, 1H), 
7.14 (d, J = 7.0 Hz, 1H), 6.85 – 6.82 (m, 1H), 6.77 (d, J = 1.8 Hz, 1H), 6.68 (dd, J = 8.2, 1.8 Hz, 
1H), 5.14 (s, 2H), 5.04 (dd, J = 9.4, 3.0 Hz, 1H), 3.90 (s, 3H), 3.46 (s, 2H), 3.03 (dt, J = 11.7, 7.1 
Hz, 1H), 2.98 – 2.90 (m, 2H), 2.85 – 2.79 (m, 2H), 2.73 (dd, J = 12.4, 9.5 Hz, 1H), 2.33 (s, 3H); 
13C NMR (150 MHz, CDCl3) δ 149.6, 146.7, 139.8, 137.2, 134.4, 131.9, 130.4, 128.5, 127.8, 
127.5, 127.2, 126.3, 125.3, 120.5, 114.0, 112.3, 71.0, 67.8, 55.9, 55.1, 50.6, 35.1, 19.0 ppm. 
C25H30NO3 [M+H]
+ 392.2147, found 392.2134. 
 
8-methoxy-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d] azepin -7-ol (70a): Synthesized according 
to general procedure C. Purified by silica gel chromatography (60% EtOAc/Hexanes) to afford the 
pure product as a white solid. Yield: 33%, mp: 183.1 – 185.7 °C.   
1H NMR (600 MHz, CDCl3): δ 7.33 (t, J = 7.6 Hz, 2H), 7.26 (t, J = 7.4 Hz, 1H), 7.12 (d, J = 7.5 
Hz, 2H), 6.67 (s, 1H), 6.46 (s, 1H), 4.19 (d, J = 6.5 Hz, 1H), 3.89 (s, 3H), 3.57 – 3.51 (m, 1H), 
3.35 (dd, J = 15.54, 6.8Hz, 1H), 3.00 – 2.97 (m, 2H), 2.86 – 2.81 (m, 2H); 13C NMR (150 MHz, 
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CDCl3): δ 144.6, 143.6, 141.5, 135.9, 132.6, 128.7, 28.1, 126.4, 116.6, 113.1, 56.0, 52.7, 52.2, 
48.0, 38.9 ppm. HRESIMS calculated for C17H19NO2 [M+H]
+ 270.1416, found 270.1493. 
 
5-(2-chlorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1H-benzo [d]azepin-7-ol (70b): Synthesized 
according to general procedure C. Purified by silica gel chromatography (3% MeOH/DCM) to 
give pure product as a white solid. Yield: 45%, mp: 186.4 – 187.0 °C.  
1H NMR (600 MHz, Acetone-d6): δ 7.46 (d, J = 6.9 Hz, 1H), 7.39 (t, J = 7.5 Hz, 1H), 7.31 (dd, J 
= 7.7, 1.5 Hz, 2H), 6.81 (s, 1H), 5.92 (s, 1H), 4.70 (d, J = 8.8 Hz, 1H), 3.82 (s, 3H), 3.35 (d, J = 
9.9 Hz, 1H), 3.24 – 3.13 (m, 4H), 2.89 – 2.83 (m, 1H), 2.75 (dd, J = 12.0, 6.2 Hz, 1H); 13C NMR 
(150 MHz, DMSO-d6): δ 145.4, 144.3, 141.3, 136.0, 133.2, 132.5, 130.3, 129.9, 128.5, 127.9, 
120.9, 118.8, 56.1, 53.7, 48.6, 48.3, 38.6 ppm. HRESIMS calculated for C17H19ClNO2 [M+H]
+ 
304.1026, found 304.1099. 
 
5-(2,6-dichlorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (70c): 
Synthesized according to general procedure C. Purified by silica gel chromatography (4% 
MeOH/DCM) to obtain pure product as a white solid. Yield: 44%, mp: 193.3 – 194.8 °C.  
1H NMR (600 MHz, CDCl3): δ 7.30 – 7.28 (m, 2H), 7.09 (t, J = 8.0 Hz, 1H), 6.63 (s, 1H), 6.15 (s, 
1H), 5.16 (d, J = 8.5 Hz, 1H), 3.80 (s, 3H), 3.55 (dd, J = 13.5, 8.6 Hz, 1H), 3.33 (d, J = 8.4 Hz, 
2H), 3.24 – 3.16 (m, 1H), 2.85 – 2.75 (m, 2H); 13C NMR (150 MHz, CDCl3): δ 144.4, 143.4, 138.5, 
132.8, 131.9, 128.6, 128.5, 128.1, 126.1, 113.9, 113.0, 55.9, 53.0, 48.0, 38.7, 31.6 ppm. HRESIMS 
calculated for C17H18Cl2NO2 [M+H]
+ 338.0636, found 338.0709. 
 
5-(2-bromophenyl)-8-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (70d): Synthesized 
according to general procedure C. Purified by silica gel column chromatography (2% 
MeOH/DCM) to give product as a whitish solid. Yield: 48%, mp: 182.3 – 183.1 °C.   
1H NMR (600 MHz, CD3OD): δ 7.60 (d, J = 7.9 Hz, 1H), 7.33 (t, J = 8.1 Hz, 1H), 7.17 (d, J = 7.6 
Hz, 1H), 7.13 (t, J = 8.4 Hz, 1H), 6.69 (s, 1H), 6.07 (s, 1H), 4.68 (d, J = 7.6 Hz, 1H), 3.88 (s, 3H), 
3.40 (dd, J = 13.1, 4.6 Hz, 1H), 3.27 – 3.17 (m, 3H), 2.91 – 2.80 (m, 2H) ; 13C NMR (150 MHz, 
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CDCl3): δ 144.4, 143.5, 142.2, 135.9, 133.2, 132.7, 129.7, 128.1, 127.7, 125.1, 114.6, 112.9, 56.0, 
53.2, 51.8, 47.9, 39.2 ppm. HRESIMS calculated for C17H19BrNO2 [M+H]
+ 348.0521, found 
348.0591. 
 
5-(4-bromophenyl)-8-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (70e): Synthesized 
according to general procedure C. Purified by silica gel column chromatography (3% 
MeOH/DCM) to give product as a whitish solid. Yield: 52%, mp: 190.8 – 192.4 °C.   
1H NMR (600 MHz, CDCl3) δ 7.32 (d, J = 8.4 Hz, 2H), 7.11 (t, J = 7.4 Hz, 2H), 6.92 (d, J = 6.9 
Hz, 1H), 6.74 (d, J = 9.2 Hz, 1H), 6.58 (s, 1H), 4.56 (d, J = 3.4 Hz, 1H), 3.89 (s, 3H), 3.57 (d, J = 
16.1 Hz, 1H), 3.39 – 3.31 (m, 2H), 3.06 (t, J = 13.0 Hz, 1H), 2.93 (t, J = 10.6 Hz, 1H), 2.82 – 2.75 
(m, 1H), 2.69 (dd, J = 17.2, 5.1 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 147.0, 137.0, 131.7, 
128.6, 127.9, 127.4, 127.3, 120.6, 114.2, 112.3, 69.9, 56.0, 55.7, 50.3, 34.1 ppm. HRESIMS 
calculated for C17H19BrNO2 [M+H]
+ 348.0521, found 348.0591. 
 
5-(2-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (70f): Synthesized 
according to general procedure C. White solid. Yield: 47%, mp: 167.5 – 169.2 °C.  
1H NMR (600 MHz, DMSO) δ 7.36 (dd, J = 14.0, 7.1 Hz, 1H), 7.26 – 7.18 (m, 1H), 6.77 (s, 1H), 
5.98 (s, 1H), 5.76 (s, 1H), 4.44 (dd, J = 7.2, 3.5 Hz, 1H), 3.72 (s, 1H), 3.22 – 3.15 (m, 1H), 3.09 
(dd, J = 12.9, 6.7 Hz, 1H), 3.02 (dd, J = 15.0, 9.7 Hz, 1H), 2.79 (dd, J = 14.8, 6.7 Hz, 1H), 2.67 (t, 
J = 12.6 Hz, 1H); 13C NMR (150 MHz, DMSO) δ 159.6, 146.1, 145.1, 134.0, 130.7, 130.1, 129.7, 
128.6, 125.4, 116.3, 116.1, 115.4, 115.1, 56.2, 50.7, 46.3, 41.4, 33.1 ppm. HRESIMS calculated 
for C17H19FNO2 [M+H]
+ 288.1431, found 288.1411. 
 
8-methoxy-5-(o-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (70g): Synthesized according 
to general procedure C. White solid. Yield: 51%, mp: 161.7 – 164.2 °C. 
1H NMR (600 MHz, DMSO) δ 7.34 – 7.30 (m, 1H), 7.27 (d, J = 4.0 Hz, 2H), 7.14 (d, J = 7.5 Hz, 
1H), 6.85 (s, 1H), 5.78 (s, 1H), 4.62 (d, J = 8.0 Hz, 1H), 3.73 (s, 3H), 3.56 (dd, J = 24.8, 12.2 Hz, 
2H), 3.31 (t, J = 13.0 Hz, 1H), 2.95 (dd, J = 15.7, 5.5 Hz, 1H), 2.86 (t, J = 12.2 Hz, 1H), 2.10 (s, 
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3H); 13C NMR (150 MHz, DMSO) δ 146.13, 145.1, 140.2, 136.0, 134.7, 131.0, 129.9, 127.8, 
127.4, 127.0, 115.2, 114.9, 56.1, 50.7, 46.0, 41.3, 32.0, 19.3 ppm. HRESIMS calculated for 
C18H22NO3 [M+H]
+ 284.1572, found 284.1570. 
 
1-(2-chlorophenyl)-2,3,4,5-tetrahydro-1H-benzo[d] azepine-7,8-diol (71b): Synthesized 
according to general procedure F. The product was obtained as an off-white solid. Yield: 36%, 
mp: 203.6 – 205 °C.  
1H NMR (400 MHz, DMSO-d6): δ 7.97 (t, J = 7.1 Hz, 2H), 7.87 (t, J = 8.0 Hz, 1H), 7.26 (s, 1H), 
6.54 (s, 1H), 6.12 (d, J = 8.8 Hz, 1H), 4.35 – 4.29 (m, 1H), 4.26 – 4.20 (m, 2H), 4.10 – 4.06 (m, 
1H), 3.64 – 3.58 (m, 2H), 3.51 – 3.46 (m, 1H); 13C NMR (150 MHz, DMSO-d6): δ 134.4, 132.0, 
131.5, 131.1, 129.2, 128.1, 126.9, 126.5, 122.5, 115.6, 112.7, 60.4, 55.0, 44.6, 32.0 ppm. 
HRESIMS calculated for C16H17ClNO2 [M+H]
+ 290.0870, found 290.0945. 
 
1-(2-bromophenyl)-2,3,4,5-tetrahydro-1H-benzo[d] azepine-7,8-diol (71d): Synthesized 
according to general procedure F. Product was obtained as an off-white solid. Yield: 56%, mp: 
203.4 – 204.8 °C.  
1H NMR (600 MHz, DMSO-d6): δ 7.67 (d, J = 8.0 Hz, 1H), 7.49 (t, J = 10.9 Hz, 1H), 7.30 – 7.26 
(m, 2H), 6.59 (s, 1H), 5.68 (s, 1H), 4.62 (d, J = 9.2 Hz, 1H), 3.10 – 3.06 (m, 1H), 2.85 (bs, 1H), 
2.69 (dd, J = 14.9, 6.2 Hz, 1H), 2.44 (bs, 3H), 2.31 (s, 1H); 13C NMR (150 MHz, DMSO-d6): δ 
142.3, 142.1, 141.6, 132.5, 132.1, 130.2, 129.1, 127.8, 127.4, 123.5, 116.5, 113.7, 61.4, 56.0, 45.6, 
32.9 ppm. HRESIMS calculated for C16H17BrNO2 [M+H]
+ 334.0634, found 334.0439. 
 
1-(4-bromophenyl)-2,3,4,5-tetrahydro-1H-benzo[d] azepine-7,8-diol (71e): Synthesized 
according to general procedure F. Product was obtained as an off-white solid. Yield: 61%, mp: 
191.5 – 193.0 °C. 
1H NMR (600 MHz, CDCl3) δ 8.06 (d, J = 11.0 Hz, 2H), 7.69 (d, J = 8.4 Hz, 2H), 7.24 (s, 1H), 
6.66 (s, 1H), 5.35 (d, J = 10.3 Hz, 1H), 4.25 (dd, J = 16.7, 5.7 Hz, 3H), 4.07 (dd, J = 19.2, 12.2 
Hz, 1H), 3.91 (dd, J = 15.6, 10.2 Hz, 1H), 3.77 – 3.68 (m, 1H), 3.47 (dd, J = 15.9, 7.1 Hz, 1H); 
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13C NMR (150 MHz, CDCl3) δ 143.3, 143.2, 139.2, 131.4, 131.3, 129.8, 128.4, 120.4, 117.3, 




1-(2-fluorophenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol (71f): Synthesized 
according to general procedure F. Off-white solid. Yield: 72%, mp: 178.4 – 180.1°C.   
1H NMR (600 MHz, Acetone) δ 7.33 (d, J = 7.7 Hz, 1H), 7.20 (d, J = 4.7 Hz, 2H), 7.15 (t, J = 7.5 
Hz, 1H), 6.68 (s, 1H), 6.12 (s, 1H), 4.49 (d, J = 4.2 Hz, 1H), 3.28 (d, J = 19.9 Hz, 2H), 3.10 (dd, J 
= 12.2, 6.7 Hz, 1H), 3.06 – 2.98 (m, 1H), 2.75 (dd, J = 12.2, 6.8 Hz, 2H); 13C NMR (150 MHz, 
Acetone) δ 142.6, 142.4, 134.4, 133.0, 130.5, 128.2, 128.1, 124.3, 117.4, 115.4, 115.3, 115.2, 53.6, 
48.3, 38.7, 29.7 ppm. HRESIMS calculated for C16H17FNO2 [M+H]
+ 274.1165, found 274.1165. 
 
1-(o-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol (71g): Synthesized according to 
general procedure F. White solid. Yield: 56%, mp: 165.4 – 166.8 °C.   
1H NMR (600 MHz, DMSO) δ 7.23 (t, J = 20.5 Hz, 3H), 7.11 (s, 1H), 6.57 (s, 1H), 5.72 (s, 1H), 
4.35 (d, J = 38.3 Hz, 1H), 3.85 – 3.66 (m, 1H), 3.14 (d, J = 36.2 Hz, 4H), 2.74 – 2.61 (m, 1H), 
2.10 (s, 3H); 13C NMR (150 MHz, DMSO) δ 144.9, 143.9, 139.0, 134.8, 133.5, 129.8, 128.7, 
126.6, 126.2, 125.8, 114.0, 113.7, 49.5, 44.8, 30.9, 30.8, 18.1 ppm. HRESIMS calculated for 
C17H20NO2 [M+H]
+ 270.1416, found 270.1420. 
 
5-(2-chlorophenyl)-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (72b): 
Synthesized according to general procedure D. Purified by silica gel column chromatography (1% 
MeOH/DCM) to give product as an off-white solid. Yield: 71%, mp: 198.2 – 200 °C.  
1H NMR (600 MHz, CDCl3): δ 7.36 (d, J = 7.9 Hz, 1H), 7.28 – 7.20 (m, 2H), 7.07 (d, J = 7.3 Hz, 
1H), 6.63 (s, 1H), 5.98 (s, 1H), 4.81 (d, J = 9.3 Hz, 1H), 3.79 (s, 3H), 3.54 – 3.47 (m, 2H), 3.40 – 
3.32 (m, 2H), 2.89 – 2.85 (m, 1H), 2.74 – 2.69 (m, 4H); 13C NMR (150 MHz, CDCl3): δ 145.6, 
144.7, 138.2, 136.7, 131.4, 129.7, 129.6, 125.6, 117.1, 116.9, 115.1, 113.6, 63.6, 58.3, 57.1, 48.2, 
36.8, 36.4 ppm. HRESIMS calculated for C18H21ClNO2 [M+H]
+ 318.1183, found 318.1256. 
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5-(2,6-dichlorophenyl)-8-methoxy-3-methyl-2,3,4,5-tetra hydro-1H-benzo[d]azepin-7-ol (72c) : 
Synthesized according to general procedure D. Purified by silica gel chromatography (40% 
EtOAc/Hexanes) to afford pure product as a white solid. Yield: 32%, mp: 205.4 – 207 °C. 
1H NMR (600 MHz, Acetone) δ 7.54 – 7.49 (m, 2H), 7.39 (dd, J = 8.9, 7.2 Hz, 1H), 6.87 (s, 1H), 
6.10 (s, 1H), 5.36 (d, J = 7.8 Hz, 1H), 3.82 (s, 3H), 3.36 – 3.27 (m, 2H), 2.93 – 2.85 (m, 5H); 13C 
NMR (150 MHz, DMSO-d6): δ 145.9, 144.7, 135.7, 135.6, 130.7, 130.0, 129.4, 128.7, 121.6, 
118.4, 115.2, 114.5, 60.2, 57.3, 56.2, 46.4, 21.2, 14.6 ppm. HRESIMS calculated for 
C18H20Cl2NO2 [M+H]
+ 352.0793, found 352.0864. 
 
5-(2-bromophenyl)-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (72d): 
Synthesized according to general procedure D. Purified by silica gel chromatography (1% 
MeOH/DCM) to obtain pure product as a white solid. Yield: 34%, mp: 180.3 – 182.5 °C. 
1H NMR (600 MHz, CDCl3): δ 7.59 (d, J = 8.0 Hz, 1H), 7.36 – 7.32 (m, 1H), 7.21 (d, J = 7.7 Hz, 
1H), 7.14 (t, J = 7.9 Hz, 1H), 6.67 (s, 1H), 5.98 (s, 1H), 4.77 (d, J = 9.2 Hz, 1H), 3.86 (s, 3H), 3.36 
– 3.29 (m, 1H), 3.19 (d, J = 11.8 Hz, 1H), 3.10 – 3.07 (m, 1H), 2.77 (dd, J = 12.9, 6.3 Hz, 1H), 
2.69 (t, J = 6.3 Hz, 1H), 2.41 (s, 3H), 2.25 (t, J = 6.5 Hz, 1H); 13C NMR (150 MHz, CDCl3): δ 
143.2, 142.3, 141.9, 135.4, 132.2, 131.8, 128.4, 127.0, 126.7, 124.2, 112.7, 111.3, 62.1, 56.2, 




5-(2-fluorophenyl)-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (72f):  
Synthesized according to general procedure D. White solid. Yield: 38%, mp: 158.3 – 161.1 °C. 
1H NMR (600 MHz, CDCl3) δ 7.10 (t, J = 6.6 Hz, 2H), 7.07 (d, J = 7.3 Hz, 1H), 7.01 (t, J = 7.8 
Hz, 2H), 6.61 (s, 1H), 6.13 (s, 1H), 4.53 (d, J = 9.0 Hz, 1H), 3.79 (s, 3H), 3.23 (t, J = 13.8 Hz, 1H), 
3.11 (d, J = 12.2 Hz, 1H), 3.04 (s, 2H), 2.82 (t, J = 9.6 Hz, 2H), 2.73 (dd, J = 15.3, 6.8 Hz, 2H); 
13C NMR (150 MHz, CDCl3) δ 161.6, 144.5, 143.5, 128.5, 128.5, 128.4, 124.5, 124.4, 115.9, 
115.8, 114.0, 112.5, 62.9, 62.5, 57.1, 56.0, 47.0, 44.9 ppm. HRESIMS calculated for C18H21FNO2 
[M+H]+ 302.1477, found 302.1479. 
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8-methoxy-3-methyl-5-(o-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (72g): Synthesized 
according to general procedure for N-methylation. White solid. Yield: 43%, mp: 142.6 – 144.0 °C. 
1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 9.7 Hz, 1H), 6.98 (d, J = 7.9 Hz, 1H), 6.87 – 6.79 (m, 
1H), 6.77 (s, 1H), 6.62 (dd, J = 8.6, 2.7 Hz, 1H), 6.42 (s, 1H), 4.93 (d, J = 9.9 Hz, 1H), 3.79 (s, 
3H), 3.54 (ddd, J = 23.1, 14.4, 8.8 Hz, 2H), 3.26 (dt, J = 16.2, 3.8 Hz, 1H), 3.14 (t, J = 12.2 Hz, 
2H), 3.04 (dd, J = 15.7, 6.5 Hz, 1H), 2.38 (s, 3H), 2.32 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
130.04, 129.81, 127.57, 126.77, 122.68, 121.04, 120.55, 118.43, 116.31, 114.67, 114.62, 114.58, 
55.31, 50.20, 42.41, 32.82, 32.14, 26.92, 20.77 ppm. HRESIMS calculated for C19H24NO2 [M+H]
+ 
298.1729, found 298.1771. 
  
1-(2-bromophenyl)-3-methyl-2,3,4,5-tetrahydro-1H-benzo [d]azepine-7,8-diol (73d): 
Synthesized according to general procedure F. Product was obtained as an off-white solid. Yield: 
63%, mp: 205.2 – 206.4 °C.  
1H NMR (600 MHz, Acetone-d6): δ 7.70 (d, J = 7.9 Hz, 1H), 7.52 (t, J = 7.4 Hz, 1H), 7.38 – 7.32 
(m, 2H), 6.80 (s, 1H), 5.79 (bs, 1H), 5.65 (s, 1H), 5.46 (d, J = 9.9 Hz, 1H), 3.95 – 3.88 (m, 2H), 
3.78 – 3.73 (m, 1H), 3.68 – 3.60 (m, 1H), 3.13 – 3.03 (m, 2H), 2.91 (s, 3H); 13C NMR (150 MHz, 
Acetone-d6) δ 143.5, 140.8, 133.3, 132.6, 129.9, 129.0, 128.3, 128.0, 124.5, 121.5, 117.1, 114.3, 
60.2, 56.0, 54.1, 44.7, 30.7 ppm.  HRESIMS calculated for C17H19BrNO2 [M+H]
+ 348.0521, found 
348.0592. 
 
1-(2-fluorophenyl)-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol (73f): Synthesized 
according to general procedure F. Off-white solid. Yield: 26%, mp: 154.7 – 156.4 °C. 
1H NMR (600 MHz, DMSO) δ 7.38 (d, J = 7.5 Hz, 1H), 7.25 (t, J = 6.3 Hz, 4H), 6.59 (s, 1H), 5.92 
(s, 1H), 4.44 (d, J = 8.9 Hz, 1H), 3.18 – 3.10 (m, 1H), 3.01 (t, J =  10.9 Hz, 2H), 2.95 (bs, 1H), 
2.68 (dd, J = 15.2, 7.1 Hz, 1H), 2.42 (s, 3H), 2.40 – 2.35 (m, 1H); 13C NMR (150 MHz, DMSO) δ 
159.6, 143.5, 143.3, 133.3, 130.8, 129.2, 129.1, 125.2, 117.8, 116.1, 116.0, 115.2, 62.2, 57.1, 46.7, 
34.1, 34.0 ppm. HRESIMS calculated for C17H19FNO2 [M+H]




3-methyl-1-(o-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol (73g): Synthesized 
according to general procedure F. White solid. Yield: 34%, mp: 164.3 – 166.6 °C. 
1H NMR (600 MHz, DMSO) δ 7.26 (t, J = 6.7 Hz, 1H), 7.24 – 7.16 (m, 2H), 7.12 (d, J = 7.5 Hz, 
1H), 6.55 (s, 1H), 5.69 (s, 1H), 4.30 (d, J = 9.0 Hz, 1H), 3.08 (t, J = 13.3 Hz, 2H), 2.99 (d, J = 4.3 
Hz, 1H), 2.59 (dd, J = 14.6, 6.1 Hz, 1H), 2.55 – 2.52 (m, 1H), 2.30 (s, 3H), 2.07 (s, 3H), 2.04 (d, 
J = 11.3 Hz, 1H); 13C NMR (150 MHz, DMSO) δ 143.1, 143.0, 142.8, 135.9, 135.0, 132.3, 130.7, 
127.8, 126.7, 126.6, 117.4, 114.7, 63.7, 57.6, 47.5, 35.1, 19.5 ppm. HRESIMS calculated for 
C18H22NO2 [M+H]
+ 284.1572, found 284.1574. 
 
3-allyl-5-(2-chlorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (74b): 
Synthesized according to general procedure E. Purified by silica gel column chromatography (40% 
EtOAc/Hexanes) to give pure product as a white solid. Yield: 55%, mp: 200.2 – 202.1 °C.  
1H NMR (600 MHz, DMSO-d6 + Acetone-d6): δ 7.65 (d, J =  6.4 Hz, 1H), 7.58 (t, J = 8.6 1H), 
7.50 (t, J = 7.9 Hz, 2H), 7.35 (bs, 1H), 6.98 (s, 1H), 6.10 (s, 1H), 6.08 – 5.98 (m, 1H), 5.38 (d, J = 
11.2 Hz, 1H), 5.29 (d, J = 11.0 Hz, 1H), 4.95 (d, J = 6.0 Hz, 1H), 4.02 (s, 3H), 3.44 – 3.32 (m, 
5H), 3.08 – 2.97 (m, 4H), 2.50 (t, J = 9.1 Hz, 1H); 13C NMR (150 MHz, DMSO-d6 + Acetone-d6 
): δ 145.7, 144.8, 142.3, 136.8, 134.2, 133.1, 130.4, 130.2, 128.5, 128.4, 127.9, 117.5, 114.9, 114.1, 




3-allyl-5-(2,6-dichlorophenyl)-8-methoxy-2,3,4,5-tetra hydro-1H-benzo[d]azepin-7-ol (74c) : 
Synthesized according to general procedure E. Purified by silica gel column chromatography (30% 
EtOAc/Hexanes) to obtain pure product as a white solid. Yield: 40%, mp: 182.6 – 183.2 °C.  
1H NMR (600 MHz, CDCl3): δ 7.28 (dd, J = 12.9, 8.0 Hz, 2H),  7.09 (t, J = 8.2 Hz, 1H), 6.62 (s, 
1H), 6.14 (s, 1H), 5.85 (m, 1H), 5.20 – 5.05 (m, 3H), 3.79 (s, 3H), 3.34 – 3.06 (m, 6H), 2.91 – 2.72 
(m, 2H), 2.47 (bs,1H); 13C NMR (150 MHz, CDCl3): δ 144.5, 143.5, 140.2, 135.6, 129.9, 129.0, 
128.5, 128.2, 128.1, 122.5, 115.9, 113.6, 112.8, 103.0, 61.6, 55.9, 54.6, 46.2, 42.2, 32.2. ppm. 
HRESIMS calculated for C20H22Cl2NO2 [M+H]
+ 378.0949, found 378.1013. 
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3-allyl-5-(2-bromophenyl)-8-methoxy-2,3,4,5-tetra hydro-1H-benzo[d]azepin-7-ol (74d): 
Synthesized according to general procedure E. Purified by silica gel column chromatography (40% 
EtOAc/Hexanes) to obtain pure product as a white solid. Yield: 32%, mp: 195.3 – 196.0 °C.  
1H NMR (600 MHz, CDCl3): δ 7.58 (d, J = 8.0 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.19 (d, J = 7.4 
Hz, 1H), 7.13 (t, J = 7.6 Hz, 1H), 6.67 (s, 1H), 5.98 (s, 1H), 5.90 – 5.83 (m, 1H), 5.41 (bs, 1 H), 
5.17 (d, J = 8.1 Hz, 1H), 5.11 (d, J = 10.1 Hz, 1H), 4.74 (d, J = 9.1 Hz, 1H), 3.85 (s, 3H), 3.32 – 
3.22 (m, 2H), 3.20 – 3.12 (m, 3H), 2.79 – 2.72 (m, 2H), 2.32 (t, J = 11.3 Hz, 1H); 13C NMR (150 
MHz, CDCl3): δ 144.2, 143.3, 143.1, 136.5, 135.4, 133.1, 133.0, 129.5, 127.9, 127.7, 125.1, 117.8, 
113.8, 112.3, 62.1, 60.6, 55.9, 55.1, 47.8, 35.9 ppm. HRESIMS calculated for C20H23BrNO2 
[M+H]+ 388.0834, found 388.0903. 
 
3-allyl-5-(2-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol 
(74f): Synthesized according to general procedure E. Yellowish solid. Yield: 56%, mp: 160.4 – 
161.8 °C. 
1H NMR (600 MHz, CDCl3) δ 7.08 -7.05 (m, 2H), 6.99 (t, J = 7.6 Hz, 2H), 6.60 (s, 1H), 6.13 (s, 
1H), 5.84-577 (m, 1H), 5.12 – 5.06 (m, 2H), 4.48 (d, J = 8.1 Hz, 1H), 3.78 (s, 3H), 3.11 (t, J = 10.2 
Hz, 4H), 3.02 (d, J = 6.7 Hz, 2H), 2.85 – 2.78 (m, 1H), 2.73 (dd, J = 15.1, 7.1 Hz, 1H), 2.30 (t, J 
= 11.0 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 161.3, 159.7, 144.3, 143.4, 136.1, 132.6, 130.2, 
128.4, 128.3, 124.3, 115.8, 115.7, 114.1, 112.5, 62.3, 60.5, 56.0, 55.1, 43.5, 35.9 ppm. HRESIMS 
calculated for C20H23FNO2 [M+H]
+ 328.1635, found 328.1631. 
 
3-allyl-8-methoxy-5-(o-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (74g): Synthesized 
according to general procedure E. Yellowish solid. Yield: 56%, mp: 160.4 – 161.8 °C. 
1H NMR (500 MHz, CDCl3) δ 7.28 – 7.25 (m, 1H), 7.23 (d, J = 4.2 Hz, 1H), 7.04 (d, J = 6.5 Hz, 
1H), 6.69 (s, 1H), 6.11 (d, J = 32.4 Hz, 1H), 6.05 (s, 1H), 5.42 (dd, J = 38.7, 13.8 Hz, 2H), 3.88 
(s, 3H), 3.63 (ddd, J = 113.8, 51.0, 31.0 Hz, 5H), 3.08 – 2.94 (m, 2H), 2.92 – 2.81 (m, 1H), 2.21 
(s, 3H); 13C NMR (125 MHz, CDCl3) δ 144.6, 143.9, 136.6, 131.0, 130.8, 128.4, 128.1, 127.0, 
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126.9, 126.4, 123.6, 123.1, 114.0, 112.1, 61.9, 60.3, 56.0, 54.5, 29.8, 29.2, 19.6 ppm. HRESIMS 
calculated for C21H26NO2 [M+H]
+ 324.1920, found 314.1885. 
 
3-allyl-1-(2-bromophenyl)-2,3,4,5-tetrahydro-1H-benzo [d]azepine-7,8-diol (75d): Synthesized 
according to general procedure F. Purified by deactivated silica gel chromatography (60% 
EtOAc/Hexanes) to obtain pure product as an off-white solid. Yield: 46%, mp: 206.3 – 207.8 °C. 
1H NMR (600 MHz, Acetone-d6): δ 7.70 (d, J = 7.9 Hz, 1H), 7.52 (t, J = 7.4 Hz, 1H), 7.38 (d, J = 
7.5 Hz, 1H), 7.33 (t, J = 7.6 Hz, 1H), 6.80 (s, 1H), 6.37 – 6.33 (m, 1H), 5.79 (bs, 1H), 5.61 (d, J = 
9.0 Hz, 1H), 5.52 (d, J = 10.0 Hz, 2H), 4.00 – 3.90 (m, 4H), 3.81 (dd, J = 12.3, 5.6 Hz, 1H), 3.62 
– 3.58 (m, 1H), 3.00 (dd, J = 12.2, 5.4 Hz, 1H), 2.91 (dd, J = 12.0, 5.1 Hz, 1H); 13C NMR (150 
MHz, Acetone-d6): δ 143.5, 143.4, 140.9, 133.4, 129.0, 128.0, 127.4, 126.5, 124.8, 124.7, 124.0, 
117.1, 117.0, 114.4, 109.1, 107.1, 60.7, 59.6, 58.3, 53.8, 30.4 ppm. HRESIMS calculated for 
C19H21BrNO2 [M+H]
+ 374.0677, found 374.0749. 
 
3-allyl-1-(2-fluorophenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol (75f): Synthesized 
according to general procedure F. Off-white solid. Yield: 40%, mp: 188.6 – 190.4 °C. 
1H NMR (600 MHz, Acetone) δ 7.20 (dd, J = 10.4, 4.5 Hz, 1H), 7.10 (dd, J = 11.4, 4.0 Hz, 1H), 
7.06 (t, J = 7.4 Hz, 1H), 7.00 (t, J = 8.2 Hz, 1H), 6.53 (s, 1H), 5.95 (s, 1H), 5.73 – 5.63 (m, 1H), 
5.05 – 4.98 (dd, J = 14.9, 9.8 Hz, 1H), 4.94 (dd, J = 15.3, 10.2 Hz, 1H), 4.32 (d, J = 8.4 Hz, 1H), 
3.04 – 2.99 (m, 1H), 2.97 (d, J = 6.3 Hz, 2H), 2.91 (d, J = 12.2 Hz, 1H), 2.86 (dd, J = 15.1, 9.7 Hz, 
1H), 2.79 (dt, J = 13.5, 6.8 Hz, 1H), 2.23 – 2.15 (m, 1H); 13C NMR (150 MHz, Acetone) δ 161.1, 
142.8, 142.7, 136.3, 134.5, 132.6, 130.3, 128.1, 124.3, 117.1, 116.3, 115.3, 115.2, 115.0, 62.0, 
60.7, 57.4, 55.6, 35.6, 28.9 ppm. HRESIMS calculated for C19H21FNO2 [M+H]
+ 314.1478, found 
314.1467. 
 
3-allyl-1-(o-tolyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol (75g): Synthesized according 
to general procedure F. White solid. 25%, mp: 148.8 – 150.2 °C. 
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1H NMR (600 MHz, DMSO) δ 7.28 (t, J = 8.9, 1H), 7.22 (d, J = 7.7 Hz, 2H), 7.11 (d, J = 7.5 Hz, 
1H), 6.59 (s, 1H), 5.88 (d, J = 6.1 Hz, 1H), 5.71 (s, 1H), 5.29 (s, 2H), 4.41 (s, 1H), 3.41 (s, 1H), 
3.36 (s, 1H), 3.16 (t, J = 10.3 Hz, 1H), 2.72 (s, 1H), 2.39 (s, 1H), 2.18 (dd, J = 35.2, 17.5 Hz, 1H), 
2.10 (s, 5H); 13C NMR (150 MHz, CDCl3) δ 145.66, 144.90, 137.61, 136.69, 131.96, 131.77, 
129.37, 128.03, 127.85, 127.36, 124.58, 124.13, 115.01, 113.14, 64.11, 62.87, 61.19, 55.45, 30.17, 
20.61 ppm. HRESIMS calculated for C20H24NO2 [M+H]
+ 310.1729, found 310.1800. 
 
3.7.2. Dopamine receptor binding Assays 







































4.1. Background  
1-phenylbenzazeines are another class of 1-phenyldopamine (76) (Figure 25) analogs with 
high-affinity towards D1-like receptors. SKF 38393100 (1) is one of the most active and selective 
agonists of this class possessing low nanomolar affinity for D1 receptors and a 100-fold selectivity 
for binding to the D1 vs. D2 receptor sub-type. Unlike 12,122 the 1-phenyl moiety in 1 has been 
shown to adopt a conformation perpendicular to the plane of the catechol ring based on both X-
ray crystal structure determinations and computer-assisted modeling studies.241 It should be noted, 
that the 1-phenyl ring in 1 is freely rotating and is minimally constrained in this conformation by 
rotational energy barrier. Another difference is that the dopamine ethylamine side chain in 1 is 
rigidified into a gauche rotameric conformation, where the side chain of 12 is constrained into the 
trans rotamer.  
 
Figure 25.   Three classes of most active D1R ligands. 
 
The conformation of the pendant phenyl ring of 1-phenylbenzazepines has a notable effect 
on D1R activity. Coplanarity of the 1-phenyl ring with the catechol moiety of SKF 38393 was 
hypothesized to play a role in binding affinity. This hypothesis was put to test by creating 
conformationally restricted analogs of SKF 38393 via connecting the 1-phenyl ring to the azepine 
moiety (1a) (Figure 26).242  This conformational restriction resulted  in a decrease in D1 receptor 
affinity, with the trans-isomer having 85-fold higher D1 receptor affinity than the corresponding 
cis-isomer. Although limited to methylene and ethylene bridged compounds, results from this 
study were used as a platform to develop other conformationally restricted benzazepines. Similar 
tethering via oxy-methylene or thio-methylene functionalities also resulted in slight decreases in 
D1R affinity.242 Conformational restriction of the 1-phenyl ring of SKF 38393 by tethering to the 
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catechol ring via a methylene or ethylene bridge (1b) results in an approximately 50-fold and 30-
fold decrease in D1R affinity respectively.243  
 
Figure 26.   Structure of rigidified benzazepines in previous studies versus this study. 
 
4.2. Ligand Design 
 
Goal: Use the benzazepine scaffold to develop novel conformationally rigid ligands and 
investigate their affinity and selectivity towards dopamine and serotonin receptors. 
 
We considered an alternative mode of rigidification (1c) (Figure 26) of the benzazepine 
scaffold in which both aryl rings are directly connected and were curious to find out the extent to 
which such molecules would retain affinity and selectivity for the D1R.  Such molecules would 
force coplanarity of the aryl rings; their evaluation would shed light on the tolerance for coplanarity 
of the aryl rings for D1 receptor affinity of 1-phenylbenzazepines. Thus, we decided to synthesize 
rigidified 1-phenylbenzazepines in which the two phenyl rings are directly connected via an aryl-
aryl bond and to evaluate the compounds for affinity across major CNS receptor families 
comprising dopamine and serotonin receptors.  We report herein the synthesis of this novel 
1,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine framework and present data on the receptor 





Targeted benzazepines (83) with variable substitutions at C7, C8 and C4’ were synthesized 
using amines and substituted bromo-epoxides precursors using previously outlined methodology. 
The secondary amine on the benzazepines were protected with boc anyhydride to give 84. After 
several ligands and catalyst screening, direct arylation was achieved using di-tert-
butylmethylphosphoniumtetrafluoroborate as a ligand and palladium acetate as catalyst in the 
presence of pivalic acid to produce rigidified benzazepine 85. Finally, the deprotection of amine 
yielded desired series of novel analogs. The analogs were tested for dopamine receptor (D1-D5) 
and serotonin receptor activity and tabulated in Tables 17 and 18. 
Reaction optimization was necessary for successful direct arylation to synthesize fluoreno 
azepine 85 from 2’-Br 84 using a palladium catalyst activated by pivalic acid. The reaction 
conditions are summarized in Table 14 along with percent yield. Three ligands were scanned for 
the purpose; PhDave-Phos (ligand A), DavePhos (ligand B) and Di-tert-
butyl(methyl)phosphonium tetrafluoroborate (ligand C). Several alkali metal carbonate bases were 
screened along with two main polar solvents DMF (dimethyl formamide) and DMSO (dimethyl 
sulfoxide). Initially, microwave conditions were used (entries 1-6) to carry out the reaction as this 
method has been previously developed in our lab for the synthesis of structurally similar 
aporphines and homoaporphines.244   
However, the conditions initially tried did not yield the desired product. For entries 1-5, no 
product was detected after the disappearance of starting material confirmed by TLC. For entry 6, 
a trace amount of product as detected via mass spectrometry (MS). For entries 7-11, TLC analysis 
showed the consumption of starting material (84) but no product was detected in MS and NMR.  
It was later hypothesized that due to the duration of reaction (18 h and 8 h), the product formed 
initially was getting decomposed in the reaction mixture. Hence, the reaction-time was reduced to 
6h (entry 12), which yielded 36% of product 85.  Further reduction of reaction time to 2h (entry 
13) yielded the best result with 86% yield, with the combination of palladium catalyst accompanied 





aReagents and Conditions: (a) CH3NO2, NH4OAc, AcOH, 60℃, 6h, (92-96)%; (b) LiBH4, TMSCl, 
anhyd. THF, reflux, 6h, (45-58)%; (c) 1. mCPBA, DCM, rt, 12h; 2. NaOH, rt, 96%; (d) LiNF2, 
THF, reflux, 24h, (46-56)%; (e) 1.TFA, H2SO4 (18M), rt, 5h; 2. NaOAc, (43-52)%; (f) Boc2O, 
TEA, ACN, rt, 18h, (36-42)%; (g) 1. Pd(OAc)3, (t-Bu)2PMeHBF4, Pivalic Acid, K2CO3, DMSO, 











Table 14.  Optimization of direct arylation reaction conditions. 
 
 
# Base Solvent Ligand Pivalic Acid Temp (℃) Time Yield (%) 
1 K2CO3 DMSO A - 135 (μw) 5 min - 
2 K2CO3 DMSO B - 135 (μw) 5 min - 
3 K2CO3 DMSO C - 135 (μw) 5 min - 
4 K2CO3 DMSO A 0.4 equiv 135 (μw) 5 min - 
5 K2CO3 DMSO B 0.4 equiv 135 (μw) 5 min - 
6 K2CO3 DMSO C 0.4 equiv 135 (μw) 5 min Trace 
7 K2CO3 DMSO C 0.4 equiv 120 18 h - 
8 K2CO3 DMF C 0.4 equiv 120 18 h - 
9 Cs2CO3 DMF C 0.4 equiv 120 18 h - 
10 Na2CO3 DMF C 0.4 equiv 120 18 h - 
11 K2CO3 DMSO C 0.4 equiv 120 8 h - 
12 K2CO3 DMSO C 0.4 equiv 120 6 h 36 
13 K2CO3 DMSO C 0.4 equiv 120 2 h 86 
 
4.4. Structure-activity correlations 
The analogs were submitted to the PDSP for testing of affinity and activity at dopamine 
receptors (D1, D3, D5) and serotonin receptors (5-HT).  Biological data available for compounds 
85a-k is presented in Table 15 for dopamine receptors and Table 16 for serotonin receptors. 
Affinity data for dopamine receptors for the rigidified analogs were found to be very 
modest. No selectivity towards D1-like vs. D2-like receptors was observed as compared to typical 
1-phenylbenzazepenines. Among the analogs, compound 85d (Ki = 864.97 nM) with a catechol 
moiety and N-Me substitution was found to be most active towards D1R with no affinity for any 
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other dopamine receptor. The C7/C8-dimethoxy analog with N-Me substitution (85c) (Ki = 78.65 
nM) had the highest overall affinity at D3R.  In fact, the analogs overall are selective towards D3R.  
Binding affinity of analogs (85a-k) against serotonin receptors are shown in Table 16. 
Analyzed compounds were significantly selective towards 5-HT6. Compounds 85a (Ki = 5.2 nM), 
85c (Ki = 4.6 nM) and 85h (Ki = 1.72 nM) showed single-digit nanomolar activity towards 5-HT6. 
All three of the most active compounds had a 7,8-dimethoxy moiety.  For example, the most active 
compound 85h has 7,8-dimethoxy moiety in ring A with a 3’-Me in ring D. 85h was 7-fold 
selective towards 5-HT6 vs. 5-HT7 and several hundred-fold more selective vs. all other studied 
5-HT receptors. Catechol 3’-Me was the most inactive compound of all against all tested 5-HT 
receptors. Comparing 85a and 85c, N-Me substitution had no noticeable effect on the activity of 
these analogs towards 5-HT6 receptor.  However, 85c was significantly more selective towards 5-
HT6 vs. 5-HT7 but 85a was more selective towards other 5-HT receptors (5-HT1A, 5-HT2A and 
5-HT5A) compared to 85c. Comparing 85e and 85f that have top-ring mono-methoxy substitution 
(7-methoxy and 8-methoxy respectively), 85e (Ki = 24.13 nM for 5-HT7A) showed higher affinity 
than 85f (Ki = 7390.95 nM for 5-HT7A) across all 5-HT receptors. However, when there is 3’-Me 
group at the bottom ring, 7-methoxy compound (85i) showed lower affinity (Ki = 7845.13 nM for 













Table 15.  Affinity of analogs at dopamine receptors. 
 
aExperiments carried out in triplicate; b [3H]SCH23390 used as radioligand; c [3H]N-methylspiperone used as radioligand; d [3H]SCH23390 used as radioligand;   
ena 










      Ki (nM)
a. 
Cmpd # R1 R2 R3 R D1R
b D3Rc D5Rd 
85a OMe OMe H H na 414.76 ± 19.5 na 
85b OH OH H H 8822.67 ± 112.5 2924.83 ± 69.2 na 
85c OMe OMe Me H 2462.07 ± 74.5 78.65 ± 7.3 na 
85d OH OH Me H 864.97 ± 43.2 na na 
85e H OMe H H na 590.74 ± 22.1 na 
85f OMe H H H na na na 
85g OCH2 OCH2 H H na 979.26 ± 49.2 na 
85h OMe OMe H Me na 345.54 ± 17.9 na 
85i H OMe H Me na na >10000 
85j OMe H H Me 1643.24 ± 24.8 1032.29 ± 51.7 na 
85k OCH2 OCH2 H Me 4268.74 ± 37.6 na 9749.90 
(+)-Butaclamol     4.0 ± 0.2   
Haloperidol      5.5 ± 0.3  
SKF 83566       3.9 ± 0.2 
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Table 16.  Affinity of analogs at serotonin receptors. 
 
# R1 R2 R3 R 5-HT1A 5-HT2A 5-HT5A 5-HT6 5-HT7A 
85a OMe OMe H H 109.88 ± 1680.35 ± 67.2 578.76 ± 11.3 5.2 ± 0.01 13.63 ± 1.5 
85b OH OH H H 151.25 ± 1564.95 ± 9.8 244.06 ± 2.5 38.05 ± 1.3 11.37 ± 0.75 
85c OMe OMe Me H 201.93 ± 811.15 ± 8.3 286.48 ± 6.2 4.6 ± 0.01 59.87 ± 2.6 
85d OH OH Me H 393.28 ± 352.7 ± 10.1 363.16 ± 5.6 123.25 ± 3.2 56.14 ± 2.4 
85e H OMe H H 54.66 ± 1585.62 ± 14.2 363.16 ± 8.1 52.75 ± 2.1 24.13 ± 1.8 
85f OMe H H H 8464.47 ± >10000 na 2565.07 ± 17.3 7390.95  
85g OCH2 OCH2 H H 29.22 ± 984.01 ± 7.9 160.36 ± 2.5 259.3 ± 3.8 15.11 ± 0.82 
85h OMe OMe H Me 140.02 ± 621.58 ± 9.4 840.04 ± 13.6 1.72 ± 0.01 14.12 ± 0.91 
85i H OMe H Me >10000 na >10000 7845.13  8931  
85j OMe H H Me 357.52 ± na 2406.58 ± 19.3 55.35 ± 1.2 69.33 ± 4.2 
85k OCH2 OCH2 H Me 5086.28 ± na >10000 5340.72  4616.36  
8-OH-DPAT     9.18 ± 0.02     
Clozapine      8.23 ± 0.01    
Ergotamine       7.61 ± 0.03   
Clozapine        8.28 ± 0.02  






4.5.  Molecular docking studies 
4.5.1. Docking studies  
In order to rationalize the unexpected lack of D1 receptor affinity and selectivity of the 
rigidified benzazepines, as well as the serendipitous discovery of their high 5-HT6 receptor 
binding, a series of computational docking studies at D1 and 5-HT6 receptors was performed to 
prepared homology models of these dopamine and serotonin receptors. In this context, we 
investigated the docked ligand poses and identified key receptor-ligand interactions that influence 
binding to the receptors and provide a deeper appreciation of the observed SAR differences 
between the conformationally mobile and rigid systems.  
 
Table 17.  Predicted binding affinity from Glidescore for ligands SKF38393 and 85a-d at D1 
and 5-HT6 receptors. 
                               Binding energies (kcal/mol) 
# D1R 5-HT6 
SKF 38393 -9.6 -9.1 
85a -7.3 -8.2 
85b -8.7 -9.2 
85c -6.4 -8.2 
85d -8.4 -9.0 
 
4.5.1.1.D1 receptor outcomes 
Homology models of the D1R target systems were constructed from the high-resolution 
crystal structure of the human α2-adrenergic G protein-coupled receptor with pdb code 2RH1
245 
followed by induced fit docking with several phenylbenzazepine analogs to generate D1 receptor 
structures with appropriate backbone and side-chain orientations within the ligand binding site. 
This process utilized the Prime Structure Prediction and Glide software modules from Schrödinger 
as well as significant manual intervention to confirm the formation of known important receptor-
ligand interactions. The docking simulations were conducted using Schrödinger’s Glide software 
in Standard Precision (SP) mode246 and comprised the conformationally rigid set of ligands, 85a-
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d, as well as the conformationally mobile SKF 38393, with an unfused 1-phenyl ring. The 
Glidescore scoring function was utilized to provide an estimate of the binding affinity and the 
value for the highest ranked pose of each ligand within the D1 target receptor as shown in Table 
17. 
 
Figure 27:   Docked poses of 85a (green C atoms) and 85c (pink C atoms) in the D1 receptor 
target (grey C atoms, colored helices and loops). Key hydrogen bonding interactions are depicted 
by the yellow dashed lines and salt bridges by the pink dashed lines. 
 
A depiction of the docked poses for the ligands SKF 38393 and compound 85b in the D1 
receptor binding site is illustrated in Figure 27. The conformationally mobile ligand SKF 38393 
showed the highest predicted binding energy towards D1R (-9.6 kcal/mol), due in part to its ability 
to form key receptor-ligand interactions, including the protonated secondary N  - Asp103 salt 
bridge, H-bonds to Ser198 and Ser202  and pi-pi hydrophobic interactions of the catechol 
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containing aromatic ring with Phe288 and Phe289. For the conformationally rigid ligands, 
compound 85b gave the best Glidescore binding energy to the D1 receptor (-8.7 kcal/mol), 
although not as good as SKF 38393 due to slightly weaker H-bonds involving the ligand hydroxyl 
groups to Ser202 and Asn292. Compound 85d with a Glidescore value of -8.4 kcal/mol forms 
similar H-bonds as 85b involving the catecholic hydroxyl groups, but a slightly weaker salt bridge 
to Asp103 due to the presence of the protonated tertiary N-methyl group. Ligands 85a and 85c 
were found to have lower predicted binding affinities to the D1 receptor -7.2 and -6.4 kcal/mol, 
respectively), due to the replacement of the ligand hydroxyl groups with methoxy moieties, which 
remove key H-bonds. Furthermore, ligand 85c has the lowest predicted binding energy due to the 
presence of the protonated tertiary N-methyl group. 
 
4.5.1.2.5-HT6 receptor outcomes 
A homology model of the serotonin 5-HT6 receptor system was developed from the high-
resolution crystal structure of the human serotonin receptor with pdb code 4IB4247 by aligning 
highly conserved residues248 followed by induced fit docking with several phenylbenzazepine 
analogs and related locked systems. This approach generated a 5-HT6 receptor structure with 
appropriate backbone and side-chain orientations within the ligand binding site. The Glidescore 
estimates of the binding affinity for the highest ranked pose of each ligand within the 5-HT6 target 




Figure 28:   Docked poses of 85a (green C atoms) and 85c (white C atoms) in the 5-HT6 
receptor target (grey C atoms, colored helices and loops). Key hydrogen bonding interactions are 
depicted by the yellow dashed lines. 
 
A depiction of the docked poses for the ligands SKF 38393 and 85b in the 5-HT6 binding 
site is illustrated in Figure 28. SKF 38393 was found to have a predicted binding energy (-9.1 
kcal/mol) that is like the value determined for D1R. The docked pose of SKF 38393 to 5-HT6 
involves H-bonding interactions between the ligand’s hydroxyl groups and Asp106, and between 
the protonated secondary N and Thr196 as well as pi-pi hydrophobic interactions to Phe188. 
Ligand 85b gave the best Glidescore value for the conformationally rigid systems docked to 5-
HT6 (-9.2 kcal/mol). The ligand displays similar H-bonding interactions to the 5-HT6 receptor as 
SKF 38393 as well as pi-pi interactions with Phe284 and Phe188. Compound 85d gave a very 
close predicted binding energy (-9.0 kcal/mol) compared to 85b as it forms analogous interactions 
with the 5-HT6 binding site residues. In a similar manner to D1R, ligands 85a and 85c have a 
111 
 
lower Glidescore binding affinity (-8.2 kcal/mol) due to the presence of the methoxy groups, which 
lead to the removal of the key H-bonding interactions.   
Overall, the serotonin 5-HT6 receptor target gives better predicted binding energies for the 
conformationally rigid ligand set than D1R.  These computational outcomes are in accord with the 
trend seen with the experimental binding affinities, which depict significantly enhanced activity 
for the 85a-d ligand set towards 5-HT6 in comparison with D1R.  
 
4.6. Conclusion 
Compounds containing the novel 1,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine 
framework were synthesized in this project.  The synthesis was accomplished via direct arylation 
methodology.  The key direct arylation reaction was unsucessful via microwave conditions and 
was time sensitive under standard thermal conditions. Direct arylation was optimized with 
compound 84 as substrate under thermal conditions with a 2 hour reaction time.  The conditions 
used for optimization of the cyclization of 84 to 85 was applied to synthesize a variety of other 
1,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepines with more diverse aryl substituents. 
Compounds 85a-k represent rigidified analogs of 1-phenylbenzazepines such as SKF 
38393 (Figure 4) – a classical selective D1-like receptor ligand.  Evaluation of the analogs at 
serotonin and dopamine receptors revealed a lack of siginificant affinity for D1 receptors upon 
rigidification.  However, the rigidified ligands display selective affinity for the 5-HT6 receptor - 
an unexpected finding, especially given reported D1-like receptor selectivity and the lack of 
appreciable binding of SKF 38393 at 5-HT receptors (data available at the PDSP database). 
Docking studies with SKF 38393 and the rigidified analog compound 85b at the D1R 
indicate that the reduced D1R affinity upon rigidification may be due to slightly different 
interactions with the D1R, including weakened H-bonds between the catechol hydroxyl groups 
and the Ser202 and Asn292 residues.  Meanwhile, binding of 85b at the 5-HT6 receptor involves 
H-bonding interactions between the hydroxyl groups and Asp106, the protonated nitrogen and 
Thr196 and pi-pi interactions bewtween the aryl rings and Phe188 and Phe284.  The predicted 
binding energies of the ligands gave a similar trend as that obtained with the experimental data 
with the four tested ligands displaying 5-HT6 versus D1 selectivity.     
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This study has resulted in the identification of a new 5-HT6 receptor selective scaffold, 
obtained via rigidification of the D1 receptor selective 1-phenylbenzazepine template.  Important 
ligand-receptor interactions that contribute to 5-HT6 receptor affinity and selectivity versus D1 
have been revealed from docking studies.  A large number of selective 5-HT6 receptor ligands are 
known, many of which contain an arysulfonyltryptamine motif.  Compounds such as 85a, 85c and 
85h are novel, structurally unique 5-HT6 receptor ligands (possessing at least 15-fold selectivity 
versus the other receptor tested) which may be further developed into useful tools to support our 
understanding of 5-HT6 receptor function.  
General trends observed from affinity data for novel conformationally rigid benzazepines 
for dopamine and serotonin receptors are summarized in Figure 29. Even though acitivity of these 
fluoreno azpeines was very modest for D1R/D5R, discovery of highly potent ligands for 5-HT6 
with significantly different scaffold from currently avaible 5-HT6 ligands was encouraging. 
Fruther in vitro and in vivo studies of the most active and selective compounds would provide a 
better understanding of the potential of fluoreno azepines as viable therapeutic agents that target 
the 5-HT6 receptor.  
 








General experimental procedures 
Unless otherwise stated, chemicals were purchased from Fischer Scientific (USA) and 
were used without further purification. Reactions were carried out in air-dried glassware under a 
nitrogen atmosphere. HRESIMS spectra were obtained using an Agilent 6520 QTOF instrument. 
1H NMR and 13C NMR spectra were recorded using Bruker DPX-600 spectrometer (operating at 
400 or 600 MHz for 1H; 100 or 150 MHz, respectively, for 13C) using CDCl3, Acetone-d6 or 
DMSO-d6 as solvents. Tetramethylsilane (δ 0.00 ppm) served as an internal standard in 
1H NMR 
and CDCl3 (δ 77.0 ppm) in 
13C NMR as solvent. Chemical shift (δ 0.00 ppm) values are reported 
in parts per million and coupling constants in Hertz (Hz). Splitting patterns are described as singlet 
(s), doublet (d), triplet (t), and multiplet (m). Reactions were monitored by TLC with Whatman 
Flexible TLC silica gel G/UV 254 precoated plates (0.25 mm). TLC plates were visualized by UV 
(254 nm). Silica gel column chromatography was performed with silica gel 60 (EMD Chemicals, 
230-400 mesh, 0.063 mm particle size). 
 
General procedure A: epoxidation of styrenes  
To a stirred solution of desired styrene (1 equiv.) in DCM (125 mL) was slowly added 
mCPBA (2 equiv.) at 0 °C and the resulting reaction mixture was warmed to rt and stirred for 12 
h. The progress of the reaction was monitored by TLC. After completion of the reaction, the 
reaction mixture was quenched with aqueous NaOH (3M, 100 mL) and extracted with DCM (3X50 
mL). The combined organic layer was washed with brine, dried over anhydrous Na2SO4 and 
concentrated under reduced pressure to give a pure product. 
 
General procedure B: coupling of 2-(4-(benzyloxy)-3-methoxyphenyl)ethan-1-amine with 
epoxides 
To a solution of epoxide  (1 equiv.) and amine (1.5 equiv.) in anhydrous THF (100 mL) 
was slowly added Bis(trifluoromethane)sulfonimide lithium (1.1 equiv.) at rt and the resulting 
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reaction mixture was refluxed for 24 h. After completion (the reaction progress was monitored by 
TLC), THF was evaporated, reaction mixture was quenched with saturated NaHCO3 (25 mL) and 
extracted with EtOAc (3 x 30 mL). The combined organic phase was dried with Na2SO4 and 
concentrated to give crude viscous liquid, which was purified by silica gel column chromatography 
to yield pure product as viscous oil. 
 
General procedure C: amino alcohol cyclization 
To a stirred solution of respective amino – alcohols (1 equiv.) in TFA (30 mL) was added 
18 M H2SO4 (cat.) at rt and the resulting reaction mixture was stirred for 5 h at rt. Anhydrous 
NaOAc (2 equiv.) was added and stirred for additional 15 min. TFA was evaporated and the 
reaction mixture was neutralized with 14 M NH4OH to give a solid residue. The residue was 
dissolved in EtOAc (25 mL), washed with water and brine. Organic phase was dried over Na2SO4 
and concentrated under reduced pressure to give crude residue, which was purified by silica gel 
column chromatography to give pure product. 
  
General procedure D: N-methylation 
To a stirred solution of secondary amine (1 equiv.) in acetonitrile (100 mL) was added 
paraformaldehyde (3 equiv.) and the reaction mixture was stirred at rt for 30 mins. Sodium 
triacetoxyborohydride (1.5 equiv.) was added to the reaction mixture and the resulting reaction 
mixture was stirred for 12 h at the same temperature. After completion of the reaction (monitored 
by TLC), it was quenched with saturated NaHCO3 (20 mL), washed with water and extracted with 
EtOAc (2 x 25 mL), dried over anhydrous Na2SO4, evaporated under reduced pressure to give 
crude compound, which was purified by silica gel flash chromatography to afford  pure N – 






General procedure E: N-allylation 
To a stirred solution of secondary amine (1 equiv.) in acetonitrile (80 mL) was added TEA 
(2 equiv.) followed by allyl bromide (1.5 equiv.) at rt and the resulting reaction mixture was stirred 
at the same temperature for 12 h. After completion of the reaction (monitored by TLC), the reaction 
mixture was quenched with water, washed with NaHCO3 (25 mL) and extracted with EtOAc (2 x 
25 mL). The combined organic layer was dried over anhydrous Na2SO4 and evaporated under 
vacuum to give crude compound, which was purified by silica gel flash chromatography to give 
pure N – allylated product. 
 
General procedure F: O-demethylation with BBr3 
To a stirred solution of compound (1 equiv.) in DCM (20 mL) was slowly added BBr3 (4 
equiv.) at 0 oC and the reaction mixture was warmed to rt and stirred at the same temperature for 
18 h. After completion, ice water was added to the reaction mixture, allowed to stir for 30 min and 
the obtained precipitate was filtered to give pure compound. 
 
General procedure G: Boc protection of secondary amine 
Benzazepine (1 equiv.) was dissolved in DCM (50 mL). To the solution was added TEA 
(1.5 equiv.) and boc anhydride (2 equiv.) and the reaction stirred at rt until completion. The 
reaction solution was evaporated under vacuum. The residue was purified by silica gel column 
chromatography (30%EtOAc/Hexanes) to give a white solid as final product.  
 
General procedure H: Biaryl cyclization 
Pd(OAc)3 (0.22 mmol, 0.2 equiv.), (t-Bu)2PMeHBF4 (0.432 mmol, 0.4 equiv.), Pivalic acid 
(0.108 mmol, 0.1 equiv.) and K2CO3 (2.2 mmol, 2 equiv.) was dissolved in DMSO (10 mL) and 
mixture stirred at rt for 15 min under nitrogen. Boc protected benzazepine (1.08 mmol, 1 equiv.) 
was dissolved in DMSO (5 mL) and added to the reaction mixture dropwise via a syringe. The 
reaction was heated to 120 ℃ and stirred until completion, as confirmed by TLC with a single 
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spot. After completion, the reaction was cooled to rt and filtered via vacuum filtration. Cold water 
was added to the DMSO solution containing the product. An off-white solid was obtained which 
was subjected to the next reaction without purification. Off-white crude product (0.92 mmol, 1 
equiv.) was dissolved in DCM (10 mL) and to the solution was added TFA (20% in DCM). The 
mixture was stirred at rt for 2 h. Completion of the reaction was confirmed by TLC. The reaction 
mixture was concentrated under vacuum. To the residue, was added saturated NaHCO3 (40 mL) to 
obtain an off-white solid which was further purified by silica gel column chromatography 
(40%EtOAc/Hexanes) to give final compound as a white solid. 
 
2-(2-bromo-4-methylphenyl)oxirane (81b): Synthesized according to general procedure A. 
Colorless liquid, Yield: 96%.  
1H NMR (500 MHz, CDCl3) δ 7.40 (s, 1H), 7.12 (s, 2H), 4.15 (dd, J = 4.0, 2.7 Hz, 1H), 3.19 (dd, 
J = 5.5, 4.3 Hz, 1H), 2.66 (dd, J = 5.7, 2.6 Hz, 1H), 2.35 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 
139.5, 134.0, 132.7, 128.4, 125.7, 122.4, 52.1, 50.7, 20.8 ppm. HRESIMS calculated for C9H10BrO 
[M+H]+ 212.9837, found 212.9830. 
 
1-(2-bromophenyl)-2-((3,4-dimethoxyphenethyl)amino)ethan-1-ol (82a):  
Synthesized according to general procedure B. The impure residue was purified by silica gel 
column chromatography (2% MeOH/DCM). Viscous liquid. Yield: 56%. 
1H NMR (600 MHz, CDCl3) δ 7.57 – 7.50 (m, 1H), 7.39 (dt, J = 16.7, 8.4 Hz, 1H), 7.25 – 7.19 (m, 
1H), 7.07 – 6.97 (m, 1H), 6.72 (d, J = 7.8 Hz, 1H), 6.69 – 6.66 (m, 2H), 4.99 (ddd, J = 35.2, 9.6, 
2.5 Hz, 1H), 3.79 (d, J = 4.7 Hz, 3H), 3.76 (s, 3H), 3.05 (dd, J = 13.7, 3.1 Hz, 1H), 2.91 – 2.84 (m, 
2H), 2.75 – 2.68 (m, 1H), 2.51 (ddd, J = 28.7, 13.5, 9.7 Hz, 2H). 13C NMR (150 MHz, CDCl3) δ 
149.0, 147.5, 141.2, 141.1, 132.6, 128.9, 127.8, 127.7, 121.7, 120.6, 112.1, 111.4, 71.6, 70.1, 62.0, 
60.0, 55.8, 33.1. HRESIMS calculated for C18H22BrNO3 [M+H]




1-(2-bromophenyl)-2-((3-methoxyphenethyl)amino)ethan-1-ol (82b): Synthesized according to 
general procedure B. The impure residue was purified by silica gel column chromatography (1% 
MeOH/DCM). Viscous liquid. Yield: 52%.  
1H NMR (600 MHz, CDCl3) δ 7.62 (d, J = 6.7 Hz, 1H), 7.52 (d, J = 8.7 Hz, 1H), 7.35 (t, J = 7.5 
Hz, 1H), 7.24 (t, J = 7.8 Hz, 1H), 7.15 (t, J = 8.4 Hz, 1H), 6.82 (d, J = 7.4 Hz, 1H), 6.79 (s, 1H), 
6.78 (s, 2H), 5.08 (dd, J = 9.0, 3.0 Hz, 1H), 3.82 (s, 3H), 3.11 (dd, J = 12.4, 3.2 Hz, 1H), 3.04 (dd, 
J = 15.6, 10.5 Hz, 1H), 2.98 – 2.92 (m, 2H), 2.84 (m, 2H), 2.63 – 2.57 (m, 1H). 13C NMR (150 
MHz, CDCl3) δ 159.7, 141.3, 141.1, 132.5, 129.6, 128.8, 127.6, 127.5, 121.7, 121.1, 114.5, 111.6, 
70.2, 55.1, 54.5, 50.1, 36.2 ppm. HRESIMS calculated for C17H21BrNO2 [M+H]
+ 350.0677, found 
350.0660. 
 
1-(2-bromophenyl)-2-((4-methoxyphenethyl)amino)ethan-1-ol (82c): Synthesized according to 
general procedure B. The impure residue was purified by silica gel column chromatography (2% 
MeOH/DCM). Viscous liquid. Yield: 49%. 
1H NMR (600 MHz, CDCl3) δ 7.62 (dd, J = 7.8, 1.6 Hz, 1H), 7.52 (dd, J = 8.0, 1.1 Hz, 1H), 7.35 
(t, J = 7.5 Hz, 1H), 7.14 (d, J = 8.5 Hz, 3H), 6.87 (d, J = 8.7 Hz, 2H), 5.07 (dd, J = 8.9, 2.8 Hz, 
1H), 3.81 (s, 3H), 3.14 – 3.09 (m, 1H), 3.01 (dt, J = 12.3, 7.1 Hz, 1H), 2.95 – 2.89 (m, 2H), 2.84 – 
2.78 (m, 2H), 2.60 (dd, J = 12.3, 9.1 Hz, 1H). 13C NMR (150 MHz, CDCl3) δ 158.1, 141.2, 132.5, 
131.4, 129.6, 128.8, 127.6, 127.5, 121.7, 113.9, 70.1, 55.2, 54.5, 50.4, 35.2 ppm. HRESIMS 
calculated for C17H21BrNO2 [M+H]
+ 350.0677, found 350.0660. 
 
1-(2-bromophenyl)-2-((2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl)amino)ethan-1-ol (82d): 
Synthesized according to general procedure B. The impure residue was purified by silica gel 
column chromatography (2% MeOH/DCM). Viscous liquid. Yield: 56%. 
1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.0 Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 7.18 (dd, J = 14.0, 
8.0 Hz, 1H), 6.80 (s, 1H), 6.78 (s, 1H), 6.63 (d, J = 8.2 Hz, 1H), 5.25 (d, J = 9.5 Hz, 1H), 4.23 (s, 
6H), 3.73 (t, J = 6.4 Hz, 1H), 3.65 (t, J = 6.4 Hz, 1H), 3.55 (t, J = 6.5 Hz, 1H), 3.12 (dd, J = 12.7, 
2.9 Hz, 1H), 3.05 – 2.98 (m, 2H), 2.97 – 2.91 (m, 1H). 13C NMR (150 MHz, CDCl3) δ 141.7, 
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140.6, 134.8, 133.4, 132.3, 129.2, 128.7, 128.3, 127.9, 124.9, 118.6, 116.6, 64.3, 51.7, 47.2, 46.9, 
34.5 ppm. HRESIMS calculated for C18H21BrNO3 [M+H]
+ 378.0627, found 378.0627. 
 
1-(2-bromo-4-methylphenyl)-2-((3,4-dimethoxyphenethyl)amino)ethan-1-ol (82e): Synthesized 
according to general procedure for amine-epoxide coupling. Purified by silica gel column 
chromatography (2% MeOH/DCM). Viscous liquid. Yield: 51%. 
1H NMR (600 MHz, CDCl3) δ 7.30 (d, J = 7.9 Hz, 1H), 7.26 (s, 1H), 7.03 (d, J = 7.9 Hz, 1H), 6.96 
(s, 1H), 6.73 (s, 1H), 6.69 (s, 2H), 5.30 (d, J = 10.4 Hz, 1H), 3.78 (s, 2H), 3.77 (s, 3H), 3.43 – 3.33 
(m, 2H), 3.31 – 3.23 (m, 1H), 3.02 – 2.96 (m, 2H), 2.23 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 
146.4, 138.1, 135.2, 132.8, 131.7, 131.4, 129.0, 127.6, 123.2, 114.3, 112.1, 110.7, 54.7, 54.6, 48.9, 
44.8, 44.1, 31.1, 19.5 ppm. HRESIMS calculated for C18H21BrNO3 [M+H]




ol (82h): Synthesized according to general procedure B. Yield: 52%. 
1H NMR (500 MHz, CDCl3) δ 7.48 (d, J = 8.1 Hz, 1H), 7.33 (s, 1H), 7.13 (d, J = 7.8 Hz, 1H), 6.78 
(d, J = 8.3 Hz, 1H), 6.71 (s, 1H), 6.66 (d, J = 8.2 Hz, 1H), 5.11 (d, J = 9.0 Hz, 1H), 4.24 (s, 6H), 
3.99 – 3.88 (m, 2H), 3.08 (d, J = 14.5 Hz, 1H), 3.01 – 2.97 (m, 1H), 2.92 – 2.88 (m, 1H), 2.81 – 
2.76 (m, 2H), 2.63 (dd, J = 12.6, 9.1 Hz, 1H), 2.31 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 146.1, 
144.7, 141.7, 140.6, 136.3, 135.0, 131.9, 130.6, 125.0, 124.1, 120.5, 119.3, 71.1, 68.1, 65.8, 57.1, 
56.0, 37.4, 23.8 ppm. HRESIMS calculated for C19H23BrNO3 [M+H]
+ 392.0783, found 392.0811. 
 
1-(2-bromophenyl)-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (83a): 
Synthesized according to general procedure C. The residue was purified by silica gel column 
chromatography (2%MeOH/DCM) to furnish a white solid. Yield: 43%, mp: 180.2−181.5 °C.  
1H NMR (600 MHz, Acetone-d6) δ 7.69 (dd, J = 8.0, 1.0 Hz, 1H), 7.49 – 7.45 (m, 1H), 7.34 (dd, 
J = 7.8, 1.4 Hz, 1H), 7.27 (td, J = 7.8, 1.6 Hz, 1H), 6.88 (s, 1H), 6.04 (s, 1H), 4.90 – 4.85 (m, 1H), 
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3.84 (s, 1H), 3.81 (s, 3H), 3.59 (dd, J = 13.1, 1.7 Hz, 1H), 3.48 (s, 3H), 3.42 (dd, J = 13.0, 9.1 Hz, 
2H), 3.31 (ddd, J = 15.1, 10.1, 1.9 Hz, 1H), 3.06 – 3.00 (m, 1H), 2.99 – 2.91 (m, 1H). 13C NMR 
(150 MHz, Acetone-d6) δ 147.7, 147.5, 142.0, 134.7, 133.1, 128.6, 128.0, 124.6, 121.2, 119.0, 
114.6, 112.8, 55.5, 55.4, 52.2, 49.8, 49.7, 36.2. HRESIMS calculated for C18H20BrNO2 [M+H]
+ 
361.0677, found 361.0687. 
 
1-(2-bromophenyl)-7-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (83b): Synthesized 
according to general procedure C. White solid. Yield: 45%, mp: 174.5-177.2 °C. 
1H NMR (600 MHz, CDCl3) δ 7.63 (d, J = 7.9 Hz, 1H), 7.36 (t, J = 8.1 Hz, 1H), 7.21 – 7.15 (m, 
2H), 6.76 (s, 1H), 6.56 (d, J = 11.3 Hz, 1H), 6.40 (d, J = 8.5 Hz, 1H), 2.97 – 2.93 (m, 1H), 2.92 (s, 
1H), 2.91 – 2.89 (m, 1H). 13C NMR (150 MHz, CDCl3) δ 159.8, 141.3, 141.1, 132.5, 129.5, 128.8, 
127.7, 127.5, 121.7, 121.1, 114.5, 111.6, 70.2, 55.2, 54.5, 50.1, 36.2 ppm. HRESIMS calculated 
for C17H19BrNO [M+H]
+ 332.0617, found 332.0616.  
 
1-(2-bromophenyl)-8-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (83c): Synthesized 
according to general procedure C. Off-white solid. Yield: 50%, mp: 162.6-163.9 °C. 
1H NMR (600 MHz, CDCl3) δ 7.61 (d, J = 8.0 Hz, 1H), 7.23 – 7.19 (m, 1H), 7.11 (dd, J = 16.5, 
8.3 Hz, 2H), 6.93 (d, J = 7.5 Hz, 1H), 6.72 (d, J = 8.2 Hz, 1H), 6.44 (s, 1H), 4.07 (dd, J = 14.5, 4.5 
Hz, 1H), 3.70 (s, 3H), 3.68 (d, J = 6.1 Hz, 1H), 3.51 (dd, J = 11.8, 5.9 Hz, 1H), 3.40 – 3.32 (m, 
1H), 3.28 – 3.18 (m, 1H), 3.15 – 3.07 (m, 1H), 3.03 – 2.95 (m, 1H). 13C NMR (150 MHz, CDCl3) 
δ 158.4, 142.2, 142.0, 132.9, 131.9, 131.1, 130.3, 128.1, 127.7, 124.3, 116.7, 111.6, 55.1, 51.8, 
48.2, 46.6, 34.5 ppm. HRESIMS calculated for C17H19BrNO [M+H]
+ 332.0617, found 332.0616. 
 
6-(2-bromophenyl)-2,3,7,8,9,10-hexahydro-6H-[1,4]dioxino[2',3':4,5]benzo[1,2-d]azepine 
(83d): Synthesized according to general procedure to produce benzazepines. White solid. Yield: 
47%, mp: 161.5-163.1 °C. 
1H NMR (600 MHz, CDCl3) δ 7.59 (d, J = 8.0 Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 7.16 (t, J = 7.7 
Hz, 1H), 7.11 (d, J = 7.7 Hz, 1H), 6.70 (s, 1H), 5.92 (s, 1H), 4.85 (d, J = 9.5 Hz, 1H), 4.21 (s, 3H), 
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4.17 (s, 2H), 3.67 (d, J = 12.9 Hz, 1H), 3.52 (dd, J = 12.1, 4.8 Hz, 1H), 3.41 – 3.28 (m, 2H), 2.89 
(t, J = 12.0 Hz, 1H), 2.84 (dd, J = 15.6, 5.5 Hz, 1H). 13C NMR (150 MHz, CDCl3) δ 143.0, 141.8, 
136.1, 134.7, 133.6, 130.4, 130.0, 129.2, 129.1, 126.2, 119.9, 117.9, 65.6, 53.0, 48.5, 48.1, 35.7 
ppm. HRESIMS calculated for C18H19BrNO2 [M+H]
+ 360.0624, found 360.0621. 
 
1-(2-bromo-4-methylphenyl)-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (83e): 
Synthesized according to general procedure C. Grey solid. Yield: 52%, mp: 143.7-146.1 °C. 
1H NMR (600 MHz, CDCl3) δ 7.44 (s, 1H), 7.16 (d, J = 7.7 Hz, 1H), 6.98 (d, J = 7.9 Hz, 1H), 6.70 
(s, 1H), 6.03 (s, 1H), 4.92 (d, J = 9.6 Hz, 1H), 3.88 (s, 3H), 3.75 (d, J = 13.8 Hz, 1H), 3.63 (d, J = 
10.2 Hz, 1H), 3.57 (s, 3H), 3.45 (dd, J = 16.5, 9.6 Hz, 2H), 3.07 – 3.01 (m, 1H), 2.97 (dd, J = 15.8, 
6.5 Hz, 1H), 2.35 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 147.6, 139.3, 136.4, 134.0, 132.6, 130.2, 
128.8, 124.4, 117.4, 115.5, 113.4, 111.9, 55.9, 55.8, 50.2, 46.0, 45.3, 32.3, 20.7 ppm. HRESIMS 
calculated for C19H23BrNO2 [M+H]
+ 376.0945, found 376.0936. 
 
1-(2-bromo-4-methylphenyl)-8-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (83g): 
Synthesized according to general procedure C. White solid. Yield: 49%, mp: 161.5-162.8 °C. 
1H NMR (600 MHz, CDCl3) δ 7.43 (s, 1H), 7.16 (d, J = 7.8 Hz, 1H), 7.11 (d, J = 8.3 Hz, 1H), 6.99 
(d, J = 7.9 Hz, 1H), 6.69 (d, J = 10.9 Hz, 1H), 6.04 (s, 1H), 4.92 (d, J = 9.7 Hz, 1H), 3.78 – 3.75 
(m, 1H), 3.71 (d, J = 13.1 Hz, 2H), 3.66 (s, 3H), 3.55 (dd, J = 12.1, 5.2 Hz, 2H), 3.46 – 3.38 (m, 
3H), 2.95 (dd, J = 22.8, 9.1 Hz, 3H), 2.34 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 159.0, 158.9, 
130.0, 129.8, 127.5, 126.7, 122.6, 120.5, 118.4, 116.3, 114.6, 114.5, 55.2, 42.4, 32.1, 26.9, 20.7 
ppm. HRESIMS calculated for C18H21BrNO [M+H]
+ 346.0728, found 346.0725. 
 
6-(2-bromo-4-methylphenyl)-2,3,7,8,9,10-hexahydro-6H-[1,4]dioxino[2',3':4,5]benzo[1,2-
d]azepine (83f): Synthesized according to general procedure C. Off-white solid. Yield: 55%, mp: 
154.1-155.8 °C. 
1H NMR (600 MHz, CDCl3) δ 7.44 (s, 1H), 7.44 (s, 1H), 7.15 (d, J = 7.9 Hz, 1H), 7.15 (d, J = 7.9 
Hz, 1H), 7.04 (d, J = 7.9 Hz, 1H), 7.04 (d, J = 7.9 Hz, 1H), 6.69 (s, 1H), 6.69 (s, 1H), 5.98 (s, 1H), 
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5.98 (s, 1H), 4.71 (d, J = 9.3 Hz, 1H), 4.20 (s, 2H), 4.16 (s, 2H), 3.48 (d, J = 13.1 Hz, 1H), 3.33 
(dd, J = 12.8, 5.6 Hz, 1H), 3.24 (dd, J = 17.7, 8.6 Hz, 2H), 2.83 (t, J = 12.2 Hz, 2H), 2.34 (s, 3H). 
13C NMR (150 MHz, CDCl3) δ 141.3, 141.3, 138.6, 138.3, 136.2, 133.8, 133.7, 129.1, 128.5, 
124.7, 118.5, 116.6, 64.3, 53.1, 49.9, 47.6, 37.5, 20.6 ppm. HRESIMS calculated for C19H21BrNO2 
[M+H]+ 374.0677, found 374.0677. 
 
tert-butyl 1-(2-bromophenyl)-7,8-dimethoxy-1,2,4,5-tetrahydro-3H-benzo[d]azepine-3-
carboxylate (84a): Synthesized according to general procedure G. White solid. Yield: 46%, mp: 
69.7-71.1 °C.  
1H NMR (600 MHz, CDCl3) δ 7.52 (dd, J = 8.0, 1.2 Hz, 1H), 7.11 (t, J = 7.4 Hz, 1H), 7.00 (td, J 
= 7.7, 1.7 Hz, 1H), 6.82 (s, 1H), 6.59 (s, 1H), 6.31 (s, 1H), 4.77 (s, 1H), 3.94 (d, J = 9.9 Hz, 1H), 
3.81 (s, 3H), 3.67 (dd, J = 19.4, 5.2 Hz, 2H), 3.63 (s, 3H), 3.52 (s, 1H), 3.15 (s, 1H), 2.84 (d, J = 
15.1 Hz, 1H), 1.25 (s, 9H). 13C NMR (150 MHz, CDCl3) δ 155.4, 147.6, 147.3, 142.4, 132.9, 
132.4, 131.0, 130.82, 130.42, 128.1, 127.7, 114.5, 113.9, 79.5, 55.9, 55.9, 51.7, 47.7, 46.5, 28.3. 
HRESIMS calculated for C23H28BrNO4 [M+H]
+ 461.1202, found 461.1422. 
 
tert-butyl 1-(2-bromophenyl)-7-methoxy-1,2,4,5-tetrahydro-3H-benzo[d]azepine-3-carboxylate 
(84b): Synthesized according to general procedure for boc protection of benzazepine. White solid. 
Yield: 36%, mp: 56.3-57.5°C 
1H NMR (600 MHz, CDCl3) δ 7.60 (d, J = 8.0 Hz, 1H), 7.20 (t, J = 8.6 Hz, 1H), 7.12 – 7.07 (m, 
1H), 6.91 (d, J = 7.5 Hz, 1H), 6.81 (s, 1H), 6.75 (d, J = 2.4 Hz, 1H), 6.66 (d, J = 8.2 Hz, 1H), 3.58 
(ddd, J = 12.9, 11.3, 6.2 Hz, 2H), 3.51 – 3.44 (m, 1H), 3.40 (ddd, J = 10.7, 10.0, 6.0 Hz, 1H), 3.26 
(dd, J = 14.6, 10.9 Hz, 1H), 2.99 (ddd, J = 15.3, 5.8, 3.5 Hz, 1H), 1.34 (s, 9H). 13C NMR (150 
MHz, CDCl3) δ 158.4, 155.3, 142.2, 142.0, 132.9, 131.8, 131.1, 130.2, 128.1, 127.7, 124.2, 116.7, 
111.6, 79.5, 55.1, 51.8, 48.2, 46.6, 34.5, 28.3 ppm. HRESIMS calculated for C22H27BrNO3 [M+H]
+ 





(84c): Synthesized according to general procedure to boc-protect benzazepine. White solid. Yield: 
38%, mp: 52.1-52.4 °C. 
1H NMR (600 MHz, CDCl3) δ 7.48 (d, J = 8.0 Hz, 1H), 7.10 – 7.06 (m, 1H), 6.98 (dd, J = 16.5, 
8.3 Hz, 3H), 6.80 (d, J = 7.5 Hz, 1H), 6.60 (d, J = 8.1 Hz, 1H), 6.31 (s, 1H), 3.94 (d, J = 14.5 Hz, 
1H), 3.68 (d, J = 8.9 Hz, 1H), 3.58 (s, 4H), 3.39 (dd, J = 11.8, 5.9 Hz, 1H), 3.27 – 3.20 (m, 1H), 
3.13 – 3.04 (m, 1H), 2.87 (dd, J = 11.8, 7.5 Hz, 1H). 13C NMR (150 MHz, CDCl3) δ 157.9, 154.8, 
141.7, 141.5, 132.4, 131.4, 130.6, 129.7, 127.6, 127.2, 123.7, 116.2, 111.1, 79.1, 54.6, 51.3, 47.7, 
46.1, 34.0, 27.8 ppm. HRESIMS calculated for C22H27BrNO3 [M+H]
+ 432.1896, found 432.1890. 
 
tert-butyl 6-(2-bromophenyl)-2,3,6,7,9,10-hexahydro-8H-[1,4]dioxino[2',3':4,5]benzo[1,2-
d]azepine-8-carboxylate (84d): Synthesized according to the general procedure to protect 
secondary amine of benzazepines. White solid. Yield: 36%, mp: 44.6-46.2°C. 
1H NMR (600 MHz, CDCl3) δ 7.59 (d, J = 9.2 Hz, 1H), 7.23 (t, J = 7.1 Hz, 1H), 7.10 (t, J = 7.7 
Hz, 1H), 7.01 – 6.93 (m, 1H), 6.71 (s, 1H), 6.37 (s, 1H), 4.84 – 4.75 (m, 1H), 4.22 (s, 2H), 4.20 (s, 
2H), 4.12 – 4.00 (m, 1H), 3.83 (d, J = 10.0 Hz, 1H), 3.67 (dd, J = 21.6, 12.7 Hz, 1H), 3.48 (d, J = 
9.0 Hz, 1H), 3.14 (s, 1H), 2.99 – 2.88 (m, 1H), 1.36 (s, 9H). 13C NMR (150 MHz, CDCl3) δ 155.3, 
142.3, 141.9, 141.7, 132.9, 132.1, 130.1, 128.0, 127.7, 119.2, 119.1, 118.9, 79.5, 64.4, 60.4, 48.6, 
46.6, 34.9, 28.3 ppm. HRESIMS calculated for C23H27BrNO4 [M+H]
+ 460.1845, found 460.1842. 
 
tert-butyl6-(2-bromo-4-methylphenyl)-2,3,6,7,9,10-hexahydro-8H-
[1,4]dioxino[2',3':4,5]benzo[1,2-d]azepine-8-carboxylate (84g): Synthesized according to 
general procedure for boc-protection. White solid. Yield: 39%, mp: 52.4-55.7 °C. 
1H NMR (600 MHz, CDCl3) δ 7.42 (s, 1H), 7.28 (s, 1H), 7.03 (d, J = 7.2 Hz, 1H), 6.83 (d, J = 7.5 
Hz, 1H), 6.69 (s, 1H), 6.36 (s, 1H), 4.75 (dd, J = 8.3, 4.2 Hz, 1H), 4.21 (s, 2H), 4.19 (s, 2H), 4.07 
– 4.00 (m, 1H), 3.84 (dd, J = 16.0, 7.8 Hz, 1H), 3.65 – 3.58 (m, 1H), 3.46 – 3.41 (m, 1H), 3.18 – 
3.09 (m, 1H), 2.95 – 2.88 (m, 1H), 2.31 (s, 3H), 1.37 (s, 9H). 13C NMR (150 MHz, CDCl3) δ 143.1, 
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142.8, 140.5, 139.2, 135.3, 134.4, 133.2, 130.9, 129.7, 125.1, 120.3, 120.26, 65.6, 65.5, 49.9, 47.7, 
36.0, 21.7 ppm. HRESIMS calculated for C24H29BrNO4 [M+H]
+ 474.1304, found 474.1304. 
 
6,7-dimethoxy-2,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine (85a): Synthesized according 
to general procedure H. Yield: 52%, mp: 163.8-166 °C.  
1H NMR (600 MHz, CDCl3) δ 8.02 (d, J = 7.5 Hz, 1H), 7.39 (d, J = 7.7 Hz, 1H), 7.31 (t, J = 7.2 
Hz, 1H), 7.24 (t, J = 7.4, 1.1 Hz, 1H), 6.57 (s, 1H), 4.58 (bs, 1H), 4.05 (dd, J = 11.3, 3.1 Hz, 1H), 
3.89 (s, 3H), 3.83 (s, 3H), 3.41 (dd, J = 12.6, 3.0 Hz, 1H), 3.42 – 3.39 (m, 1H), 3.23 – 3.12 (m, 
1H), 2.77 – 2.66 (m, 2H), (t, J = 11.7 Hz, 1H). 13C NMR (150 MHz, CDCl3) δ 151.9, 144.2, 143.4, 
140.2, 139.5, 134.4, 133.5, 127.8, 126.8, 123.9, 123.7, 112.3, 60.30, 56.4, 51.6, 50.7, 48.8, 37.8. 
HRESIMS calculated for C18H19NO2 [M+H]
+ 281.1416, found 281.1500. 
 
2,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine-6,7-diol (85b):  
Synthesized from using the general procedure for demethylation. The final pure product was 
obtained as a gray solid. Yield: 54%, mp: 187.3-192.1 °C.  
1H NMR (600 MHz, DMSO-d6) δ 8.03 (d, J = 7.2 Hz, 1H), 7.63 (s, 1H), 7.40 (t, J = 6.9 Hz, 1H), 
7.29 (s, 1H), 6.64 (s, 1H), 4.25 (s, 1H), 4.01 (s, 1H), 3.60 (s, 1H), 3.28 (s, 1H), 3.17 (s, 1H), 2.96 
– 2.74 (m, 2H), 2.58 (s, 1H).13C NMR (150 MHz, DMSO-d6) δ 146.4, 145.0, 142.6, 141.3, 140.6, 
136.3, 128.3, 127.7, 126.45, 124.7, 123.7, 115.4 49.14, 47.5, 45.2, 31.4. HRESIMS calculated for 
C16H15NO2 [M+H]
+ 253.1103, found 253.1112. 
 
6,7-dimethoxy-2-methyl-2,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine (85c): 
Synthesized according to general procedure H. Yield: 78%, mp 168.3-170.6 °C.  
1H NMR (600 MHz, CDCl3) δ 8.02 (d, J = 7.1 Hz, 1H), 7.40 (d, J = 7.5 Hz, 1H), 7.31 (t, J = 7.2 
Hz, 1H), 7.24 (t, J = 6.8 Hz, 1H), 6.57 (s, 1H), 4.05 (d, J = 11.2 Hz, 1H), 3.89 (s, 3H), 3.83 (s, 3H), 
3.39 (d, J = 16.9 Hz, 1H), 3.24 (dd, J = 14.6, 11.7 Hz, 1H), 3.08 – 3.03 (m, 1H), 2.63 (dd, J = 15.1, 
5.4 Hz, 1H), 2.24 (t, J = 12.0 Hz, 1H), 1.88 (t, J = 11.7 Hz, 1H). 13C NMR (150 MHz, CDCl3) δ 
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151.8, 145.2, 143.1, 140.3, 139.8, 134.7, 133.2, 127.6, 126.7, 124.0, 123.6, 111.8, 60.7, 60.3, 57.7, 
56.4, 48.0, 47.7, 35.2. HRESIMS calculated for C19H21NO2 [M+H]
+ 295.1572, found 295.1560. 
 
2-methyl-2,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine-6,7-diol (85d): 
Synthesized following the general procedure for demethylation. Off-white solid; Yield: 46%, mp 
194.2-196.5 °C.  
1H NMR (600 MHz, DMSO) δ 7.99 (d, J = 7.5 Hz, 1H), 7.53 (d, J = 7.4 Hz, 1H), 7.34 (t, J = 7.4 
Hz, 1H), 7.24 (t, J = 7.3 Hz, 1H), 6.56 (s, 1H), 4.02 (d, J = 10.5 Hz, 1H), 3.10 (t, J = 12.9 Hz, 2H), 
2.56 (d, J = 4.8 Hz, 1H), 2.52 (d, J = 10.3 Hz, 3H), 2.28 (s, 1H), 1.86 (d, J = 26.8 Hz, 1H) 13C 
NMR (150 MHz, CDCl3) δ 150.9, 144.3, 142.1, 139.3, 138.8, 133.7, 132.2, 126.6, 125.7, 123.0, 
122.7, 110.8, 59.4, 56.8, 55.4, 47.0, 34.3 ppm. HRESIMS calculated for C17H17NO2 [M+H]
+ 
267.1259, found 267.1264. 
 
6-methoxy-2,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine (85e): Synthesized according to 
general procedure for biaryl cyclization. Yield: 36%, mp: 178.4-180.6 °C. 
1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 1H), 7.52 (d, J = 7.4 Hz, 1H), 7.46 (t, J = 7.4 
Hz, 1H), 7.37 (t, J = 7.4 Hz, 1H), 7.21 (s, 1H), 6.71 (s, 1H), 4.40 (d, J = 11.8 Hz, 1H), 4.11 (d, J = 
12.7 Hz, 1H), 3.93 (s, 3H), 3.83 (dd, J = 12.7, 4.1 Hz, 1H), 3.66 – 3.59 (m, 1H), 2.96 (dd, J = 14.7, 
10.1 Hz, 2H), 2.58 (t, J = 12.5 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 160.1, 143.0, 142.3, 141.1, 
137.7, 136.9, 128.2, 127.6, 124.4, 120.4, 113.7, 103.5, 55.6, 49.6, 47.2, 45.5, 33.3 ppm. HRESIMS 
calculated for C17H18NO [M+H]
+ 252.1310, found 252.2100. 
 
8-methoxy-2,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine (85f): Synthesized according to 
general procedure for biaryl cyclization. Yield: 47%, mp: 177.3-179.7 °C. 
1H NMR (600 MHz, CDCl3) δ 8.05 (d, J = 7.7 Hz, 1H), 7.41 (d, J = 7.5 Hz, 1H), 7.31 (t, J = 7.6 
Hz, 1H), 7.21 (t, J = 7.0 Hz, 2H), 6.96 (d, J = 8.1 Hz, 1H), 6.72 (d, J = 8.1 Hz, 1H), 4.09 (dd, J = 
11.2, 3.1 Hz, 1H), 3.92 (s, 3H), 3.75 (dd, J = 12.9, 3.4 Hz, 1H), 3.46 – 3.39 (m, 1H), 3.24 – 3.12 
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(m, 2H), 2.80 (dd, J = 15.3, 5.1 Hz, 1H), 2.65 (t, J = 12.5 Hz, 1H), 2.35 (t, J = 10.4 Hz, 1H). 13C 
NMR (150 MHz, CDCl3) δ 155.6, 142.4, 142.2, 133.1, 132.1, 131.3, 130.4, 128.3, 127.9, 124.5, 
116.9, 111.8, 55.3, 52.0, 48.4, 46.8, 34.7 ppm. HRESIMS calculated for C17H18NO [M+H]
+ 
252.1310, found 252.1867. 
 
2,3,7,8,9,9a-hexahydro-6H-[1,4]dioxino[2',3':3,4]fluoreno[9,1-cd]azepine (85g): Synthesized 
according to general procedure for biaryl coupling. Yield: 40%, mp: 174.7-176.0 °C. 
1H NMR (600 MHz, CDCl3) δ 9.93 (s, 1H), 8.07 (d, J = 7.6 Hz, 1H), 7.49 (d, J = 7.5 Hz, 1H), 7.44 
(t, J = 7.5 Hz, 1H), 7.33 (t, J = 7.9 Hz, 1H), 6.68 (s, 1H), 4.47 (s, 3H), 4.38 (s, 3H), 4.13 (d, J = 
13.0 Hz, 1H), 3.86 (d, J = 10.9 Hz, 2H), 3.63 – 3.53 (m, 1H), 3.01 – 2.95 (m, 1H), 2.92 (dd, J = 
16.2, 5.0 Hz, 1H), 2.62 (dd, J = 23.5, 11.9 Hz, 1H). 13C NMR (150 MHz, CDCl3) δ 143.2, 141.8, 
140.1, 138.8, 137.6, 129.1, 128.7, 128.3, 127.0, 126.9, 123.9, 116.1, 64.6, 64.4, 49.4, 47.5, 45.1, 
31.7 ppm. HRESIMS calculated for C18H18NO2 [M+H]
+ 280.1259, found 280.1312. 
 
6,7-dimethoxy-9-methyl-2,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine (85h): Synthesized 
according to general procedure for biaryl coupling. Yield: 40%, mp: 168.3-170.1 °C. 
1H NMR (600 MHz, MeOD) δ 7.91 (s, 1H), 7.48 (d, J = 7.7 Hz, 1H), 7.22 (d, J = 7.6 Hz, 1H), 
6.88 (s, 1H), 4.19 (d, J = 12.1 Hz, 1H), 4.07 (d, J = 12.7 Hz, 1H), 3.96 (s, 3H), 3.92 (s, 3H), 3.77 
(dd, J = 13.2, 4.8 Hz, 1H), 3.45 – 3.36 (m, 1H), 3.06 (dd, J = 16.0, 14.1 Hz, 2H), 2.65 (t, J = 12.5 
Hz, 1H), 2.46 (s, 3H). 13C NMR (150 MHz, MeOD) δ 152.6, 143.5, 139.9, 139.2, 138.2, 137.3, 
133.1, 132.1, 127.8, 123.9, 123.5, 111.9, 59.2, 55.3, 49.0, 47.0, 44.3, 31.4, 20.3 ppm. HRESIMS 
calculated for C19H22NO2 [M+H]
+ 296.1634, found 296.1621. 
 
7-methoxy-9-methyl-2,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine (85j): Synthesized 
according to general procedure for biaryl cyclization. Yield: 43%, mp: 157.6-158.9 °C. 
1H NMR (600 MHz, CDCl3) δ 7.96 (s, 1H), 7.44 (d, J = 6.0 Hz, 1H), 7.00 (d, J = 7.8 Hz, 1H), 6.89 
(d, J = 8.0 Hz, 1H), 6.62 (d, J = 6.8 Hz, 1H), 4.83 (s, 1H), 3.94 (s, 3H), 3.55 (s, 2H), 3.12 (s, 3H), 
2.40 (s, 4H). 13C NMR (150 MHz, CDCl3) δ 154.4, 135.2, 135.0, 132.9, 127.4, 125.7, 125.4, 125.2, 
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124.2, 123.8, 116.0, 105.4, 55.4, 53.4, 45.5, 37.4, 29.7, 21.7 ppm. HRESIMS calculated for 
C18H20NO [M+H]
+ 266.1467, found 266.1421. 
 
12-methyl-2,3,7,8,9,9a-hexahydro-6H-[1,4]dioxino[2',3':3,4]fluoreno[9,1-cd]azepine (85k): 
Synthesized according to general procedure for biaryl cyclization. Yield: 41%, mp: 160.0-161.8 
°C. 
1H NMR (600 MHz, CDCl3) δ 7.89 (s, 1H), 7.28 (s, 1H), 7.14 (d, J = 7.7 Hz, 1H), 6.63 (d, J = 
10.4 Hz, 1H), 4.45 (d, J = 4.8 Hz, 2H), 4.36 (d, J = 4.2 Hz, 2H), 4.29 – 4.14 (m, 1H), 3.11 (ddd, J 
= 40.8, 27.6, 13.4 Hz, 1H), 2.86 – 2.74 (m, 1H), 2.70 (dd, J = 15.4, 4.8 Hz, 2H), 2.53 (t, J = 12.3 
Hz, 2H), 2.47 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 141.9, 141.6, 139.3, 138.0, 134.1, 133.2, 
132.0, 129.7, 128.5, 123.8, 119.1, 119.0, 64.3, 64.3, 60.3, 48.7, 46.5, 34.7, 20.5 ppm. 
 
4.7.2. Dopamine and serotonin receptor binding assay 
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